







Humanized Mouse Models for Xenotolerance and 
Autoimmunity 









Submitted in partial fulfillment of the  
requirements for the degree of  
Doctor of Philosophy  































Humanized Mouse Models for Xenotolerance and Autoimmunity 
Grace Nauman 
 
Mice with human immune systems, generated by transplanting human CD34+ cells into 
immunodeficient mice, are essential tools for studying phenomena unique to the human immune system 
or poorly reproduced in existing mouse models.  Human immune tolerance induction, function and 
autoimmunity have been poorly modeled in conventional murine models [1-4], which often have poor 
predictive value for preclinical development.  Models that allow the study of human immune cells with 
the reproducibility and flexibility of small animal models are required.  In our lab, humanized mouse 
models have been used to study preclinical protocols for human xenotolerance induction [5-8] and to 
better understand the immunological underpinnings of human autoimmunity [9, 10].  These are each areas 
of critical unmet medical need.  Xenotolerance-inducing protocols may be necessary to allow long-term 
survival of a transplanted pig organ in a human patient [11], and, with more than 113,000 Americans 
currently waiting for a life-saving organ, the need to expand the pool available for transplantation is 
urgent.  Additionally, clinical options for patients with autoimmune diseases are limited.  Currently, most 
patients with autoimmunity are only diagnosed after significant immune damage of target organs.  
Predicting who will develop autoimmunity – and who will not – before damage occurs would be very 
useful but is currently very difficult.  Small animal models that can better help us understand how human 
autoimmunity develops could help us develop protocols for early detection and even prevention.  We 
have developed a personalized immune model to study the development of an individual patient’s 
immune system in a transplanted mice to better understand immune abnormalities that underlie 
autoimmunity [9, 10]. 
We have used existing humanized mouse models to answer important questions related to human 
xenotolerance induction and autoimmunity, but in the studies described here we have worked to extend 
our capacity to use these models to study human T cell development and peripheral function.  We would 
 
 
like to be able to study both the initial selection of T cell receptors (TCRs) in the thymus based on their 
ability to recognize antigen in the context of presenting MHC without reacting unduly to self-antigen, as 
well as in the periphery, where T cells interact with peripheral antigen-presenting cells (APCs) to 
maintain homeostasis and respond to antigen.  First, we have incorporated TCR transgenesis into our 
humanized mouse models to allow greater precision in studying thymic selection in our humanized mice.  
Developing a system for this would allow us to study in greater detail mechanisms of human 
xenotolerance induction, including confirming that a swine thymus can support positive selection of T 
cells with human-restricted TCRs to allow a future xenotransplantation patient to maintain immune 
competence, while also robustly tolerizing human T cells expressing pig-reactive TCRs.  We will also 
expand this system to study the thymic selection of human T cells with autoreactive TCRs to better 
understand mechanisms of central tolerance and understand how they fail in autoimmunity. 
Finally, while processes of thymic selection are critical for human T cell development and function, 
peripheral interactions also have a large impact on human T cell function and homeostasis and may 
contribute to the development of autoimmunity.  For these interactions to occur appropriately requires 
robust engraftment and reconstitution of APCs, especially of myeloid and B cell lineages, in transplanted 
immunodeficient mice.  APC reconstitution tends to be suboptimal in humanized mice and is even more 
so in mice transplanted with patient-derived CD34+ cells.  Better characterization of human APC 
populations and their progenitors could allow us to develop approaches to improve long-term human APC 
reconstitution in patient-derived humanized mice, allowing us to more fully model patient peripheral T 
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CHAPTER 1: INTRODUCTION 
 
T cells are key mediators of adaptive immunity.  They act as central organizers of the immune 
response, receiving information from antigen-presenting cells (APCs), integrating it, and using it to 
coordinate an appropriate defense.  Depending on the situation, they can be cytotoxic effectors; crucial 
partners to other immune cell types, including B cells; or even immune suppressive cells, limiting the 
damage done by an ongoing immune response.  However, the very properties of T cells that make them 
key coordinators of the adaptive immune response often put them in the center of autoimmune attack and 
make them key culprits in immune rejection in solid organ transplantation.  T cells interact with APCs by 
recognizing antigens in the context of self-molecules, called major histocompatibility complex molecules 
(MHC).  These interactions are critical for allowing T cells to function properly and protectively.  
However, they must also be delicately controlled.  Better understanding and controlling T cell responses 
has important clinical relevance in transplantation, xenotransplantation, and autoimmunity.   
Much of our knowledge of T cell biology comes from research using mouse models.  Mouse models 
are useful and reproducible, and the murine and human immune systems share many properties.  Mice are 
amenable to highly controlled and rigorous experiments: they reproduce relatively rapidly, are small, and 
can be maintained as isogenic stocks in carefully controlled environments.  Additionally, useful naturally-
occurring mutations, recombinant DNA and gene editing technology make it possible to use genetic 
approaches to precisely elucidate pathways, processes, and molecules underlying immune functions.  
However, as our understanding of murine immunology has grown, it has become clear that observations 
made using these systems do not always reflect what happens in humans.  This may be due to differences 
between the mouse and human immune system that as yet are poorly understood [1, 2, 12, 13]. These 
differences have frequently meant that therapeutic interventions that showed striking efficacy in mouse 




extensive modification to achieve results in patients [15-19].  This has been particularly concerning for 
studying immune tolerance induction for transplantation and xenotransplantation, and for better 
understanding clinical autoimmunity.  Models that better recapitulate human immune cell development 
and function, including of T cells, will be necessary to better understand these cells and prevent unwanted 
reactivity in transplantation and autoimmunity to address major and growing unmet medical needs. 
Because T cells have a central role in coordinating the rest of the immune response, the ability to 
specifically tolerize human T cells to a desired non-self would be extremely useful therapeutically.  This 
would be particularly relevant in transplantation, where a patient is grafted with an organ of non-self-
origin that they require to survive.  The immune system, especially T cells, readily attacks tissues 
recognized as non-self, which can lead to rejection of the transplanted organ.  Currently, this T cell-
mediated immune attack on transplanted organs is prevented by profound pharmacological suppression of 
the patient’s immune system, which puts transplanted patients at severe risk for infection, neoplasms, and 
excruciating side effects [20-22], while chronic rejection may still occur.  Thus, current approaches to 
control the immune response in human-to-human transplantation without tolerance induction leave much 
to be desired.   
Problems caused by immune attack on transplanted organs are likely to be exacerbated by future 
approaches to expand the pool of available organs.  Recently, major progress has been made in pre-
clinical models of pig-to-human xenotransplantation [23, 24].  Genetic modification of pigs and 
improvements in immune suppressive medicine have dramatically increased the survival of pig organs in 
non-human primate models and clinical xenotransplantation may be on the horizon.  This will be a major 
achievement, given the enormous, desperate need for more transplantable organs [25].  However, the 
immune incompatibilities between pigs and humans are quite high.  Without tolerance induction, the 
immune suppression required to support survival of a pig organ in the transplanted patient will likely need 
to be further increased, with more side effects and, likely, less effectiveness.  Thus, approaches to induce 




essential to make pig-to-human xenotransplantation possible.  Because T cells are often major participants 
in transplant rejection, mechanisms to induce immunological tolerance will have to control and retrain T 
cell compartments.  However, approaches that lead to tolerance induction in murine models often are 
unsuccessful in larger animals, including dogs, pigs, and non-human primates [26].   
The failures of immunological tolerance that lead to autoimmunity may also be poorly modeled in 
mice.  Differences between mouse models of T cell-mediated autoimmune diseases and humans with 
those diseases have meant that insights obtained using mouse models cannot always be translated to 
human clinical application [27, 28].  Possibly some of the factors that make mice very amenable to highly 
sophisticated studies, including the ability to generate isogenic, or genetically identical, strains with 
reproducible characteristics, may make them less likely to appropriately model human disease.  For 
instance, one of the most widely-used mouse models for Type 1 diabetes (T1D), the non-obese diabetic 
(NOD) mouse is an isogenic mouse strain.  Studies in the NOD mouse have helped confirm that T1D is a 
T cell-mediated autoimmune disease [29, 30].  They have also identified pathogenic T cell reactivities 
that are often found in patients with T1D [31-39].  T1D pathogenesis has been exhaustively described in 
the NOD model, which has demonstrated numerous immunological abnormalities associated with the 
strain.  However, it is unclear which of these abnormalities are relevant to disease development in many 
of the individual humans who develop T1D [28, 40].  Differences between the human and mouse immune 
systems may contribute to these discrepancies, or they may occur simply because patients with T1D are 
outbred and each comes with a unique assortment of predisposing genetic variants [41-43] and a different 
history of exposures that ultimately led to disease development.  Therefore, future studies to better 
understand clinical T cell autoimmune pathogenesis should study human immune cells specifically and 
should allow us to model immune development from human immune cells with different, known 
characteristics in terms of both genetics and environmental exposures.  This would permit better 




would be additionally useful, to facilitate more precise mechanistic studies of human T cell-mediated 
autoimmunity. 
Clearly, conventional mouse models are likely inadequate for answering outstanding questions in 
human xenotolerance induction and autoimmunity.  Some of these difficulties are almost certainly due to 
differences between human and mouse immune cells.  Therefore, to better understand how to tolerize 
human T cells in transplantation and to prevent or predict the development of human T cell autoreactivity, 
we will have to develop models to facilitate studies specifically on human immune cells.  Understanding 
the human immune system is vitally important, but ethical concerns for the well-being of research 
participants severely limit the sorts of studies that can be done on humans.  Generally, human studies 
have been limited to studying peripheral blood, and thus only provide a limited window on human 
immune cells and function and preclude longitudinal analysis of disease pathogenesis, since disease 
development is usually unpredictable.  Recently, human tissues from deceased donors have become a new 
resource for human research and have provided valuable insight into human T cell and APC 
compartmentalization and maturation in health and disease [44-46].  However, these studies tend to look 
at snapshots of a human immune system and are usually descriptive in nature.  The vast array of genetic 
tools that have made detailed mechanistic and kinetics studies possible in mouse models have so far been 
difficult to apply to these more descriptive human studies.   
Ultimately, models that combine the experimental tractability of mouse models but allow us to study 
the development of human immune cells will be necessary.  To address these concerns, we and others 
have turned to using humanized mouse models.  In particular, we and others have used transplantation 
models where human immune progenitor cells and tissues, specifically human CD34+ hematopoietic 
progenitor cells and human thymus tissues, are grafted into genetically-engineered immunodeficient mice 
[47-49].  Human CD45+ cells, including B cells and monocytes, repopulate recipient mice.  If a fragment 
of fetal human thymus is transplanted under the renal capsule, naïve human T cells selected in a human 




T cell development under controlled conditions possible.  We have also developed a humanized mouse 
model compatible with the use of patient-derived CD34+ stem cells for personalized studies of immune 
systems reconstituted from individuals with or without autoimmune diseases [9].  Both models have been 
used in the lab to better understand human xenotolerance induction [7, 47] and autoimmunity [9, 10]. 
In my doctoral studies, I have built upon this work, using lentiviral transgenesis to introduce a TCR 
transgene into human CD34+ cells for transplantation.  This will allow studies of TCR selection in the 
context of human cells, allowing us to perform mechanistic studies using human cells in an 
experimentally tractable mouse model.  While this model is not wholly new, I have used it to begin 
addressing longstanding questions about the selection of human TCRs in xenotolerance induction and 
autoimmunity and have generated reagents to continue these studies.  I have also performed preliminary 
experiments studying selection of a known autoreactive TCR in normal human thymopoiesis.  
Additionally, I have contributed to studies characterizing and optimizing peripheral APCs in our patient-
derived humanized mouse model for autoimmunity, since these models cannot faithfully recapitulate 
human immune function unless physiologically relevant levels of human APCs repopulate the periphery.  
Together, these projects represent progress in generating humanized mouse models that allow studies of 
human T cell development for tolerance induction and autoimmunity in an experimentally tractable 
system. 
In the remaining pages of this chapter, I will review basic principles of T cell development, 
maturation, and central tolerance, which largely occur in the thymus.  I will also touch briefly on 
peripheral T cell function, and its dependence on interactions with the APCs found there.  I will then 
address the relevance of these processes to xenotolerance induction and autoimmunity.  I will describe 
what is known so far about these systems, and especially what we have learned about these processes 
using other humanized mouse models, before describing outstanding questions that require use of a TCR 




T cell development 
T cells have unique specificities due to expression of T cell receptors generated by stochastic 
genetic rearrangement 
T cells can respond to a vast variety of antigens because each individual T cell expresses a receptor 
with a unique specificity, known as a T cell receptor or TCR.  Each αβ T cell has a TCR consisting of two 
receptor chains, the TCRβ and the TCRα chains.  These are generated by stochastic rearrangements of 
gene fragments encoded by the TCRβ and TCRα genomic loci in a process known as V(D)J 
recombination.  Both the TCRβ and TCRα loci encode numerous TCR variable (V) and joining (J) 
regions, while the TCRβ additionally encodes two diversity (D) regions.  A process of genomic 
recombination allows each developing T cell to rearrange a different combination of V, D, and J regions 
on the TCRβ locus.  This genomic rearrangement is mediated by two proteins, known as recombination-
activating genes, or RAG1 and RAG2, which are endonucleases which create double strand breaks to 
allow rearrangement of the gene segments [50, 51].  The resulting double strand breaks are repaired via 
non-homologous end joining, a process of DNA repair that allows the non-template directed insertion of 
nucleotides, known as P and N nucleotides, at the sites of recombination.  This generates mutational 
diversity in addition to the combinatorial diversity generated by recombining different V, D, and J 
regions.  This process is largely repeated on the TCRα chain, although the TCRα only arranges V and J 
regions.  In all, this process generates sequences of DNA at the sites of recombination, known as the 
CDR3s, that are highly diverse and responsible for the specificity of the TCR [52].  Each αβ T cell will 
have rearranged both a β chain and at least one α chain, and this combination adds additional diversity to 
the TCR repertoire.   
Ultimately, this process can generate an immune repertoire with an enormous array of specificities.  
Theoretically 1015 unique TCRs could be arranged in each individual [53, 54].  This leaves the adaptive 
immune system prepared for whatever may come its way.  However, because the process occurs 




molecules with inappropriate reactivity.  Therefore, developing T cells go through a tightly-controlled 
process of selection in a specialized organ, called the thymus, to ensure the development and maturation 
only of T cells that have arranged functional TCRs that do not respond to most self-antigens. 
T cells recognize antigen in the context of self-MHC molecules 
TCRs recognize antigen in the context of surface proteins, known as major histocompatibility complex 
molecules, or MHC, expressed on the surface of the organism’s cells.  MHC molecules each contain a 
binding cleft that can accommodate a large diversity of antigenic peptides.  Minor variations in binding 
cleft configuration can dramatically affect the repertoire of antigenic peptides an MHC molecule can 
present, and thus the immune responses the MHC molecule can elicit.  MHC molecules are highly 
polymorphic, and the MHC locus is the site of the greatest degree of allelic diversity in most vertebrate 
species, including humans.  This ensures on a population level that a group of individuals can respond to 
a wide variety of pathogens.  Each TCR responds to antigen presented on a specific MHC molecule, and 
thus is said to be restricted to that specific MHC molecule. 
There are two major types of MHC molecules, which generally present peptides to different types of T 
cells that mediate different functions.  Co-receptors on the surface of T cells, known as CD8 or CD4, bind 
to MHC molecules and in some cases facilitate TCR and MHC interactions [55], and distinguish between 
the T cells with TCRs that recognize either of the two types of MHCs, with the CD8 co-receptor binding 
to class I MHC and the CD4 co-receptor binding to class II MHC.   
Class I MHC are expressed on the surface of almost all healthy cells and present antigens found within 
the cytosol of the cells themselves.  T cells restricted to class I MHC are CD8+ T cells.  CD8+ T cells thus 
recognize cells that have been infected with viruses or other intracellular pathogens, or cells that have 
experienced potentially oncogenic mutagenesis.  CD8+ T cells are cytotoxic effector cells, so they can 




The second type of MHC are class II MHC.  These are primarily expressed by professional APCs, 
types of cells with specialized abilities to process and present exogenous antigens to CD4+ T cells, that is, 
those obtained from the extracellular environment and/or endosomes.  CD4+ T cells are generally referred 
to as “helper” T cells.  CD4+ T cells respond to antigen and to additional signals from APCs that direct 
their differentiation to multiple types of helper T cells depending on the conditions of the environment to 
mediate a variety of effector functions.  Class II-restricted TCRs tend to have a lower affinity for their 
cognate antigen/MHC combination compared to those that are class I-restricted [56].  Additionally, while 
class I MHCs present antigens of uniform sizes (typically between 9 and 11 amino acids) generated by 
intracellular proteases, class II MHCs can present larger peptide antigens with a wider variety of sizes 
[57-59].  Peptides presented by class II MHCs can often bind in multiple configurations, or registers [60].  
This allows multiple T cells each expressing very different class II-restricted TCRs to respond to a single 
peptide/class II MHC complex.  Both factors suggest that the requirements for development, maturation, 
and activation are different for CD4+ compared to CD8+ T cells 
Thymocyte selection and central tolerance 
In the thymus, T cells undergo V(D)J recombination to generate a diverse array of cells each 
expressing a unique TCR.  The thymus is a specialized organ that supports a selection process to ensure 
that the maturing T cell pool ultimately will contain T cells that express functional TCRs that are not 
autoreactive.  T cells are known as thymocytes while they are developing in the thymus.  A major focus 
of the work described here centered on developing a TCR Tg humanized mouse model to study what 
happens to thymocytes expressing a human TCR with known properties during this process.   
One of the first steps of thymocyte development, TCRβ VDJ recombination, occurs before thymocytes 
upregulate their CD4 and CD8 co-receptors, while the thymocytes are “double negative”.  The rearranged 
TCRβ must pair appropriately with a molecule called the pre-TCR surrogate α-chain to ensure 
functionality of the rearranged receptor [61].  If this occurs successfully, the thymocyte will complete β-




Cells expressing a pre-arranged TCR, as in a TCR Tg system, are able to express a functional TCRβ chain 
without undergoing VDJ recombination and so are thought to bypass or pass through β-selection 
efficiently, preventing rearrangement of the endogenous TCRβ loci [62].  
After rearranging a functional TCRβ chain, thymocytes upregulate both their CD4 and CD8 co-
receptors, begin rearranging their TCRα chains [61], and begin thymocyte selection, which takes place in 
two steps.  The first step, called positive selection, takes place in the cortex of the thymus and selects for 
T cells expressing TCRs that weakly bind to peptide/MHC complexes (pMHC) expressed in the thymus.  
These are TCRs that have proper MHC restriction, that is, that can respond to peptides presented by the 
MHCs present in the thymus of the organism.  T cells must express TCRs with proper MHC restriction to 
be able to function and mediate a T cell response in the periphery of the organism.  The second step 
occurs in the medulla of the thymus and is known as central tolerance, during which developing 
thymocytes are exposed to a wide variety of self-antigens and are eliminated if they are reactive to these 
self-antigens. 
Positive selection is necessary for the development of a functional TCR repertoire 
Because the process for generating TCRs is stochastic, and because MHCs are so diverse, one of the 
first steps in T cell development is positive selection, which ensures that the thymocytes have rearranged 
a receptor that can interact functionally with the individual’s MHCs.  Thymocytes are allowed to survive 
and mature based on the ability of their TCRs to weakly interact with selecting antigens presented on 
MHCs expressed on the surface of epithelial cells in the thymic stroma [63, 64].  These specialized cells 
are called cortical thymic epithelial cells, or cTECs.  Cells expressing TCRs that lack the proper MHC 
restriction and do not respond to pMHC complexes present on the selecting thymus epithelium are 
eliminated by a process called death by neglect [65, 66].  A large proportion of developing thymocytes 
fail to rearrange an appropriate TCR and fail to be positively selected, and are lost to this process [67].  
This occurs even though the affinity requirements for positive selection are quite low; an observation that 




weak cross-reactivity is sufficient to allow positive selection of a variety of TCRs [68].  Recent studies 
have increasingly recognized that thymocytes expressing TCRs that respond too strongly to self pMHC 
complexes can also be deleted at this stage of development [69, 70].   
Thymocytes differentiate to the CD8+ or CD4+ T cell fate during positive selection.  Immature 
thymocytes will upregulate both co-receptors after successful TCRα chain rearrangement, such that 
thymocytes undergoing positive selection can be identified based on being both CD4 and CD8 double 
positive (DP) [71].  As the thymocyte determines which MHC its TCR responds best to, it will retain 
expression of the co-receptor appropriate for the MHC to which it best responds – CD4 for class II, or 
CD8 for class I and silence the expression of the other co-receptor.  Committing to the CD4 or CD8 
lineage is an important part of thymic selection and thymocytes after this are either CD4 or CD8 single 
positive (SP).  
Central tolerance  
Thymocytes that are successfully positively selected and do not succumb to either death by neglect or 
clonal deletion migrate to medulla of the thymus, where they undergo a rigorous process of central 
tolerance.  The thymic medulla is populated with a wide variety of APCs, including multiple types of 
dendritic cells (DCs) and B cells, as well as a population of highly-specialized stromal cells called 
medullary thymic epithelial cells (mTECs) which present a wide variety of hematopoietic and tissue-
specific self-antigens to the immature thymocytes, ensuring that any that express an autoreactive TCR are 
appropriately tolerized upon encountering its cognate self-antigen [63].  mTECs in the thymus express 
specialized proteins, including the transcription factor AIRE, which allow them to stochastically express a 
large number of genes throughout the cell’s genome [72-74].  This ensures that developing thymocytes 
are tolerized to many antigenic proteins that are normally restricted to specific tissues or organs.  These 
proteins are therefore called tissue-restricted antigens, or TRAs, and their expression in the thymus helps 




can also be transferred from mTECs to thymic DCs [63], meaning that multiple cell types can participate 
in tolerizing thymocytes to TRAs. 
If a thymocyte expresses a TCR that reacts to a self-antigen, it can be tolerized in one of two ways: by 
deletion [75-77], or by conversion to the regulatory T cell (Treg) fate [78-81].  If the cell is selected to be 
a Treg, it will upregulate the transcription factor FoxP3 and acquire suppressive functions.  This ensures 
that if any autoreactive TCRs escape tolerization, or if unwanted reactivity develops in the periphery, 
Tregs can halt it.  Thymocytes expressing autoreactive TCRs may also be forced to undergo apoptosis and 
are thus deleted from the thymus [82-85].  How developing thymocytes are directed to undergo deletion 
versus Treg conversion during central tolerance has been the subject of intense study, but more research is 
needed to determine how this decision is made.  Studies assessing central tolerance of human thymocytes 
are especially needed.  In any case, a developing thymocyte typically spends 4-5 days in the thymic 
medulla, moving in an apparent “random walk” through a tight network of autoantigen-presenting cells, 
ensuring the TCR is assessed for reactivity to a wide repertoire of self-antigens [63].  Subsequently, 
thymocytes with a functional TCR that did not encounter self-antigens become mature T cells and 
emigrate to the periphery. 
T cells rely on peripheral antigen-presenting cells for homeostasis and 
function 
T cell peripheral survival and function depend on interactions with antigen-presenting cells 
Studies in mice have shown that peripheral T cells depend upon interactions with peripheral APCs 
both to stimulate appropriate antigen-dependent T cell responses, and for signals to support their 
maturation and homeostasis.  Immediately after T cells migrate from the thymus, these cells, termed 
recent thymic emigrants (RTEs) undergo a period of post-thymic selection and maturation that is thought 
to last approximately two weeks [86, 87].  During this period, RTEs are hypo-functional, and their 
repertoire is shaped by interactions with MHC-expressing APCs as they mature to be functional naïve T 




MHCs on which they were selected to persist and function in the periphery [89-92].  It has been shown 
that T cells do not persist in the periphery without these signals in steady state [93, 94], and they certainly 
are not able to mount antigen-specific responses in their absence.   
In mice, interactions between peripheral APC populations and T cells can also help prevent – or 
initiate – autoimmunity.  Interactions between specialized APC populations in the periphery have been 
shown in mice to induce deletion, anergy, or Treg conversion in T cells with unwanted reactivity [95-97].  
These peripheral interactions can suppress reactivity by T cells with autoreactive TCRs that escaped 
thymic deletion, or which express TCRs that react to innocuous environmental, food, or commensal 
antigens.  However, in situations where normal, healthy individuals have a sudden reduction in their 
peripheral T cells, naïve T cells with higher affinity for self-MHC preferentially interact with peripheral 
APCs to proliferate [91, 98].  During this process, known as lymphopenia-induced proliferation, 
proliferating T cells can become memory cells, which are more easily stimulated to mediate effector 
functions, and may contribute to the development of autoimmunity [99-102].   
Studies of human peripheral T cell homeostasis are virtually non-existent, due to the lack of 
appropriate model systems.  One study in our laboratory confirmed that human naïve T cells require 
interactions with peripheral human APCs to mediate proliferation and phenotypic conversion in a 
lymphopenic environment [103], but more studies using humanized mouse models will be needed to 
determine whether insights about peripheral T cell homeostasis gleaned from mice also apply to human T 
cells.  Accurately recapitulating human peripheral T cell-APC interactions will require humanized mouse 
models with physiological human APC engraftment, which has been difficult to achieve [14, 104, 105]. 
APC populations are suboptimal in humanized mice 
Interactions between T cells and APC populations are critical for normal T cell function and 
development, so models to study normal human T cell development must appropriately reconstitute 




transplanted with human CD34+ cells.  Some APC populations have been described as being poorly-
maintained in transplanted mice [14, 104, 105].  Notably, class-switched antibody responses to 
vaccinations, which require interactions between T cells and APCs including B cells, are difficult to 
achieve in humanized mice [106-109], suggesting that non-physiological human APC reconstitution and 
function is a barrier to modeling normal immune behavior in humanized mice.  We have observed that the 
persistence of human T cells in humanized mice can depend on engraftment of specific human APC 
populations [103].  In a secondary transplant model where T cells from humanized mice were 
transplanted to mice engrafted with human B cells or monocytes, but not T cells, lymphopenia-driven 
expansion and conversion to the effector/memory phenotype correlated with the level of human APC 
reconstitution in secondary recipients, with CD4+ T cell proliferation correlating with human CD14+ cell 
engraftment and CD8+ proliferation depending on B cells [103].  Human T cell survival was dependent on 
the presence of these APCs in secondary hosts, as transferred T cells could not be recovered in 
unreconstituted mice lacking human APCs. These data further confirm that appropriate human T cell 
function in a humanized mouse model will require good reconstitution of multiple human APC 
populations. 
Decades of effort have gone into improving human APC reconstitution in mice transplanted with 
human CD34+ cells.  Most have focused on providing human cytokines in transplanted mice, typically by 
introducing human cytokines into the genome of immunodeficient mice [14, 108, 110, 111].  These 
efforts have improved APC engraftment and myelopoiesis but can come at the expense of mouse lifespan 
or T cell function.  Animals with too many human cytokines knocked-in may have a shortened lifespan, 
perhaps due to anemia in the mice (personal communication from Dr. Chiara Borsotti, previously a 
student in the Flavell laboratory).  Poor cross-reactivity between the knocked-in human cytokines and 
murine cytokine receptors may contribute to the health concerns observed in these mice.  Because these 
animals die so young, experiments using these animals must be performed in neonates, which are too 




the context of the mouse native thymus, limiting the utility of these models for studying human thymic 
selection.  In another human cytokine Tg model [112], human T cells rapidly converted to memory 
phenotype and were poorly maintained, suggesting human APC-T cell interactions in the mice are 
nonphysiological in this model.  Transplanted mice ultimately developed a histiocytosis-like syndrome 
[113], again, limiting their utility for extended studies of transplanted human cells.  Thus, humanized 
mouse models that support robust engraftment of both human APCs and human T cells have been 
difficult to develop.  Approaches to better characterize why human APC engraftment and development is 
suboptimal in transplanted mice might lead to better strategies to improve these models. 
Hematopoietic APCs  
There is a wide variety of APCs in the body with many characteristics and purposes.  Most of them are 
considered to be part of the myeloid lineage, and participants in the more rapid, less-specific innate 
immune response.  However, because these cells can present antigens to T cells on their MHC, typically 
along with costimulatory and cytokine signals, they act as a bridge between the adaptive and innate 
immune system.  Fully recapitulating all human APCs in a human CD34+ cell-transplanted mouse model 
will be challenging and may not be possible.  Many APC populations, such as the skin-resident 
Langerhans cells, are laid down during fetal development, and these and other “non-professional” APCs 
of non-hematopoietic origin likely cannot be repopulated by transplanted human CD34+ cells [114, 115].  
However, numerous other APCs are derived from hematopoietic cells, including monocytes, B cells and 
multiple types of DCs, and improving their engraftment and maintenance will facilitate modeling human 
immune responses in humanized mouse models. 
Monocytes are an important immune cell type in humans.  They make up a large proportion of human 
blood nucleated cells (~10%), larger than their proportion in murine blood [116, 117].  Monocytes are 
frequently among the first immune cells present in a site of infection or inflammation, typically arriving 
within 12-15 hours [116, 117].  Upon arrival, they are able to direct the unfolding immune response in 




physically clear pathogens, and support a pro-inflammatory or pro-resolution environment.  They can also 
differentiate to inflammatory DCs and become involved in activating T cells [119-121].  In mice, 
monocyte-derived inflammatory DCs have been shown to contribute to priming T cells and were 
necessary for eliminating pathogens [122-124].  It is likely that human monocytes can do the same, so 
robust human monocyte development will be needed in humanized mouse models, although there is 
evidence that they are immature and hypofunctional in current models [104]. 
Other important cell types include DCs, including the plasmacytoid DCs (pDCs).  pDCs are a unique 
subset of small, round DCs that are specialized in the production of type I interferon [125, 126], the 
cytokine signal that is the essential first step for initiating CD8+ T cell-mediated antiviral and anti-tumor 
immunity [127, 128].  pDCs have also been shown to induce Treg development in both the thymus and 
periphery [129, 130]. 
Two subsets of conventional DCs found within CD11c+ cells are specialized for presenting antigens to 
the two main types of T cells.  Human CD141+ cDC1 cells, which correspond to murine CD8α+ DCs, 
specialize in cross-presenting extracellular antigens to cytotoxic CD8+ T cells [131].  This means they 
have a specialized ability to take in antigens from outside the cell and present them on class I MHC, 
which typically only present endogenously-produced antigens.  CD141+ DCs therefore are important for 
CD8+ T cell-mediated immunity.  CD1c+ cDC2s, by contrast, generally present antigen to CD4+ T cells, 
integrating and coordinating their helper T cell responses [120, 131, 132].  These functions are not 
exclusive, as CD141+ DCs can activate helper T cells and CD1c+ DCs can perform antigen cross-
presentation, but good reconstitution of both populations is likely necessary for normal, functional human 
T cell immunity and will be needed in humanized mouse models to support studies of physiological 
human T cell development, homeostasis and function. 
While B cells may be more classically known for producing antibodies, specialized molecules which 




roles presenting antigens to T cells.  Indeed, their antigen-presenting ability has often been utilized in 
vitro, where polyclonal pools of virally immortalized B cells are frequently used as support cells for 
culturing T cells.  Their role as APCs in vivo is also very important.  In some cases, B cells have been 
shown to be the primary APC priming a T cell response [133-135].  Interactions between T and B cells 
where B cells present antigens to helper T cells coordinate the germinal center reaction, where T cells and 
B cells interact to optimize the B cell-mediated antibody response [136-138].  Thus, humanized mouse 
models must reconstitute mature, functional, well-maintained B cells that can participate in these 
interactions to allow class-switched antibody responses to vaccinations [134, 138, 139]. We have 
additionally shown that human CD8+ T cells require B cells to proliferate in a lymphopenic environment 
[103], suggesting that human T cells may rely on them for homeostatic signals as well as antigen 
presentation in ways that are as yet poorly understood. 
Good, physiological reconstitution and maintenance of these human APC populations will be 
necessary to appropriately model human T cell function and development in a transplanted humanized 
mouse model.  Many of these populations could, theoretically, be reconstituted by human cells if they are 
able to adequately receive the signals needed for development.  Indeed, a major reason humanized mouse 
research has so thoroughly explored exogenous human cytokine expression for humanized mouse models 
is to ensure that appropriate human cytokines are provided to promote development of these APCs [14, 
140].  However, these approaches may not address all the missing signals needed to promote appropriate 
APC differentiation and maintenance in a humanized mouse.  One challenge in reconstituting APCs in 
humanized mice, especially compared to other populations, is that their survival kinetics are shorter 
compared to lymphocytes, and especially to T cells.  The typical half-life of these cells is on the order of 
days or weeks [141-144], while human T cells are known to persist for decades [145-147].  Human 
memory B cells and antibody-producing plasma cells can also persist for years, but these populations 
develop poorly in transplanted mice and the more immature B cell populations that are better represented 




physiologically useful, because it helps ensure that the antigens APC populations present to T cells reflect 
up-to-date information about the immunological challenges facing the organism.  Therefore, better 
understanding human APC biology and the hematopoietic processes that support human APCs in 
humanized mice would be helpful.  We have begun addressing this by characterizing both human APC 
reconstitution and human hematopoietic progenitor populations in humanized mouse models made with 
human CD34+ cells of multiple ontogenetic sources – both fetal liver and adult bone marrow (aBM)-
derived sources.  Our goal was to better understand human APC populations and how they were 
maintained, with a goal of improving APC maintenance in a humanized mouse model transplanted with 
patient-derived bone marrow samples.   
Hematopoiesis 
Humanized mouse models rely on the transplantation of human CD34+ cells to repopulate 
immunodeficient mice with human white blood cells.  This approach is successful because CD34 marks a 
variety of progenitor populations that give rise to white blood cells and other hematopoietic populations.  
Among these populations are hematopoietic stem cells (HSCs), a rare population of stem cells that can 
give rise, via differentiation through a variety of hematopoietic progenitor cells and intermediates, to 
virtually every blood cell in the body, including those concentrated in lymphoid tissues.  Traditionally this 
has been thought to occur via a hierarchical progression through sequentially more lineage-committed 
progenitor populations [148], although more recent studies suggest that developing hematopoietic cells 
commit to clonal lineages much earlier than previously believed [149-151].  Cytokine signals and 
interactions with surface proteins on stromal cells are necessary to direct progenitors through 
differentiation [149, 150, 152, 153].  Even before this, interactions with the external HSC niche, including 
localization to specialized vascular niches and association with unique supportive cell types [154, 155], 
have been shown to be important for regulating HSC engraftment and persistence.  Species differences in 
any of these interactions may affect the ability of human stem, progenitor, and mature populations to 




rather than a human one would impact how developing hematopoietic lineage cells commit to clonal 
fates.  Moreover, conditioning regimens used to prepare recipient animals for engraftment with human 
cells may disrupt or alter the environment in which the transplanted stem cells find themselves, further 
altering their persistence and differentiation potential.  More studies of human stem cell engraftment and 
differentiation might be useful for improving this.  
Using different sources of human CD34+ cells can affect engraftment and cell output in humanized 
mice.  We have used CD34+ cells from human fetal livers and from bone marrow taken from healthy 
adults.  We observed differences in the abilities of these cell sources to repopulate immunodeficient mice, 
and especially to maintain APC populations.  APC populations seem to be poorly maintained among 
peripheral blood mononuclear cells in mice transplanted with aBM CD34+ cells.  Differences in 
repopulation potential and lineage biases between ontogenetically different sources of human CD34+ cells 
have been reported before [149, 156, 157] and are not surprising, since the physiological requirements in 
fetal and adult hematopoiesis are different.  However, the result that APC populations are reduced in mice  
transplanted with older CD34+ cells appears to conflict with the observation in both mice and humans that 
aged HSCs display a bias towards myeloid differentiation [158].  This observation provides support for 
the idea that poor APC maintenance in transplanted mice is likely due to as yet poorly-understood 
differences between species in the stromal and cytokine signals needed to promote optimal HSC 
engraftment and hematopoiesis.   
If we can better understand and improve human hematopoietic stem and progenitor cells engraftment 
in mice and better facilitate their survival, maintenance, and differentiation through the various APC 
lineages, perhaps we would be able to improve human hematopoietic engraftment in mice long-term, to 
allow longer-term biological and mechanistic studies related to human immune development, in an 




Humanized mouse models to study human T cell development 
Humanized mouse models generated by transplanting immunodeficient mice with human fetal CD34+ 
cells and fetal thymus fragments can provide a useful model to study human T cell development and 
biology.  These models have been used to study HIV infection, persistence, and treatment approaches 
[159-167].  They can be used to study cancer biology and test therapeutics for immune oncology [168-
171], and to model human autoimmunity [172].  We have used them in the laboratory to model 
approaches to clinical tolerance induction in allo- and xenotransplantation.  We have also used them to 
study human lymphopenia-induced proliferation [103] and, using a descriptive repertoire analysis-based 
approach, TCR selection during thymopoiesis [173].  These models have facilitated novel insights into 
human T cell biology that were not previously possible.   
Early studies have begun to expand on these approaches by adding genetic manipulation to humanized 
mouse research, which could allow more precise, hypothesis-driven studies of human T cell development.  
Studies of T cell development, especially in thymopoiesis, are much more possible to do using defined 
receptor systems, where cells expressing a TCR with a known specificity can be observed and monitored.  
Much of what we know about murine T cell development comes from defined receptor studies using TCR 
Tg mice.  Mice encoding a single pre-rearranged TCR can be generated by cloning mice from nuclei from 
a clonal T cell population [174].  Obviously, such technologies are not possible – nor ethical – for use in 
humans.  Instead, TCR transgenes must be introduced into human CD34+ cells prior to transplant without 
impairing their capacity to repopulate mice.  This can be done using lentivirus, a genetically engineered 
viral vector with a high capacity to infect non-dividing cells [175, 176].  While this is a technically 
challenging experimental system, studies using this system have begun to address fundamental questions 
about human T cell development.   
Many of these previous studies were proof-of-concept studies, showing that introduction of a TCR 
transgene largely prevents arrangement of endogenous TCRs in transplanted cells and that a human-




selection [62, 177, 178].  Studies have explored TCR Tg humanized mice as potential sources of TCR Tg 
T cells for tumor- or virus-specific immunotherapy [177-179].  More recently, a study transplanting 
humanized mice with cells transduced for a TCR and for its target antigen was used to study human T cell 
deletion [180].  This study demonstrated the utility of this model to study fundamental questions of 
human TCR selection and development, which we hope to build on to study xenotolerance induction and 
autoimmunity.   
Using humanized mice to understand xenotolerance induction 
Tolerance approaches for xenotransplantation 
Transplantation remains the only curative treatment for organ failure.  Unfortunately, there are far 
more people who need or would benefit from organ transplantation that there are available transplantable 
organs.  Currently over 100,000 people are waiting for a life-saving organ transplant in the United States 
alone [25].  Additional sources of transplantable organs are desperately needed.  Fortunately, recent 
progress in pig-to-human xenotransplantation suggests that clinical transplantation of pig organs into 
patients will happen within the next few years.  Significant progress has been made, increasing the 
survival of pig organs in non-human primate transplantation models from minutes to months [23, 181, 
182].  Much of this progress has relied on genetic modifications of the swine donors themselves, 
eliminating certain immune incompatibilities [181, 183]; much of the rest is due to improvements in 
immunosuppressive medications [184, 185].   
However, even with these promising results, long-term life-supporting graft survival has not been 
demonstrated and clinically relevant pig-to-human xenotransplantation might not be possible without 
tolerizing the patient’s immune system to the donor pig.  Even in the longest-running preclinical 
experiments, organ survival has rarely been reported beyond a year or two [186], and typically the pig 
organ has shown signs of rejection by the time of removal from the transplanted primate [187, 188].  
Transplanting grafts not expected to survive longer than two years may not be justifiable in patients.  




immunosuppression have been remarkably promising in laboratory settings, it is quite possible that this 
level of immunosuppression will not be tolerable for a future patient.  Levels of immunosuppression 
currently used for human-to-human allotransplantation often come with severe side effects and leave 
patients vulnerable to infections and cancer [22, 189, 190], and the levels needed to control the human 
anti-pig response would likely be even more extreme.  Problems that pose a major barrier to human-to-
human allotransplantation, including the high incidence of chronic rejection that is thought to be the result 
of a delayed immune reaction to antigenic differences between the donor and recipient [191-193], are 
likely to present even more significant problems when the donor and recipient are of different species.  
Finally, the genetic and immunological differences between pigs and humans are substantial and may not 
be fully predicted by non-human primate models, meaning that immunological barriers may arise in 
clinical xenotransplantation that were not predicted in primate models.  Rather than risk immune rejection 
of the transplanted pig organ on one hand and profound patient immunological vulnerability on the other, 
approaches to xenotransplantation that induce immunological tolerance in the recipient patient to the 
donor swine organ would be preferable.   
Over many decades of studies, our lab and others have established two approaches to induce 
immunological tolerance that have shown efficacy in preclinical models.  These are induction of mixed 
chimerism and xenogeneic thymus transplantation.  Studies performed in non-human primates by our 
collaborators are adapting these approaches for clinical use and have shown considerable promise.  
However, approaches to induce tolerance in a patient to a pig organ will require extensive interventions 
on the patient’s immune system.  Questions remain about how these approaches will tolerize the patient’s 
T cell compartment and whether they will leave that patient with a functional immune system.  
Experimental systems that allow studies on how these approaches affect the development of human T 





Mixed chimerism for xenotolerance induction 
Mixed chimerism is the oldest known and most robustly-tested approach to generating immune 
tolerance.  It was initially observed in studies of male and female twin cows that shared a placenta during 
fetal development and demonstrated immunological tolerance to each other [194].  It was later determined 
that tolerance could be accomplished by injecting material from one mouse strain into a developing 
embryo of another strain [195].  Nearly a century later, mixed chimerism induction has become the only 
approach to immune tolerance induction that has shown clinical efficacy [196-198].  Therefore, induction 
of mixed xenogeneic chimerism is likely to be part of future clinical xenotransplantation.  Studies in our 
laboratory have shown that mixed chimerism induction can tolerize B cells [199] and NK cells [8, 200] as 
well as T cells [47, 201].   
T cell tolerization in mixed xenogeneic chimerism is typically thought to occur via a central tolerance 
mechanism.  In small animal models, deletion of mouse T cells depended on the presence of rat class II 
MHC positive cells in the mouse thymus [202].  These hematopoietically-derived class II MHC positive 
cells were relatively short-lived, and as these cells turned over naturally, murine T cells that had 
previously been deleted reappeared [202].  Mixed chimerism induction tends to be transient in current 
non-human primate and large animal studies [198, 203-205].  This would mean that clinical tolerance 
approaches to xenotransplantation would likely need to incorporate additional steps to ensure that patient 
T cells continue to be tolerized to pig antigens even after mixed chimerism has faded.  So far, the most 
promising additional approach is co-transplanting patients with a porcine thymus graft.  In this system, 
the transplanted swine thymus would be able to continue selecting swine-tolerant T cells even after mixed 
chimerism was lost. 
Swine thymus transplantation 
Studies in pig-to-mouse and pig-to-humanized mouse models have demonstrated that xenogeneic 
thymus transplantation robustly tolerizes T cells to pig [206-209].  In the pig-to-humanized mouse model, 




subrenally-grafted pig thymus fragment, and those T cells can populate the periphery of recipient mice 
[209].  These T cells have a very diverse TCR repertoire by spectratyping [210].  Preclinical efforts to 
incorporate thymus transplantation in pig to non-human primate studies have also shown promise [181, 
211].  Therefore, swine thymus transplantation is a robust and effective technique for inducing lasting 
immunological tolerance to a donor pig and will likely be a component of clinical xenotransplantation. 
Maintenance of immune function in pig thymus transplantation 
The effective tolerization and apparent normality of human T cells developing in a pig thymus in the 
pig-to-humanized mouse model is very promising.  However, more work is needed to ensure that a 
transplanted pig thymus can support the development of a human TCR repertoire that mounts robust 
human-restricted immune responses, is durably tolerant to the transplanted pig, and is not prone to 
autoimmunity.  Studies in small animal models indicate that TECs are solely responsible for positive 
selection of mouse-restricted TCRs in a pig thymus [7-9], which means TCRs selected in a pig thymus 
may respond less well to mouse MHCs on peripheral APCs.  In the pig-to-mouse model, T cells selected 
on a pig thymus produce a mouse-restricted vaccination response and protect against opportunistic 
pathogens [10-12].  However, in some cases, mouse T cells selected in a transplanted pig thymus could 
cause autoimmunity [212, 213].  This autoimmunity is likely partly due to the absence of mouse tissue 
restricted antigens (TRAs) in a pig thymus, which would ordinarily tolerize developing thymocytes to 
peripheral tissues and generate Tregs with those specificities.  Even TRAs with high homology between 
mouse and pig might not be appropriately tolerized, since these TRAs are unlikely to be expressed on pig 
rather than mouse MHCs; thymocytes selected in a pig thymus would not be exposed to TRA 
peptide/mouse MHC complexes prior to exit to the periphery.  This leads to both incomplete self-
tolerance as well as poor peripheral T cell – and Treg – homeostasis [10-12].  Peripheral T cells, 
especially Tregs, selected based on recognition of pig MHC will typically not encounter selecting MHC 
in a mouse or human periphery and may have a difficult time receiving the survival signals needed to 




this autoimmunity [214].  Similar results were seen in the pig-to-humanized mouse, where human T cells 
selected on swine thymic epithelium (TECs) show peripheral homeostatic defects likely due to the 
absence of selecting MHC in the periphery [4].  Additionally, while human T cells positively selected in a 
swine thymus could mount a human-restricted tetanus vaccination response, it appears to be less robust 
than the one mounted by human T cells selected in a human thymus [7].  If this is true, a future patient 
may have reduced immune function if their T cell compartment is fully selected on swine MHC.  Worse, 
the autoimmunity risk observed in the pig-to-mouse model would be an unacceptable outcome for a 
transplanted patient.  Therefore, we will need to see if immunologically relevant human-restricted TCRs 
can be positively selected in a pig thymus and assess if human T cells bearing autoreactive TCRs are 
adequately tolerized in a pig thymus.  If we find that these TCRs are not selected optimally in a pig 
thymus, we will also need experimental models to test the efficacy of any proposed solutions.   
Studying mechanisms of human xenotolerance induction in mouse models 
As efforts continue to move these approaches into preclinical and clinical development, it will be 
important to understand the immunological mechanisms by which these approaches for xenotolerance 
induction tolerize human T cells.  It is likely that ideal human xenotolerance would be achieved largely by 
deletional mechanisms but would also produce a reasonably robust population of human swine-reactive 
Tregs.  In mouse models of allogeneic tolerance induction by mixed chimerism, differences in protocols 
induced tolerance via different mechanisms or with different kinetics, depending on the 
immunosuppressive medications used [215, 216], the immune cell depletion strategies employed [217], or 
even the bone marrow cell dosage used to induce chimerism [218].  Mouse models of tolerance induction 
by mixed chimerism sometimes showed that specific cell populations were required to induce or maintain 
T cell tolerance [219], including, for example, donor class II MHC positive cells in the thymus, which 
would need to be maintained and renewed to continue tolerizing patient T cells [202, 220].  Meanwhile, in 
clinical combined kidney and bone marrow transplantation, which uses transient mixed chimerism to 




that both clonal deletion and Treg expansion contribute to tolerance [221, 222].  It would be important to 
know if current proposed strategies for clinical xenotolerance induce both deletional and regulatory 
tolerance, and to be sure we know what is required for both mechanisms of tolerance to be induced.  
Additionally, it will be important to assess how these approaches tolerize human T cells specifically, 
since immunological processes in mice and humans can be quite different.  Approaches for xenogeneic 
tolerance induction that have worked well in mice have not always effectively tolerized human cells [4].  
Additionally, human and mouse cells seem to have meaningful differences in their ability to interact 
immunologically with pig cells, as evidenced in part by the fact that peripheral human CD8+ T cells are 
detected in humanized mice transplanted with a pig thymus but murine CD8+ T cells do not appear in 
immunocompetent mice transplanted with a pig thymus [206, 210, 223]. 
Thus, it will be vital to understand how xenotolerance induction protocols we are pursuing will 
tolerize and maintain tolerance of human T cells.  To accomplish this we will need in vivo experimental 
models to more thoroughly investigate mechanisms by which various approaches to xenotolerance 
induction tolerize human pig-reactive T cells specifically, to assess how robust and lasting these 
approaches are, and to verify that we know all of the pieces required to make these approaches work 
reproducibly.  Preliminary work in the lab has suggested that human T cells selected in a pig thymus are 
tolerized via a combination of deletional and regulatory mechanisms [7].  However, the conclusions 
drawn from these experiments relied upon characterization of bulk populations of T cells, without being 
able to tell with certainty how the xenotolerance approaches used had selected or shaped that population.  
Incorporating xenoreactive TCRs with known properties into the TCR Tg mouse model could allow us to 
study their selection and tolerance.  We could use this system to address important questions that remain 
about how human xenotolerance induction works to tolerize human T cells. 
Using humanized mice to understand autoimmunity 
While autoimmune diseases are relatively and increasingly common, the existence of autoimmune 




thymus and the periphery are dedicated to preventing autoimmune attack on target organs, and yet, 
somehow, these mechanisms fail, with devastating clinical consequences.  Better understanding the 
factors that lead to the initiation of human autoimmunity – including T cell-mediated autoimmunity like 
that which characterizes T1D – might help us develop ways to reduce the incidence of these diseases or 
develop mechanisms to reduce the damage they cause.  In a disease like T1D, predicting or detecting 
disease onset would be very valuable.  Currently, it is typically diagnosed after severe attack on the 
patient’s pancreatic  cells has occurred, leaving them dependent on exogenous insulin for life.  
Understanding what steps lead to autoimmune attack on the  cells could help identify biomarkers, 
diagnostic tools to detect these early events to permit clinical intervention before disease commences or 
damage has reached a point of no return.  To facilitate these studies, we have developed experimental 
systems to study how human tolerance to self-antigens, including those relevant to T1D, fails in the 
thymus.  We have also developed a patient-derived humanized mouse model to assess differences 
inherent to the immune systems of patients with autoimmunity compared to those of healthy controls with 
the same HLA disease risk alleles.  This is a valuable model, but mice transplanted with CD34+ cells from 
adults with T1D have yet to develop overt immune attack on their -cells, suggesting that some aspect of 
T1D initiation is missing in this model.  We have observed that mice transplanted with aBM have reduced 
APC maintenance at late time-points compared to other humanized mouse models, which could 
contribute to the lack of autoimmunity seen in these animals.  In utilizing these models, we are 
developing ways to understand how both central and peripheral mechanisms of human T cell tolerance 
may contribute to the pathogenesis of T cell-mediated autoimmunity.    
Selection of autoreactive TCRs 
Relatively little is known about how autoreactive TCRs escape thymic selection, even in mouse 
models, although it largely seems to occur when alterations in protease or AIRE expression in the thymus 
limit the repertoire of self-peptides that can be presented to tolerize developing thymocytes.  Evidence in 




tolerance contribute to the risk of developing T1D [224-229].  Most of these mutations seem to reduce 
expression of insulin in the thymus or impair other mechanisms of self-antigen presentation such as those 
associated with autophagy [229, 230].  However, even healthy humans have autoreactive TCRs in their 
periphery [231-233], so the mechanisms by and the efficiency with which autoreactive human TCRs are 
tolerized remains relatively unknown.  Additionally, many of the well-known pathogenic TCRs that have 
been identified in autoimmune disease recognize unusual antigens.  For instance, the insulin B9:23 
peptide, which is known to be an important target in T1D disease initiation in both mice and humans 
[234-238], is also known to bind weakly to HLA-DQ8, the MHC molecule on which it is presented.  
Because the protein binding cleft on class II MHC is less restricted than that of class I MHC, antigens like 
B9:23 can bind to the MHC in multiple registers, some of which may not be well recapitulated in thymic 
antigen presentation [238].  Therefore, this target antigen and others like it may simply not be sufficiently 
presented in the thymus to mediate efficient central tolerance induction.  Assessing whether and how 
human autoreactive TCRs are tolerized in a human thymus – and what prevents them from being tolerized 
– would be helpful for understanding the immunological origins of T cell-mediated autoimmunity. 
A recent study using a TCR Tg humanized mouse model demonstrated deletion of a human TCR with 
known properties when expression of its cognate antigen was enforced in non-stromal thymic APCs in a 
transplanted human thymus [180].  We have instead studied the selection of a naturally-occurring 
autoreactive TCR in an unmodified human thymus.  We have used the TCR Tg humanized mouse model 
to study selection of a human TCR that is restricted to a high-risk HLA allele and that recognizes the 
insulin B9:23 peptide.  The TCR, known as Clone 5, has also been shown to mediate immune attack on 
the mouse pancreas in a humanized mouse model [172].  These factors have made it a very interesting 
initial candidate to study to begin understanding how human autoreactive TCRs are selected and 
tolerized.  The study described here is done at a relatively small scale, but hopefully provides a proof of 




of the selection environment to see if perturbations can further disrupt tolerization of T cells with 
autoreactive TCRs.  
Using humanized mice to study patient immune systems 
Genome-wide association studies and other evidence in humans suggest that peripheral interactions 
between human T cells and APCs and peripheral tissues are also important for preventing T cell-mediated 
autoimmunity.  Patients treated with checkpoint inhibitors for cancer have been known to develop T1D 
[239, 240], suggesting that peripheral tolerance mechanisms like those mediated by PD1 interaction with 
PDL1 and PDL2 help maintain peripheral tolerance to target organs like the insulin-producing β cells.  
Other perturbations of peripheral T cell homeostasis, including lymphopenia, can often precede 
development of autoimmunity [241], suggesting that carefully-balanced immune mechanisms prevent 
development of overt autoreactivity. 
We have observed differences in B cell repopulation in immune systems reconstituted with CD34+ 
cells from patients with T1D compared to healthy controls, as well as reduced central deletion of 
autoreactive B cells [10].  This suggests that differences in immune cell development, maintenance, and 
tolerance could be a hallmark of a T1D-prone immune system.  So far, though, transplantation with T1D 
bone marrow has not led to spontaneous development of autoimmunity.  It is unclear whether this is 
because the patient’s immune system would not spontaneously develop autoimmunity without some sort 
of perturbation, or if it is due to a deficiency in the humanized mouse model itself.  So far only one report 
exists of a patient-derived immune system that gave rise to fulminant autoimmunity, in mice transplanted 
with bone marrow from a patient with IPEX, a genetic disease that leads to a complete loss of Treg 
immune suppression [242].  This is a much more major perturbation than is typically seen in patients with 
T1D; IPEX is normally fatal in infancy, while the combination of genetic risk factors that lead to T1D 
generally manifest later in childhood or adolescence.  It is possible that overt T1D only develops after an 
immunological insult, such as lymphopenia due to a viral infection.  The patient-derived mouse model 




However, the observation that human APC repopulation is largely suboptimal in humanized mice 
[110], suggests we cannot rule out the idea that optimizing the patient-derived model on its own would 
lead to more reliable development of T cell-mediated autoimmunity.  To ensure that, we have worked to 
better understand how APCs are reconstituted in mice transplanted with aBM CD34+ cells and have 
explored ways to improve it.  We hope by this to better model an individual patient’s immune system in 
an experimentally tractable mouse model. In the meantime, because TCR transgenic selection studies use 
mice transplanted with fragments of the desired thymus, humanized mouse and TCR transgenic 
humanized mouse models are likely appropriate for studying normal human thymocyte development.  
Because the complete desired niche for thymocyte development can be provided via transplantation, this 
approach likely faithfully recapitulates what would happen to human thymocytes under the same 
conditions.  These models allow us to study human T cell development while we continue optimizing 
models to more faithfully recapitulate human peripheral T cell homeostasis and function. 
In the next pages, we will describe our efforts to study human TCR development in transplanted 
humanized mouse systems, addressing questions of immune function, xenotolerance induction, and 
autoimmunity.  This, coupled with studies to expand and improve human HSC and APC engraftment, 
especially in a patient-derived personalized immune mouse model, will hopefully provide tools that can 







CHAPTER 2:  RESEARCH METHODS 
 
Adapted in part from: Nauman G., Borsotti C., Danzl N., Khosravi-Maharlooei M., Li H-W., Chavez É., 
Stone S., Sykes M.  Reduced positive selection of a human TCR in a swine thymus using a humanized 
mouse model for xenotolerance induction.  Under review at Xenotransplantation.   
And 
Nauman G., Danzl N., Lee J., Fu J., Borsotti C., Hölzl M., Dahmani A., Dorronsoro Gonzalez A., 
Chavez E., Satwani P., Liu K., Sykes M. (2019).  Reduced APC progenitor production from adult 




TCR transgenes used in these experiments were encoded in a pHR-EF1α_IRES_GFP_SIN (pHR) 
second-generation lentiviral backbone [243], which, along with the associated packaging vectors, 
consisting of pDelta R8.2 and the pVSV-G pseudotyping vector, were a kind gift from Dr. Remi Creusot.  
pHR_MART1 TCR, which contained an HLA-A2-restricted [Leu27] Melan-A MART1-reactive TCR 
encoded as a transgene [244] was also obtained as a kind gift from Dr. Remi Creusot.  We used the 
MART1 TCR from clone DMF5, and was originally isolated from a population of tumor infiltrating 
lymphocytes [244].  The Clone 5 TCR sequence was provided by Dr. Yong-Guang Yang, and the plasmid 
was originally obtained as a gift from Drs. Maki Nakayama and Bart Roep [237].  The Clone 5 TCR was 
subcloned in-house into the pHR vector.  Constructs were validated using restriction digestion analysis 
followed by Sanger sequencing (performed by Genewiz, South Plainfield, NJ).  The viral packaging 
plasmid was originally described by Breckpot et al. [243].  Dr. Larry Luchsinger had modified the 
Breckpot vector such that the lentiviral insertion is driven by the human EF1α promoter rather than the 
CMV promoter, to avoid silencing in transduced HSCs [245-247].  The human EF1α promoter was used 
because it is constitutively expressed and not silenced in human HSCs [248, 249].   
The TCR transgenes were arranged with the TCRα sequence followed by the TCRβ sequence 




eGFP expression reporter   Using this transgene design we observed eGFP protein expression in 
transduced cells but only detected surface expression of TCRs on cells that also expressed CD3, as shown 





Figure 2 - 1: Lentiviral transgenesis of the TCR construct gives appropriate expression of eGFP reporter 
in transduced cells but surface TCR expression is detected only on CD3+ cells. 
a. JRT3-T3.5 Jurkat cells are TCRβnull, and do not express surface MART1 TCR, TCRαβ, or CD3, but b. JRT3-
T3.5 cells that have been lentivirally transduced with the MART1 TCR construct express eGFP and stain 
positive for MART1 tetramer and TCRαβ, and TCRαβ staining correlates with CD3 staining.  c. GFP expression 
is detected in HEK-293 FT cells transduced with the MART1 TCR lentivirus, but surface MART1 tetramer 
staining, TCRαβ and CD3 staining are not detected.  d.  Human splenocyte staining of humanized mice 
transplanted with MART1 TCR-transduced HLA-A2+ fetal liver CD34+ cells and co-transplanted with an HLA-





Plasmids were propagated in OneShot Stbl3 Chemically Competent E. coli (ThermoFisher Scientific, 
Waltham, MA) and isolated using Endotoxin-free Maxi-Prep and Mega-Prep kits (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions.  All plasmid stocks were periodically validated 
using restriction digest assays to confirm identity and prevent contamination. 
Virus was produced in HEK293 FT cells.  HEK293 FT cells were propagated in high glucose 
Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich, St. Louis, MO) with 10% heat-inactivated fetal 
bovine serum (FBS, Gemini BioProducts, West Sacramento, CA), 2mM L-glutamine (Gibco 
Laboratories, Gaithersburg, MD), and Penicillin-Streptomycin (ThermoFisher Scientific).  HEK293 FT 
cells were seeded to poly-D-lysine-coated (poly-D-lysine hydrobromide, Sigma-Aldrich) plates, then 
transfected with viral plasmids using Lipofectamine 2000 according to the manufacturer’s instructions 
(ThermoFisher Scientific).  Forty-eight hours post-transfection, supernatants were harvested, filtered 
through a 0.45µm filter (ThermoFisher Scientific) and concentrated 100x by ultracentrifugation, then 
flash frozen and stored at -80⁰C prior to use.  Supernatant titer was determined by transducing HEK 293 
FT cells using serial dilutions of freeze-thawed virus.  Titer was calculated based on the number of cells 
that were GFP+ after transduction with a given volume of virus, adjusted for dilution.  Titers were 
assessed 96 hours after transduction; it was determined empirically that this time was required to allow 
full expression of the TCR-GFP construct. 
Transduction of fetal liver-derived CD34+ cells 
Prior to transduction, human fetal liver CD34+ cells were thawed and pre-stimulated in retronectin-
coated plates (25μg/mL, Clontech, Mountain View, CA) by incubation in stem cell medium with 
cytokines for 3 hours.  All incubations were performed at 37°C and 5% CO2.  Stem cell medium with 
cytokines consisted of Stemline II medium (Sigma-Aldrich, St. Louis, MO) with 10μg/mL protamine 
sulfate (Sigma-Aldrich) and 60ng/mL, 300ng/mL and 150ng/mL recombinant human IL-3, Stem Cell 




least 13 hours) at a multiplicity of infection of 30 (30 MOI) for the MART1 TCR lentivirus, or 50 MOI 
for Clone 5 lentivirus.  Much higher transduction efficiency was seen using GFP only virus, so GFP only 
transductions for a given experiment were performed using one-tenth of the MOI used for the TCR virus.  
After transduction, cells were harvested and prepared for intratibial injection.  In some cases, more CD34+ 
cells were transduced than could be injected intratibially.  In this case, additional cells were transplanted 
intravenously. A small number of transduced CD34+ cells were cultured in stem cell medium with 
cytokines but without protamine sulfate for 96 hours, then assessed for transduction efficiency by flow 
cytometry.   
In vitro TCR characterization  
Jurkat and JRT3-T3.5 culture 
Jurkat cells, an immortalized human T cell line, and JRT3-T3.5 cells, a variant of Jurkat cells that do not 
express TCRβ [250, 251] were received from the laboratory of Dr. Yong-Guang Yang.  Cell lines were 
cultured in CML medium, which consisted of RPMI 1640 (Thermo Fisher Scientific) supplemented with 
10% heat-inactivated fetal bovine serum (FBS, Gemini BioProducts), 10mM HEPES (Gibco, 
Gaithersberg, MD), 20mM L-glutamine (ACROS Organics, Geel, Belgium), 1mM sodium pyruvate 
(Fisher BioReagents, Fair Lawn, NJ) and 0.2% 2-Mercaptoethanol (MP Biomedicals, LLC, Santa Ana, 
CA).  Cell lines were cryopreserved in 90% FBS and 10% dimethyl sulfoxide (DMSO, Sigma Aldrich). 
Transduction of JRT3-T3.5 lines 
Typically, 1x105 JRT3-T3.5 cells were transduced with 1-10μL of concentrated, unfrozen viral 
supernatant in medium containing 10μg/mL total protamine sulfate (Sigma-Aldrich).  Transduction was 
performed overnight (12-18 hours), after which JRT3-T3.5 cells were diluted in complete RPMI without 
protamine sulfate.  After approximately 96 hours, transduced cells were assessed by flow cytometry for 




TCR characterization assay  
TCR-transduced JRT3-T3.5 cells 
were incubated with desired 
stimulators.  Controls, which were 
exposed to medium alone or plate-
bound OKT3 (1μg/mL, 
eBiosciences, San Diego, CA) and 
soluble anti-CD28.2 (Biolegend, San 
Diego, CA), were included in every 
in vitro TCR characterization assays.  
After 5 days, reaction supernatants 
were harvested and frozen at -20°C, 
then assayed for IL-2 production by 
proliferation of CTLLs, an IL-2-sensitive murine lymphoma cell line [252, 253].  CTLL proliferation was 
assayed by incorporation of tritiated thymidine (Perkin Elmer, Waltham, MA).  CTLLs were maintained 
in complete RPMI containing 20U/mL recombinant IL-2 (NIH AIDS Reagent Program, Bethesda, MD).  
CTLLs were conditioned by culturing for approximately 60 hours to allow depletion of IL-2 and prior to 
incubation with thawed supernatants for approximately 24 hours.  Wells containing CTLLs and 
supernatant were pulsed with tritiated thymidine for 12-15 hours and then harvested to fiberglass plates 
(Perkin Elmer), which were air dried, saturated with Ultima Gold liquid scintillation cocktail (Perkin 
Elmer) and read using a 1450 Microbeta counter (Perkin Elmer).  This assay could be used to detect 
Jurkat IL-2 response to polyclonal stimulation, as shown in Figure 2 - 2.  TCRnull JRT3-T3.5 cells do not 
respond to polyclonal stimulation.  To correct for any IL-2 production by irradiated stimulators in some 
assays, IL-2 production of antigen-stimulated JRT3-T3.5 cells transduced with the TCR of interest was 
Figure 2 - 2: Detection of T cell response in vitro by measuring IL-2 
secretion by CTLL proliferation. 
IL-2 in CML medium only, or in supernatants of TCRnull JRT3-T3.5 
cells or wild type Jurkat cells cultured with medium or with 
αCD3/αCD28 stimulation, as measured by tritiated thymidine 




compared to IL-2 production by JRT3-T3.5 cells under the same stimulation condition, calculated as fold 
IL-2 production of TCR Tg JRT3/TCRnull JRT3-T3.5 cells. 
In vitro TCR characterization assay development and validation 
Stimulators for TCR characterization assays were typically human or swine peripheral blood 
mononuclear cells (PBMCs), which had been irradiated with 35Gy X-ray irradiation, although in later 
work we demonstrated that the in vitro TCR characterization assay was also compatible with monocyte-
derived DCs. 
For MART1 TCR reactivity assays, stimulators were pulsed with the indicated concentration of 
MART1 peptide, the [Leu27] Melan-A MART 1 (26-35) ELAGIGILTV peptide (Anaspec, Fremont, 
CA), as described.  Peptide pulsing was performed simultaneously to responder addition. 
We observed in some cases that irradiated stimulators alone could produce measurable IL-2 in this 
assay system, as shown in Figure 2 - 3.  This 
was observed particularly when multiple 
irradiated stimulators were mixed.  This 
backstimulation by irradiated cells has been 
observed previously [254, 255].  However, IL-2 
production by irradiated stimulators can lead to 
artifactual or misleading results.  To avoid this 
problem, we did not perform assays involving a 
mix of multiple irradiated stimulators.  
Additionally, the observation of 
backstimulation led us to calculate TCR 
response as the fold change of TCR Tg 
Figure 2 - 3: Irradiated stimulators can secrete IL-2 that 
is detectable by CTLL proliferation. 
A mixture of 35Gy X-ray irradiated human and swine 
PBMCs produces detectable IL-2 to levels comparable to 




cpm/TCRnull JRT cpm under the same stimulator conditions. 
Animals and human tissues and cells 
NOD/SCID IL2Rγko (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, NSG [256]) and NSG mice Tg for human 
HLA-A2 or HLA-DQ8 were obtained from Jackson Laboratory (Bar Harbor, ME).  NSG mice transgenic 
for porcine IL-3, GM-CSF, and SCF (pig cytokine transgenic, or PCT, mice) [47] were regenerated from 
frozen embryos at Jackson Laboratory (Bar Harbor, ME).  Animals were crossed in our facility to 
generate HLA-A2 and/or PCT Tg mice.  Mice were bred, maintained, and housed in microisolator cages 
in a Helicobacter, Pasteurella pneumotropica and Specific Pathogen Free (HPPF) animal facility.  All 
human fetal liver tissues (gestational age 17-21 weeks) were obtained from Advanced Biosciences 
Resource (Almeda, CA).  
Fetal thymus and liver were prepared as previously described [48].  Briefly, fetal thymi were 
processed to 2x2x2mm fragments and cryopreserved in 10% DMSO and 90% human AB serum (Gemini 
Bio-Products, Sacramento, CA).  Single cell suspensions were generated from fetal livers by Liberase 
digestion (Sigma-Aldrich, St. Louis, MO).  Adult bone marrow cells (aBM) were isolated from healthy 
adult volunteer bone marrow aspirates or from discarded human bone marrow infusion filters obtained 
from the Columbia University Irving Medical Center (CUIMC) Department of Pediatrics.  For both fetal 
liver and adult bone marrow samples, CD34+ cells were isolated using positive selection by magnetic-
activated cell sorting (MACS) and anti-human CD34+ microbeads according to the manufacturer’s 
instructions (Miltenyi Biotec, Bergish Gladbach, Germany).  Allele-level molecular HLA typing of fetal 
tissue was performed using Sanger sequencing to identify HLA-A2+ and HLA-A2- fetal liver and thymus 
tissue, or to facilitate partial HLA-matching between aBM CD34+ cells and fetal thymus tissue.  Human 
CD34+ and CD34 negative fractions and human fetal thymus fragments were cryopreserved in 10% 




Swine thymus tissue was provided from the Massachusetts General Hospital/Columbia University 
SLA-defined miniature swine herd generated by Dr. David H. Sachs.  Swine thymi were harvested from 
fetuses (60-90 days gestational age), processed, and cryopreserved as described [7].   
The use of human tissues and cells and animals were approved by the CUMC Institutional Review 
Board and Institutional Animal Care and Use Committee, respectively. 
MSC Culture 
Mesenchymal stem cells (MSCs) were prepared from CD34-negative human aBM cells, obtained as 
described above.  MSCs were cultured in low-glucose Dulbecco’s Modified Eagle’s Medium (Sigma-
Aldrich) supplemented with 10% fetal bovine serum (Gemini), 10,000 units/mL each penicillin and 
streptomycin (Thermo Fisher Scientific, Waltham, MA), and 200mM L-glutamine (Thermo Fisher) for 
about two weeks, until confluent, then detached using 0.25% trypsin-EDTA (Thermo Fisher).  MSC 
phenotypic identity was verified by flow cytometric analysis as previously described [257] and MSCs 
were cryopreserved in 10% DMSO (Sigma-Aldrich) and 90% human AB serum (Gemini) prior to use.  







As previously reported [258, 259] and as 
shown in Figure 2 - 4, human thymopoiesis can 
occur in the native mouse thymus in transplanted 
NSG mice.  Thymopoiesis in sites other than the 
grafted thymus fragment can complicate the 
interpretation of human TCR selection studies.  
To avoid this, members of our lab developed an 
approach to surgically remove the mouse thymus 
from animals prior to transplantation [258].  5-8-
week-old mice were anesthetized, and their limbs 
were gently restrained using rubber bands. A 
midline skin incision was performed in the 
thyroidal region. Skin was gently pulled aside, 
and the thyroid gland mobilized by blunt dissection. By inserting a 0.8mm curved Iris forceps (World 
Precision Instruments, Sarasota, FL), the sternum was elevated from the pleura and the mediastinal cavity. 
A second 0.8mm forceps was inserted and the left thymic lobe (usually anterior superior) was grabbed 
and pulled out of the pleural cavity, then the right thymic lobe (usually posterior inferior) was grabbed 
using the first 0.8mm curved Iris forceps. Thymic lobes were detached from the connective tissue and 
removed. Special attention was given to avoid injury to large vessels in this region to avoid 
pneumothorax.  The skin was closed with staples (9mm autoclips, SAI Infusion Technologies, Lake Villa, 
IL) and mice were allowed to recover.  The thymectomy procedures described in this work were 
performed by Dr. Mohsen Khosravi Maharlooei. 
Figure 2 - 4: The native mouse thymus supports robust 
human thymopoiesis.  Human and murine CD45 and CD4 and 
CD8 staining of cells from a. the native thymus rudiment in 
unthymectomized mice or b. the anterior mediastinum of 






8-16-week-old mice were anaesthetized and transplanted with fragments of human or porcine fetal 
thymi under the renal capsule, typically using a midline incision surgical approach.  Subrenal thymus 
grafting described in this work was performed by Dr. Nichole Danzl or Dr. Hao-Wei Li. 
Grafted thymus fragments were depleted of pre-existing thymocytes prior to subrenal grafting.  2mm x 
2mm x 2mm fetal thymus fragments were cryopreserved in 90% human AB serum and 10% DMSO, as 
described above.  Cryopreservation reduces the pre-existing thymocyte burden by 1,500 fold [9].  Thymus 
fragments were thawed, washed three times in Medium 199 (Fisher Scientific) supplemented with 1% 
bovine DNaseI (Sigma-Aldrich) and 4µg/mL Gentamicin (Thermo Fisher Scientific).  Thymus fragments 
were agitated by pipetting to remove any remaining thymocytes prior to subrenal grafting, as described 
[9].  To remove any remaining pre-existing thymocytes, mice were treated with an anti-CD2 antibody 
[260] intravenously to deplete T cells remaining emerging from the grafted thymus, in two doses of 
0.4µg/mouse on the day of transplantation and seven days post-transplantation as previously described 
[9].   
Intratibial injection 
To create space for stem cell transplantation, a 26-gauge 3/8-inch sterile disposable needle (Fisher 
Scientific, Waltham, MA) was used to penetrate the knee joint surface of anesthetized mice, through the 
patellar tendon, and inserted into the tibia or femur bone marrow cavity. The 26-gauge needle was 
removed and a 27-gauge Hamilton microsyringe (Hamilton Company, Reno, NV) containing human 
CD34+ cells in a volume of 10-20µL was inserted into the preformed cavity.  The HSCs were injected 
into the bone marrow cavity, and the needle removed.  
TCR transgenic humanized mouse transplantation 
Mice were surgically thymectomized and allowed to recover for at least two weeks, then irradiated 




Suwanee, GA).  Mice were then transplanted with a fragment of human fetal thymus under the kidney 
capsule, and 2-5x105 lentivirally-transduced CD34+ cells were injected intratibially.  In some cases, 
additional transduced cells were transplanted intravenously.  
Transplantation of Hu/Hu and PI mice 
Fetal liver CD34+ cells (FLC)-transplanted Hu/Hu and aBM-transplanted Personalized Immune (PI) 
mice were generated as previously described [9, 10, 47]. Briefly, 6-12-week-old immunodeficient mice 
were received 1-2Gy TBI, as described above.  Mice were then transplanted with a fragment of human or 
swine fetal thymus, as applicable, under the renal capsule, and with 1-3x105 CD34+ cells injected either 
intravenously or intratibially as indicated.  
Secondary transplantation 
In secondary transplantation experiments, whole bone marrow was obtained from aBM-transplanted 
animals, which were euthanized 22-30 weeks post-CD34+ cell transplant.  Tibias and femurs from hind 
legs were harvested and crushed using a mortar and pestle under sterile conditions.  Cell isolate was 
dispersed with a 19-gauge needle and filtered through a 70µm nylon filter (Falcon, Corning, NY).  T cells 
were depleted from mouse bone marrow using a magnetic bead-based human CD3 depletion kit according 
to the manufacturer’s instructions (Miltenyi Biotec).  Six-week-old female NSG mice conditioned with 
1.5Gy TBI were injected intravenously with 1-2x107 T cell-depleted total bone marrow cells from the 
primary recipients.  Peripheral blood chimerism was monitored every two weeks post-transplantation.    
In some mice, human aBM CD34+ cells were treated for two hours with prostaglandin E2 (PGE2) 
(Cayman Chemicals, Ann Arbor, MI) or with a DMSO vehicle control prior to the primary 
transplantation.  PGE2 treatment has been shown to support expansion of HSCs [261] but did not 
consistently improve human chimerism in our hands or seem to affect secondary repopulation in the 




Analysis of engrafted human cells 
Monitoring peripheral blood chimerism 
Human chimerism in peripheral blood of transplanted mice was monitored biweekly, beginning 3 to 6 
weeks post-transplantation.  For secondary transplantation experiments, the initial peripheral chimerism 
check was performed 2 weeks post-transplant.  Approximately 100μL of whole blood was collected by 
tail vein puncture. PBMCs were isolated from peripheral blood by density gradient separation using 
Histopaque 1077 (Sigma Aldrich) for flow cytometric (FCM) analysis.   
Thymus and peripheral tissue processing 
Humanized mice transplanted with fetal liver or aBM CD34+ cells were euthanized 22-25 weeks post-
transplant. TCR-transduced humanized mice were euthanized at 10-16 weeks post-transplant. Because 
human T cells typically emerge in transplanted animals between 10-14 weeks post-transplant, we expect 
peak thymopoiesis at 12-16 weeks post-transplant, so this earlier time-point was chosen for optimal 
analysis of thymopoiesis.  
At harvest, blood was collected by cardiac puncture, and spleens, grafted thymus, residual anterior 
mediastinum, and bone marrow were collected. Spleens were crushed to make a single cell suspension, 
which was passed through a 70μm nylon filter and treated with Ammonium-Chloride-Potassium (ACK) 
lysis buffer (Life Technologies, Carlsbad, CA) prior to counting and staining.  Single-cell bone marrow 
suspensions from the tibia and femur were prepared by crushing using a mortar and pestle, counted, and 
stained for FCM. Grafted thymi were dissected from kidneys and crushed to single cell suspension, and 
residual tissue in the anterior mediastinum was collected and processed to single cell suspension to verify 
removal of the mouse native thymus.  Animals that showed residual thymopoiesis in the mouse native 




Flow Cytometric (FCM) analysis 
FCM data were acquired in the Columbia Center for Translational Immunology Flow Core. Data were 
collected using a BD FACSCanto, a BD LSRII or a BD Fortessa cytometer and analyzed using FlowJo 
(TreeStar, Ashland, OR). 
Table 1: List of reagents used for FCM analysis 
Reactivity/Reagent Target Fluorochrome Clone Source 
Mouse CD45 BV711 30-F11 BD Biosciences 
Mouse CD45 APC-Cy7 30-F11 BD Biosciences 
Mouse Ter119 PE-Cy7 TER-199 BD Biosciences 
Human CD45 PE-CF594 H130 BD Biosciences 
Human CD45 V500 H130 BD Biosciences 
Human CD19 BV650 HIB19 BioLegend 
Human CD19 APC HIB19 BioLegend 
Human CD3 PerCP-Cy5.5 SP34-2 BD Biosciences 
Human CD3 BV650 OKT3 BioLegend 
Human CD14 APC 61D3 eBioscience 
Human CD14 PE HCD14 BioLegend 
Human CD14 BV650 M5E2 BioLegend 
Human CD14 Pacific Blue M5E2 BD Biosciences 
Human CD4 BV500 RPA-T4 BD Biosciences 
Human CD4 BUV395 SK3 BD Biosciences 
Human CD8 AF700 RPA-T8 BD Biosciences 
Human CD45RA FITC HI100 BD Biosciences 
Human CD45RA BV510 HI100 BioLegend 
Human CCR7 BV421 G043H7 BioLegend 
Human CD45RO BV711 UCHL1 BioLegend 
Human CD31 BV605 WM59 BD Biosciences 
Human HLA-DR BV605 G46-6 BD Biosciences 
Human CD11b APC-Cy7 M1/70 BD Biosciences 
Human CD11c PE-Cy5 B-ly6 BD Biosciences 
Human CD1c PE-Cy7 L151 BioLegend 
Human CD141 VioBlue REA674 Miltenyi 
Human CD123 Pacific Blue 6H6 BioLegend 
Human CD123 Biotinylated 9F5 BD Biosciences 
Human CD303 FITC AC144 Miltenyi 
Human CD34 PE Clone 581 BioLegend 
Human CD34 APC AC136 Miltenyi 




Human CD10 APC-Cy7 H10A BioLegend 
Human CD115 APC 9-4D2-1E4 BioLegend 
Human CD90 PerCP-Cy5.5 5E10 eBioscience 
Human CD1a BV510 HI149 BD Biosciences 
Human CD69 BV650 FN50 BioLegend 
Human CD7 PE-Cy5 CD7-6B7 BioLegend 
Human PD-1 PE-Cy7 EH12.2H7 BioLegend 
Mouse IFNγ FITC XMG1.2 BioLegend 
N/A Streptavidin AF 594 N/A Life Technology 
N/A Streptavidin PE-Cy7 N/A BD Biosciences 
Human αβ TCR PE IP26 BioLegend 
Human TCR-Vβ21.3 FITC REA894 Miltenyi 
N/A Anti-FITC APC NAWESLEE eBioscience 
 
Detection of MART1 TCR+ cells 
MART1 TCR+ cells were detected using the MART1 MHC tetramer A*02:01 – ELAGIGILTV 
(Proimmune, Oxford, UK).   
Detection of Vβ11+ cells for Clone 5 selection experiments 
No tetramer is currently available to detect the Clone 5 TCR, so we detected Clone 5 TCR+ cells by 
staining for the Clone 5 TCR Vβ, which is Vβ11.  Due to limited reagent availability, we only had access 
to FITC-labeled anti-Vβ11.  To distinguish GFP signal from anti-Vβ11 signal, we used an anti-FITC APC 
Figure 2 - 5: Clone 5 TCR detection approach. 
Clone 5 transduced cells were detected by staining with αVβ11-FITC followed by an αFITC-APC secondary 
antibody, as shown in a.  Using Clone 5 TCR transduced Jurkat cells, we examined b. GFP/Vβ11-FITC 





antibody as a secondary reagent, as diagramed in Figure 2 - 5.  This approach allowed us to detect Vβ11+ 
GFP+ cells, which would include Clone 5 Tg T cells.  
Cloning pig-reactive TCRs  
Limiting dilution cloning 
To identify human pig-reactive T cells, we stimulated human PBMCs with irradiated swine PBMCs 
prior to performing limiting dilution cloning.  Freshly isolated human PBMCs were mixed 1:1 with 35Gy 
irradiated swine PBMCs from either SLA-CC or SLA-DD miniature swine.  Stimulation was performed 
using T cell medium, consisting of RPMI 1640 (Thermo Fisher Scientific), 10% human AB serum 
(Gemini Biosciences), 10mM HEPES (Gibco, Gaithersberg, MD), 20mM L-glutamine (ACROS 
Organics, Geel, Belgium), 1% non-essential amino acids (Life Technologies), and 0.2% 2-
Mercaptoethanol (MP Biomedicals, LLC).  After 6 days, wells were supplemented with recombinant 
human IL-2 at 10U/mL (NIH AIDS Reagent Program).  At day 13, wells were restimulated.  35Gy 
irradiated autologous PBMCs and stimulator pig PBMCs were mixed 1:1 for SLA-CC condition and 1.3:1 
for the SLA-DD condition and ~106 of each stimulator was added to the culture wells.  At day 21, pig-
stimulated wells were harvested and cryopreserved for later analysis.   
Limiting dilution analysis was performed on thawed cells.  Cells were diluted to three conditions, 30 
cells/well, 3 cells/well, 0.3 cells/well, similarly to what had been previously described [262].  Each well 
received 2x104 irradiated swine PBMCs of the SLA used in its original stimulation, 9x103 each of 
irradiated huPBMCs from two allogeneic human PBMC donors, and 5ng/mL Phytohemagglutinin (PHA, 
Sigma Aldrich).  Wells were supplemented with recombinant human IL-2 (10U/mL) on day 4.  
Subsequently, wells with growing clones were expanded as needed and supplemented with irradiated 
stimulators and IL-2 as appropriate.  On day 28, clones that showed robust growth were harvested, 




Mixed lymphocyte reactions 
T cell clones were thawed and characterized using a dye-dilution mixed lymphocyte reactions (MLR).  
Responding T cells were labeled with 0.5μM CFSE (Molecular Probes) or eFluor 450 cell proliferation 
dye (eBioscience) according to the manufacturer’s instructions.  To prevent confusing stimulators with 
CFSE low responders, stimulators were labeled with eFluor 670 dye (eBioscience) and irradiated with 
35Gy X-ray irradiation.  Clones and stimulators were mixed at 1:1 and incubated for five days prior to 
harvest and FCM analysis. 
Long-term TCR characterization will require us to determine the restriction of identified TCRs.  We 
intend to determine the MHC restriction of identified TCRs by using MHC blocking antibodies to assess 
which antibodies will abrogate reactivity.  Currently, we have identified and validated antibodies to block 
individual HLA-class II alleles.  These reagents will be useful for determining the class II MHC 
restriction of CD4+ human xenoreactive T cell clones or cloned TCRs.  We have used PBMC MLRs to 
validate anti-HLA-DQ, HLA-DR and HLA-DP reagents that can block class II MHC activation in an 
allogeneic MLR.  These assays were performed as described above, with responder PBMCs labeled using 
eFluor 450 dye and stimulators labeled with eFluor 670 dye per manufacturer’s instructions and irradiated 
with 35Gy X-ray irradiation.  We used the following monoclonal antibodies to block class II MHC-
restricted activity: SPV-L3 to block HLA-DQ; L243 to block HLA-DR; and B7/21 to block HLA-DP, 
respectively (Abcam, Cambridge, UK).  A mouse IgG2a kappa monoclonal antibody C18C8Bc7AD10; 
Abcam) was used as an isotype control.  In some cases, anti-class II MHC antibodies were stored in a 
sodium azide-containing buffer, so dialysis in PBS using the Pierce Slide-A-Lyzer Dialysis Cassette and 
Kit (Thermo Fisher Scientific) for three changes of buffer was necessary prior to use.  Assays were 
harvested at day 6 and assessed by FCM.   
Clone expansion 
To ensure that adequate cells were available for characterization and cloning, we used a protocol 




Briefly, in a V-bottomed 96-well plate (Fisher Scientific), the T cell line to expand is co-cultured with 
7x104 35Gy-irradiated allogeneic PBMCs and 1.5x104 60Gy-irradiated EBV-immortalized B cells, 
100U/mL recombinant human IL-2, and 90ng/mL activating anti-CD3 (OKT3).  Ideally, human 
stimulator cells should consist of cells from two unique allogeneic donors each.  Cultures are 
supplemented with IL-2 every two days and with new irradiated stimulators as appropriate.  This 
expansion protocol allows culture and expansion of human T cells in an antigen-independent manner (Dr. 
Emmanuel Zorn, personal communication).   
Identifying TCR sequences 
TCR Vα and Vβ sequences were identified using the approach described by Wälchli, et al. [264].  T 
cell clones for TCR identification were frozen in Tri Reagent (Life Technologies) at -80°C and RNA was 
isolated according to the manufacturer’s instructions.  Unused RNA was stored at -80°C.  RNA was 
converted to cDNA using the SuperScript III First-Strand Synthesis System kit (Thermo Fisher 
Scientific).  Nested PCR to amplify the TCR variable regions were performed as described [264] using 
primers purchased from Integrated DNA Technologies (Coralville, IA) and Q5 High-Fidelity DNA 
Polymerase (New England BioLabs, Ipswich, MA).  Appropriately-sized bands were isolated by gel 
purification using the illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Chicago, 
IL), then cloned into the NEB PCR Cloning Kit (New England BioLabs) by manufacturer’s instructions.  
Clones were Sanger sequenced (Genewiz) to identify TCR sequences. 
Once appropriate sequences were obtained for the TCR Vα and Vβ of C05, a construct was designed 
in silico to manually place these sequences within the appropriate TCR V family.  We designed a full 
TCR expression construct, consisting of the TCR Vα followed by a P2A skip sequence and the TCR Vβ, 
and including appropriate restriction sites for subcloning into the pHR vector in the multiple cloning sites 
upstream of IRES-eGFP.  This sequence was codon optimized and purchased as a synthetic gBlock from 




approaches.  Appropriate cloning was validated by restriction digestion and Sanger sequencing 
(Genewiz). 
DC generation for indirect characterization assay 
CD209+ DCs were differentiated from human peripheral blood monocytes in RPMI 1640 with 10% 
human AB serum (Gemini Biosciences), 10mM HEPES (Gibco), 20mM L-glutamine (ACROS 
Organics), 1mM sodium pyruvate (Fisher BioReagents).  Human peripheral blood was incubated in a 
tissue culture plate in a 37°C incubator at 5% CO2 for 1.5hrs, after which non-adherent cells were 
removed by washing three times with medium.  Typically, mature DCs were obtained by culture of 
monocytes with 50ng/mL GM-CSF and 20ng/mL IL-4 (Peprotech) for 5 days, feeding with fresh 
cytokines on day 3.  If DCs were intended for use in indirect assays, on day 5 human or swine PBMCs 
were thawed, irradiated at 100Gy, and allowed to undergo apoptosis for 4-6hrs in a tissue culture plate in 
a 37°C incubator at 5% CO2, allowing generation of mostly cell-free antigens that could be pulsed to 
DCs.  After 4-6 hours, immature DCs were harvested and added to apoptotic cells along with GM-CSF 
and IL-4.  After a 12-hour incubation, 1000U/mL TNFα and 3μg/mL PGE2 were added to each well to 
provide maturation stimuli.  Maturation was allowed to occur for 24-30 hours, after which DCs were 
harvested and positively selected for CD209+ cells by MACs isolation using anti-CD209 beads, according 
to manufacturer’s instructions (Miltenyi).  Isolation of CD209+ cells enriches for DCs specifically, 
helping deplete any remaining apoptotic cells.  CD209+ DCs received 30Gy of X-ray irradiation and then 
used as stimulators in appropriate assays.  For peptide-loaded DC assays, maturation and CD209 
enrichment was done in the same way, but appropriate amounts of peptide were added concurrently with 
responder T cells. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism Version 7 (La Jolla, CA) as described.  




Two-way ANOVA analysis between the human immune reconstitution kinetics of FLC and aBM-
reconstituted animals was used to determine if there was an effect of HSC source on frequency of human 
cells. When a significant effect was found by ANOVA (p < 0.05), post-hoc Sidak’s multiple comparison 
analysis was used to compare differences in human peripheral blood chimerism over time.  Two-tailed 
unpaired student t-tests were used to compare proportion and absolute numbers of human APC 
populations.  When the difference in variance between populations was significant (p < 0.05 by F test of 
variance), Welch’s correction was applied.  Two-tailed paired t-tests were used to APC populations 





CHAPTER 3: POSITIVE SELECTION OF A HUMAN-RESTRICTED 
TCR IN A TRANSPLANTED SWINE THYMUS 
 
Adapted from: Nauman G., Borsotti C., Danzl N., Khosravi-Maharlooei M., Li H-W., Chavez É., Stone 
S., Sykes M.  Reduced positive selection of a human TCR in a swine thymus using a humanized mouse 
model for xenotolerance induction.  Under review at Xenotransplantation.   
 
Introduction 
Recent progress in pig-to-nonhuman primate models suggests that human trials of clinical solid-organ 
xenotransplantation from pigs may be imminent [23, 182, 265, 266].  Long-term rejection-free survival of 
a pig organ in a human patient may require induction of tolerance in the recipient human to the swine 
graft [11].  While improved pharmaceutical immunosuppression and genetically engineered swine source 
animals have dramatically increased the survival of porcine organs in non-human primates, xenogeneic 
immune responses are extremely strong [267, 268].  Therefore, the level of immune suppression needed 
to control anti-swine immune responses may be difficult for patients to tolerate, leaving them highly 
vulnerable to infections and neoplasms.  Methods to induce immunological tolerance to the swine organ 
would be optimal for clinical xenotransplantation and would allow both recognition of the transplanted 
pig organ as self while maintaining robustly protective immunological function.   
Inducing T cell tolerance is paramount, as T cells are primary mediators of xenograft rejection [181, 
269-275].  Transplanting a pig thymus can tolerize human T cells to pig antigens [7, 208, 209].  Over the 
past twenty-five years, we have demonstrated that xenogeneic thymus transplantation induces robust T 
cell tolerance across xenogeneic barriers in both pig-to-mouse and pig-to-humanized mouse models [7, 
206-208, 276].  Protocols incorporating swine thymus transplantation in pig-to-non-human primate 
models have shown promising results, with survival of transplanted primates up to 193 days, with no 
signs of graft rejection [181, 211, 277-282].  Swine thymus transplantation allows de novo generation of a 




one of the major benefits of xenotolerance, a transplanted pig thymus must also support selection of a 
human TCR repertoire with robust HLA-restricted immune function.   
Positive selection of developing T cells in the thymus is based on the ability of a TCR to weakly 
interact with selecting antigen presented in the context of MHC present on the surface of cTECs [63, 64].  
Experiments in the pig-to-mouse system have previously demonstrated that swine TECs are exclusively 
responsible for positive selection in a transplanted swine thymus [283-285].  In this model, TCR Tg mice 
were thymectomized, T cell depleted using antibodies, and transplanted with a fragment of fetal pig 
thymus.  When recipient mice were euthanized 13-19 weeks post thymus transplant and swine thymus 
grafts were examined, Tg mouse cells were present at the same frequency in the grafted pig thymus as 
they were in a mouse thymus expressing selecting MHC.  TCR Tg cells were also present in the grafted 
pig thymus in the same frequency in mice that expressed MHCs that did not select the Tg TCR as those 
that did, suggesting that murine thymic stroma did not contribute to positive selection of mouse TCR 
transgenes in a grafted pig thymus [285].  Despite exclusive positive selection on swine MHC, robust 
mouse-restricted vaccination responses were seen and opportunistic infections could be cleared [286].   
Based on these results, human T cells selected in a swine thymus would also be expected to 
preferentially recognize antigens in the context of swine MHC (SLA), rather than human MHC (HLA), 
potentially leading to poor recognition and responses to human APCs in the periphery.  We have 
previously shown that a swine thymus can select human T cells with a diverse TCR repertoire, containing 
at least some T cells capable of responding to antigens presented on HLA by human DCs [7, 209, 210].  
However, experiments in the pig-to-mouse system showed that T cells selected in a swine thymus 
exhibited defects in peripheral immune homeostasis, including reduced ability to repopulate lymphopenic 
secondary recipients [5], which may be due to suboptimal interactions between pig-restricted TCRs and 
peripheral murine host APCs [5, 212, 214].  Similar suboptimal homeostasis, including poor maintenance 




model [7].  These studies also suggested that the human-restricted T cell response may be reduced in 
animals transplanted with a pig compared to a human thymus [7].   
More studies in animal models are needed to assess the ability of a swine thymus to support selection 
and development of functional and swine-tolerant human TCRs to evaluate this strategy for immune 
tolerance induction pre-clinically.  Previous studies did not address whether a grafted swine thymus could 
support the positive selection of TCRs that are known be specifically able to recognize antigen in the 
context of HLA, i.e. HLA-restricted TCRs.  We used a TCR Tg humanized mouse model to assess the 
selection and development of T cells bearing a well-characterized human HLA-A2+ restricted TCR that is 
positively selected by the class I MHC molecule HLA-A2 [62, 178] and recognizes a MART1 peptide as 
a cancer neoantigen [180, 287, 288], in a grafted pig thymus.  Using this system, we addressed the ability 





MART1 TCR does not respond to MART1 peptide presented by pig cells 
To characterize cross-reactivity of the MART1 TCR to SLA, we assessed the ability of the MART1 
TCR to respond to MART1 peptide presented by swine MHC using the TCR characterization developed 
in-house and described in Chapter 2.  We assessed TCR reactivity by measuring IL-2 production of JRT3-
T3.5 cells lentivirally transduced with a MART1 TCR transgene (MART1 TCR Tg JRT3-T3.5 cells).  We 
measured IL-2 production by MART1 TCR Tg JRT3-T3.5 cells in response to irradiated human or swine 
PBMCs in the presence or absence of the MART1 peptide.  IL-2 production was assayed by measuring 
proliferation of CTLLs, an IL-2-sensitive cell line [252], in response to IL-2 in culture supernatants.  
CTLL proliferation was measured by incorporation of tritiated thymidine in counts per minute and 
normalized to CTLL proliferation in response to supernatants from untransduced JRT3-T3.5 cells 
exposed to the same stimulators.  We confirmed that, while HLA-A2+ huPBMCs could present the 
MART1 peptide to MART1 TCR+ JRT3-T3.5 cells, swPBMCs, including those sharing SLA with the 
swine thymus donor in selection experiments, and HLA-A2- huPBMCs did not induce a response in 
Figure 3 - 1: The MART1 TCR does not respond to MART1 peptide presented by swine PBMCs 
Using an in house-developed TCR reactivity assay, we used tritiated thymidine incorporation of CTLLs, a 
murine IL-2 sensitive cell line, to measure IL-2 production of MART1 transduced JRT3-T3.5 Jurkat cells, which 
do not express their own TCRβ, in response to irradiated stimulators that had been pulsed with medium alone or 
with 1µg/mL of MART1 peptide.  IL-2 production by MART1 Tg cells was calculated as fold over IL-2 
production by TCRnull JRT3-T3.5 cells to account for any backstimulation from irradiated stimulators.  Using this 
assay, we determined that a. MART1 TCR Tg JRT cells can respond to MART1 peptide-loaded HLA-A2+ 
PBMCs, but do not respond to peptide loaded on human HLA-A2- or swine stimulators.  Swine PBMCs with 
multiple haplotypes from the Columbia/MGH herd were assessed and none could present MART1 peptide to the 
MART1 TCR.  b. The assay detects the MART1 Tg cells’ response to polyclonal stimulation. **** p < 0.0001 




MART1 TCR+ JRT3-T3.5 cells, even when pulsed with MART1 peptide (Figure 3 - 1a).  Additional 
swPBMCs of multiple SLA types were assayed and were also unable to present MART1 peptide to the 
MART1 TCR (Figure 3 - 1a).  The assay could detect responses from TCR stimulation, as indicated by 
the increased IL-2 secretion of MART1 TCR+ JRT3-T3.5 cells in response to polyclonal stimulation by 




















Successful repopulation in transplanted mice of MART1 TCR transduced CD34+ cells 
To compare positive selection of the MART1 TCR in a selecting HLA-A2+ thymus or an A2- non-
selecting thymus to selection of MART1 TCR in a pig thymus, we developed a TCR Tg humanized 
mouse model.  We used lentivirus to transduce the MART1 TCR transgene into human HLA-A2+ fetal 
liver CD34+ cells for transplantation to NSG mice.  The MART1 TCR expression system is depicted in 
Figure 3 - 2a.  It consists of the constitutively expressed human EF1α promoter driving the MART1 TCR 
α and β chains separated by a P2A self-cleaving sequence.  This is followed in the same cistron by an 
internal ribosomal entry site (IRES) and an eGFP reporter.  Human fetal liver CD34+ cells that were 
mock-transduced or transduced with the MART1 TCR lentivirus as described in Chapter 2 were cultured 
for 96 hours and then assessed by FCM for eGFP expression.  The results in Figure 3 - 2b and 2c are 
representative of several experiments and demonstrate that, while mock transduced CD34+ cells did not 
express eGFP (3 - 2b), between 40 and 70% of fetal liver CD34+ cells were transduced in a typical 
experiment (3 - 2c).  We find that we achieve robust and consistent transduction of fetal liver CD34+ cells 
using the MART1 TCR Tg lentiviral system. 
To study thymic selection of the MART1 TCR, transduced fetal liver CD34+ cells were transplanted to 
thymectomized, irradiated immunodeficient NSG mice along with a thymus fragment under the renal 
capsule, as described in Chapter 2 and as depicted in Figure 3 - 2d.  In brief, to ensure that T cell 
development occurred exclusively in the human or swine thymus grafts, immunodeficient HLA-A2 Tg 
NSG mice were first thymectomized and allowed to recover, since an NSG mouse native thymus can 
Figure 3 - 2: Successful repopulation of transplanted mice with MART1 transgene transduced fetal liver 
CD34+ cells.  
a. Diagram of the MART1 TCR expression construct, which is driven by the human EF1α promoter and expressed 
in a single cistron, including an eGFP reporter.  b. Mock transduced and c. MART1 TCR transduced fetal liver 
(FLC) CD34+ cells 96 hours after transduction.  d. Diagram of the TCR transgenic humanized mouse model, where 
transduced FLC CD34+ cells are transplanted to thymectomized immunodeficient mice along with a cryopreserved, 
thymocyte-depleted fragment of a human HLA-A2+, A2-, or swine thymus under the kidney capsule.  Following 
intravenous antibody depletion of any additional transplanted pre-existing thymocytes, peripheral blood is monitored 
every two weeks and animals are taken down for thymus and peripheral analysis between 10-14 weeks post-
transplant.  e. Example peripheral blood chimerism staining showing detectable GFP+ populations in both B and T 
cells in a mouse transplanted with MART1-transduced FLCs and an A2+ human thymus 10 weeks post-transplant.  





support human thymopoiesis [118, 258, 259].  Thymectomized mice then received X-ray irradiation and 
were transplanted with transduced CD34+ cells that were HLA-A2+ and co-transplanted with a fragment 
of thymocyte-depleted human HLA-A2+, HLA-A2- or swine thymus, as appropriate.  Human and swine 
fetal tissues used in selection experiments, including detailed HLA molecular typing data, are described in 
Table 2. 
Peripheral blood of transplanted mice was monitored regularly.  A representative example of blood 
chimerism at week 12 post-transplant is shown in Figure 3 - 2e, demonstrating that human CD45+ cells, 
Figure 3 - 3: Peripheral reconstitution of mice transplanted with MART1 TCR transduced CD34+ cells. 
Peripheral blood chimerism of transplanted mice.  Data is a compilation of chimerism data from A2+ n = 6, Sw = 6 
and A2- n = 4 mice.  a. human CD45+; b. % GFP+ of total human PBMCs; c. CD19+ B cell chimerism in PBMCs; 
d.% GFP+ of human B cells; e. CD3+ T cell chimerism in PBMCs; f. % GFP+ of human T cells; g. CD3+ CD4+ and 
h. CD3+ CD8+ T cells.  Mean + SEM is shown.  Some data points are excluded because proportions of B cells, T 
cells, %GFP+ cells in a given population and T cell subsets were only included when greater than 50 events were 
detected in the preceding gate.  T cells develop more slowly in transplanted mice than do B cells, so %GFP+ and 





B cells and T cells were detectable in the blood of transplanted mice and that these included GFP-
expressing B cells and CD4+ and CD8+ T cells.  Aggregated chimerism kinetics is depicted in Figure 3 - 
3 showing human chimerism, B and T cell kinetics, as well as the percentage of human B and T cells that 
are GFP+ in the peripheral blood of transplanted mice. 
Figure 3 - 4: MART1+ cells are enriched in an A2+ compared to an A2- or Swine thymus.   
Representative FCM staining of thymus grafts at takedown of transduced cells developing in a a. human HLA-A2+, 
b. swine or c. human HLA-A2- thymus. Proportion of d. GFP+
 
cells and e. GFP+ MART1+ cells in the thymus grafts 
of transplanted mice (A2+ n = 6, Sw n = 6, A2- n=4; one A2- mouse was excluded from tetramer analysis due to too 
few detected GFP+ events). f., g. Example control staining of thymus grafts of animals transplanted with f. CD34+ 
cells transduced with a TCRnull GFP-only lentivirus and with g. untransduced CD34+ cells. * = p < 0.05% by Mann-





MART1+ cells are present in reduced proportions in HLA-A2- and swine thymi compared to 
HLA-A2+ thymi 
At 10-14 weeks post-transplant, mice were sacrificed, and thymus grafts examined for human 
thymocyte engraftment and the presence of MART1 tetramer+ cells.  Human CD45+ cells (Figure 3 - 5b, 
c), GFP+ cells and GFP+ MART1 Tetramer+ cells were detected in grafted human HLA-A2+ (Figure 3 - 
4a), swine (3 - 4b) and human HLA-A2- thymi (3 - 4c).  Thymocyte staining of thymus grafts from 
animals transplanted with mock-transduced CD34+ cells (3 - 4f) and with animals transplanted with 
eGFP-only virus (3 - 4g) were used to set GFP+ and GFP+ MART1 tetramer+ gates.  We observed that all 
three types of thymus grafts supported similar proportions of transduced GFP+ thymocytes (3 - 4d), as 
well as similar total numbers of thymocytes (Figure 3 - 5a), proportions and numbers (Figure 3 - 5b, c) 
of human CD45+ cells, and similar numbers of GFP+ cells (3 - 5d).  However, the proportion of 
thymocytes that were GFP+ MART1 tetramer+ was significantly greater in human HLA-A2+ thymi 
compared to either swine or human A2- thymi (Figure 3 - 4e). 
Altered development of MART1+ cells in HLA-A2- and swine thymi compared to HLA-A2+ 
thymi 
In thymocyte development, somatic recombination leads to development of a diverse array of TCR 
specificities.  Each thymocyte expresses a TCR on its surface along with both the CD4 and CD8 
coreceptor.  Because HLA-A2 is a human class I MHC molecule, MART1 TCR+ thymocytes would be 
expected to be selected to the CD8 lineage, as previously described in humanized mice [62, 178].  To 
Figure 3 - 5:  Thymopoeisis in grafted thymus, engraftment of transduced cells is comparable regardless of grafted 
thymus.  a. Absolute counts of thymus grafts at takedown, 10-12 weeks post-transplantation. b. percent and c. 
absolute counts of human CD45+ cells in thymus grafts.  d. Absolute counts of GFP+ cells in grafted thymi at 





assess the progression of MART1+ T cells through thymic selection in an HLA-A2+ thymus or a non-
selecting HLA-A2- human or swine thymus, we gated on GFP+, GFP+ MART1 tetramer-, and GFP+ 
MART1 tetramer+ cells and analyzed their distribution among thymocyte subpopulations.  Representative 
staining in human HLA-A2+ (Figure 3 - 6a), swine (3 - 6b) or human HLA-A2- (3 - 6c) thymus grafts is 
shown.  GFP- and GFP+ MART1 tetramer- thymocytes showed similar thymocyte distributions, with large 
proportions of CD4+ CD8+ DP thymocytes, as expected in human thymopoiesis.[62]  Since the MART1 
TCR is class I-restricted, GFP+ MART1 tetramer+ cells would be expected to be detected among double 
positive and enriched among CD8 SP thymocytes as transgenic thymocytes undergo positive selection.  
Indeed, GFP+ MART1 tetramer+ cells were enriched among CD8 SP cells compared to CD4 SP cells in 
the human HLA-A2+ thymus (Figure 3 - 6f).  However, we did not see this progression among GFP+ 
MART1 tetramer+ thymocytes in a swine or human HLA-A2- thymus (Figure 3 - 6b, c, f), in which clear 
preference for CD4 or CD8 fate was not detected.  These data suggest that MART1 TCR selection occurs 






Figure 3 - 6: Selection of MART1 TCR in A2+ compared to A2- or Swine thymi. 
Representative flow staining of thymus grafts at takedown of transduced cells developing in an a. human HLA-A2+, 
b. swine or c. human HLA-A2- thymus.  Distribution among thymocyte subpopulations of d. GFP-, e. GFP+
 
MART1 
tetramer-, and f. GFP+
 
MART1 tetramer+ thymocytes (A2+ n = 6, Sw n = 6, A2- n=3 mice per group; * = p < 0.05% 








Figure 3 - 7: MART1 TCRbright T cells are reduced in the spleens of mice transplanted with A2- or swine 
compared to A2+ thymus. 
a-d. Quantification of spleen chimerism, analyzed 10-14 weeks post-transplant, including a. proportions of 
huCD45+ cells among total CD45+, b. percentages of GFP+ cells within huCD45+ cells, and c. proportions of CD3+ 
and d. CD4+ CD3+ and CD8+ CD3+ splenocytes (SPCs), respectively.  * = p < 0.05, ** = p < 0.01 by the Kuskal-
Wallis test using Dunn’s correction for multiple comparisons. Representative FCM staining of spleens of mice 
transplanted with MART1 TCR-transduced cells and co-transplanted with either e. human HLA-A2+, f. swine or g. 
human HLA-A2- thymus, showing MART1 tetramer staining of huCD45+ CD3+ CD4+ or CD8+ GFP+ gated cells.  
Percent of MART1 TCRbright cells among h. CD4+ GFP+ and CD8+ GFP+ T cells and among i. splenocytes. * = p < 






MART1bright T cells are reduced in the spleens of mice transplanted with HLA-A2- and Swine 
thymus grafts 
PBMCs and splenocytes of animals transplanted with MART1 TCR-transduced CD34+ cells and 
human or swine fetal thymus grafts were analyzed for immune cells by FCM 10-14 weeks post-transplant.  
Human peripheral chimerism and T cell reconstitution was assessed in the spleen at 10-14 weeks post-
transplant.  HuCD45+ reconstitution (Figure 3 - 7a), as well as the proportion of human CD45+ cells that 
were GFP+ (3 - 7b) were similar regardless of the grafted thymus.  By contrast, T cell reconstitution was 
more variable.  Proportions of T cells (3 - 7c) including both CD4+ and CD8+ T cells (3 - 7e) were highest 
in animals grafted with human HLA-A2- thymi.  Similar results were observed in the blood of 
transplanted mice (Figure 3 - 8a-d).  CD8+ T cells were reduced in the spleens of mice transplanted with 
a swine thymus compared to mice transplanted with either an HLA-A2+ or HLA-A2- human thymus 
(Figure 3 - 7d), consistent with previous observations that human CD8+ T cell reconstitution is reduced in 
humanized mice transplanted with a swine compared to a human thymus graft [7].   However, no 
significant differences between groups was detected in absolute numbers of human T cells in the spleens 
of transplanted animals (Figure 3 - 8h, i).   
Despite reduced human T cell reconstitution in the periphery of mice transplanted with swine 
compared to HLA-A2- human thymi, the proportion of human T cells that were GFP+ in the periphery 
was similar for both CD4+ and CD8+ T cells in the peripheral blood (Figure 3 - 8j) and spleen (Figure 3 - 
8k), regardless of selecting thymus.  Absolute numbers of GFP+ CD4+ and CD8+ T cells were also similar 
in the spleens of transplanted mice, regardless of transplanted thymus (Figure 3 - 8l).  Thus, transduced T 
cells made up a similar proportion of human T cells in the periphery of all animals, including those 
transplanted with a swine or non-selecting human HLA-A2- thymus.   
GFP+ splenic T cells were analyzed for MART1 tetramer staining.  Representative examples of 





A2+ (Figure 3 - 7e), swine (3 - 7f), or HLA-A2- (3 - 7g) thymi are shown.  We examined proportions of 
GFP+ CD4+ and CD8+ cells for high expression of Mart1 TCR (i.e. proportions of MART1 TCRbright 
cells).  As expected, MART1 TCRbright cells were largely found among GFP+ CD8+ cells (Figure 3 - 7h).  
MART1 TCRbright cells were also enriched as a proportion of GFP+ T cells (Figure 3 - 7h) and of total 
splenocytes (Figure 3 - 7i) in the spleens of mice transplanted with an HLA-A2+ thymus compared to 
mice transplanted with a swine thymus.   
Bimodal expression of Mart1 TCR was noted on GFP+ T cells; a population of MART TCRdim cells 
was detected within both GFP+CD4+ and CD8+ T cell populations, and in the spleens of mice transplanted 
with HLA-A2+, swine, and HLA-A2- thymi.  Representative bimodal MART1 staining is shown in 
Figure 3 - 8: Peripheral reconstitution of transduced cells in peripheral blood and spleen.   Proportions of a. 
huCD45+ cells; b. percent of GFP+ of huCD45+ cells; and c. proportions of T cells and d. CD4+ and CD8+ T cells of 
PBMCs.  Absolute counts in transplanted mice, of e. total splenocytes, f. total huCD45+ cells per spleen, g. total 
GFP+ cells per spleen, h. total CD3+ T cells, i. total CD4+ CD3+ and CD8+ CD3+ cells.  Percent GFP+ of CD4+ and 
CD8+ T cells in j. PBMCs or k. splenocytes, and absolute counts of l. GFP+ CD4+ and GFP+ CD8+ T cells among 





Figure 3-9a-c, as well as MART1 tetramer staining of splenocytes from a mouse transplanted with a GFP 
only virus (Figure 3 - 9d).  We examined MART1 TCRdim and MART1 TCRbright cells and found that 
they had similar CD3 expression, as shown in Figure 3 - 9a-c.  Because TCR and CD3 are expressed on 
the surface of T cells with a well-described stoichiometry [289, 290], the fact that MART1 TCRdim cells 
showed reduced MART1 TCR expression with unchanged CD3 expression suggests that these T cells 
may express endogenously rearranged TCRα chains, which has been previously observed in murine [291] 
and humanized mouse Tg TCR systems [180], and in ordinary humanized mouse models, where 10% of 
normal human thymocytes selected in a human thymus graft expressed multiple TCRα chains [173, 292].  
MART1 TCRdim cells were present in similar proportions among both GFP+ CD4+ and CD8+ cells (Figure 
3 - 9e) and as a proportion of splenocytes (3 - 9f) regardless of selecting thymus.  In general, peripheral 
analysis confirms the observation that positive selection of the HLA-A2-restricted MART1 TCR is 







Figure 3 - 9: A GFP+MART1 TCRdim population is detected among splenic T cells that may be selected to 
express multiple, alternate TCRα chains.  
Tetramer staining of GFP+ CD4+ cells and GFP+ CD8+ cells in the spleens of mice transplanted with a. human HLA-
A2+, b. human HLA-A2-, or c. swine thymus grafts showing CD3 expression on MART1 TCRdim and MART1 
TCRbright cells. Quantification of MART1 TCRdim cells as e. a percent of GFP+ T cells or of f. MART1 TCRdim CD4+ 






Xenotolerance induction may be necessary for successful long-term clinical solid organ transplantation 
from pigs to humans, as it would allow preservation of patient immune function to protect against 
infections, zoonosis, and neoplasms.  Xenogeneic thymus transplantation is a promising approach to 
xenotolerance induction but is expected to produce a human T cell population with a TCR repertoire 
selected by transplanted swine thymic epithelium.  This may lead to suboptimal patient immune function 
if TCRs are not capable of responding to homeostatic signals from or recognize antigens presented by 
peripheral HLA.  We have begun to interrogate the ability of a grafted swine thymus to support the 
positive selection of known human-restricted TCRs.  We compared examined the ability of a swine 
thymus to support positive selection of a MART1 TCR, which has previously been identified for its anti-
tumor activity [244, 288, 293] and which has been shown to be positively selected and not deleted in a 
normal human HLA-A2+ thymus [62, 178, 180].  We compared selection of the MART1 TCR in HLA-
A2+ selecting or HLA-A2- non-selecting thymus grafts or swine thymus grafts.  By using lentiviral 
transgenesis to introduce a human TCR transgene into transplanted human fetal liver-derived HLA-A2+ 
CD34+ cells, we generated a TCR Tg humanized mouse model to test the ability of a swine thymus graft 
to support the positive selection of a human-restricted TCR.   
Overall, our results indicated that this human-restricted TCR was positively selected with poor 
efficiency in a swine thymus.  We detected a distinct population of GFP+ MART1 TCR+ cells in 
transplanted HLA-A2+ thymi that, as expected, was preferentially selected into the CD8+ T cell 
population.  While we were able to detect GFP+ MART1 TCR+ cells in grafted swine thymus tissue, it 
made up a significantly smaller proportion of thymocytes in these grafts than in grafted HLA-A2+ human 
thymi.  These smaller proportions resembled those in human HLA-A2- thymus grafts, which have been 
shown to not support positive selection of an HLA-A2-restricted TCR [62, 294].  In contrast to the HLA-
A2+ thymus, preferential CD8 lineage differentiation was not seen in an HLA-A2- human or swine 





the spleens of mice transplanted with swine or human HLA-A2- thymi compared to those transplanted 
with HLA-A2+ thymi, further evidence that this human HLA-A2-restricted TCR is positively selected 
inefficiently in a transplanted swine thymus. 
We detected a MART1 TCRdim population in the periphery of mice that was similar between mice 
regardless of their transplanted thymus.  Such populations have been observed previously in TCR Tg 
mouse [291] and humanized mouse models [180], and have been shown by antibody staining or 
sequencing to express multiple TCRα chains.  Our observation that MART1 TCRdim cells have similar 
CD3 expression as MART1 TCRbright cells, indicating similar expression of surface TCR [290, 291] but 
reduced expression of tetramer-stainable MART1 TCRs, suggests a similar phenomenon is taking place in 
our system.  Thus, in the absence of HLA-A2, positive selection of MART1 TCR Tg T cells is limited to 
those that have rearranged an additional TCRα chain to generate a receptor that can be positively selected.  
MART1 TCRdim populations were observed in the spleens of mice regardless of selecting thymi and were 
observed among both CD4+ and CD8+ T cells.  By contrast, MART1 TCRbright cells were mostly 
detectable on CD8+ T cells, as would be expected of a class I-restricted TCR.  Additionally, MART1 
TCRbright cells were only enriched among splenocytes of mice transplanted with an A2+ human thymus 
graft.  This result suggests that only a human HLA-A2+ thymus could mediate efficient positive selection 
of MART1 TCRbright T cells.  However, it also suggests that cells with low levels of MART1 TCR 
expression could be positively selected and emerge to the periphery due to co-expression of a second 
TCRα chain.  More studies will be needed to see if this observation represents a generalizable 
phenomenon for HLA-restricted thymocytes selected in a pig thymus.  T cells expressing dual TCRα 
chains are commonly-observed [173, 292, 295], although some data suggests they may be less functional 
[296].  Further characterizing the MART1 TCRdim population found in these mice may allow us to 
determine whether co-expression of a human-restricted TCR improves human-restricted functionality of 





In summary, our results demonstrate inefficient positive selection of a human-restricted TCR in a 
grafted swine thymus, which contrasts with previous studies of murine TCR selection in a xenogeneic 
thymus [212, 283, 285, 297].  In studies in our lab using the pig-to-mouse model, both murine MHC class 
II-restricted TCRs examined were positively selected with similar efficiency in a pig thymus compared to 
the native mouse thymus, whereas a known non-selecting murine MHC did not select these TCRs [285, 
298].  However, in those experiments, both mouse TCRs examined were class II MHC-restricted, while 
MART1 TCR is class I MHC-restricted.  The selection criteria for class I MHC-restricted TCRs are likely 
different from those for class II MHC-restricted TCRs [56, 299-301].  It is worth noting in that murine 
CD8+ T cells are not detected in the periphery of mice transplanted with a pig thymus, although mature 
mouse CD8+ T cells develop in the pig thymus [206, 223].  By contrast, human CD8+ T cells are detected 
in the periphery in the pig-to-humanized mouse model [210].  The differences seen in the current study 
and previous efforts in the lab are likely due to a combination of species differences and characteristics of 
the specific TCRs being studied.  Further studies with other class I MHC as well as some class II MHC-
restricted TCRs may be necessary to distinguish among these possibilities.  In all, the current studies 
highlight the importance of using humanized models to study xenotolerance induction, since studies of 
mouse thymocyte development for xenotolerance induction may not reflect what happens to human cells.   
The current study provides a proof-of-concept for the utility of TCR Tg humanized mouse models to 
better understand how proposed approaches to xenotolerance induction affect the human T cell pool and 
better predict consequences of these approaches for patients who may receive these treatments in the 
future.  Our previous data had shown that a highly diverse human T cell repertoire that is specifically 
tolerant of the donor pig’s SLA and that can mediate a weak human-restricted vaccination response is 
selected in pig thymi [7, 210].  Adding a known TCR with defined specificity to this model allowed 
demonstration for the first time that a human class I MHC-restricted TCR with therapeutic value is not 
selected efficiently in a swine thymus.  As a way to overcoming this limitation in positive selection, we 





approaches originally developed in the pig-to-mouse model [5].  The TCR Tg humanized mouse 






CHAPTER 4:  PIG-REACTIVE HUMAN T CELL CLONES FOR USE IN 
THE TCR TRANSGENIC HUMANIZED MOUSE 
 
Using the TCR Transgenic humanized mouse to study mechanisms of 
xenotolerance induction 
Studying mechanisms of human xenotolerance induction in mouse models 
Tolerance approaches will likely be necessary for clinically feasible pig-to-human xenotransplantation.  
Clinical tolerance approaches to pig-to-human xenotransplantation will likely involve a combination of 
mixed xenogeneic chimerism induction and porcine thymus transplantation, both of which have shown 
promise in non-human primate models [259, 278, 281, 294, 302].  As these xenotolerance induction 
approaches proceed through preclinical and clinical development we will need to understand the 
immunological mechanisms by which they tolerize human T cells.  It is likely that ideal human 
xenotolerance would be achieved largely by deletional mechanisms but would also produce a reasonably 
robust population of human swine-reactive Tregs.  In mouse models of allogeneic tolerance induction by 
mixed chimerism, differences in induction protocols induced immunological tolerance via different 
mechanisms or with different kinetics [215-218].  Studies using mouse models of tolerance induction by 
mixed chimerism sometimes found that specific cell populations were required to induce or maintain T 
cell tolerance [219], including, for example, donor class II MHC positive cells in the thymus, which 
would need to be maintained and renewed to continue tolerizing patient T cells [202, 220].  Meanwhile, in 
clinical combined kidney and bone marrow transplantation, which uses transient mixed chimerism to 
induce immunological tolerance to a grafted kidney in human allotransplant patients, we have observed 
evidence that both clonal deletion and Treg expansion contribute to tolerance [221, 222].  It would be 
important to know if current proposed strategies for clinical xenotolerance induce both deletional and 
regulatory tolerance, and to be sure we know what is required for both mechanisms of tolerance to be 
induced.  Additionally, it will be important to assess how these approaches tolerize human T cells 





have induced xenogeneic tolerance in mice have not always effectively tolerized human cells [4].  
Additionally, human and mouse cells seem to have meaningful differences in their ability to interact 
immunologically with pig cells, as evidenced in part by the fact that peripheral human CD8+ cells are 
detected in humanized mice transplanted with a pig thymus but peripheral murine CD8+ cells do not 
appear in immunocompetent mice transplanted with a pig thymus [206, 210, 223]. 
Thus, studies are needed to understand how xenotolerance induction protocols we are pursuing will 
tolerize and maintain tolerance of human T cells.  This will require in vivo experimental models to more 
thoroughly investigate mechanisms by which various approaches to xenotolerance induction tolerize 
human pig-reactive T cells specifically, to assess how robust and lasting these approaches are, and to 
verify that we know all of the pieces required to make these approaches work reproducibly.  Preliminary 
experiments in the lab have suggested that human T cells selected in a pig thymus are tolerized via a 
combination of deletional and regulatory mechanisms [7].  However, these experiments relied upon 
characterizing bulk populations of T cells, without being able to tell with certainty how the xenotolerance 
approaches used had selected or shaped that population.  An ideal in vivo experimental system would 
permit tracking T cells expressing known xenoreactive T cell receptors so we could observe their deletion 
or conversion to Treg over time under xenotolerance-inducing conditions.  To do this we will need to 
incorporate the TCR Tg mouse model and use it to look at selection and tolerance of human xenoreactive 
TCRs with known properties.  We could use this system to address any number of important questions 





Types of xenoreactivity 
In transplantation, T cell reactivity to the transplanted organ or tissue can occur in three different 
ways, as diagramed in Figure 4 - 1.  First, recipient T cells can respond directly by interacting with MHC 
molecules expressed on the surface of donor cells.  For instance, recipient T cells can interact with MHC 
molecules expressed on the surface of APCs that are co-transplanted with the grafted organ. A relatively 
high proportion of TCRs are thought to have direct alloreactivity [303, 304], perhaps in part due to the 
inherent affinity that TCRs may have for MHC molecules [305-309]. 
Alternatively, recipient T cells can respond to donor antigens presented by donor APCs, in the same 
way that the T cells might respond to any other antigen processed and presented by their endogenous 
APC populations.  This is considered indirect reactivity.  Indirect xenoreactivity is likely to be a major 
barrier to clinical xenotransplantation.  Indirect reactivity occurs due to MHC presentation of antigens 
with sequence differences between donor and recipient.  In a situation where the organ donor and 
recipient are of different species, the burden of antigens with significant sequence differences is likely to 
Figure 4 - 1: Antigen presentation in xenotransplantation. 
Human T cells can recognize swine xenoantigens in three major ways.  a. T cells can respond directly to swine 
p/MHC complexes presented on swine APCs or b. to swine peptides presented on human MHC by human APCs.  





be quite high. Experimental evidence of robust indirect human xenoreactivity supports this notion [310, 
311].  Thus, ensuring that indirectly-reactive TCRs are robustly tolerized by proposed approaches to 
clinical xenotolerance will be extremely important, and will be facilitated by developing indirectly-
xenoreactive TCR reagents for TCR Tg humanized mouse studies.   
Finally, recent data also suggests that what is known as semi-direct reactivity can be important in 
transplantation and xenotransplantation.  APCs can pick up MHC from the environment, from exosomes, 
or from phagocytosis of dying or damaged cells, including from the transplanted graft.  When that 
happens, recipient APCs can trigger reactivity by presenting donor MHC [312, 313].  This could be of 
particular concern in xenotransplantation.   
It is imperative to ensure that approaches to xenotolerance induction are capable of tolerizing human 
TCRs with all kinds of xenoreactivity.  This represents another advantage to using a TCR Tg humanized 
mouse model to studying mechanisms of xenotolerance induction.  By using well-characterized human 
xenoreactive TCRs, we could design TCR Tg humanized mouse models that would allow us to study the 
mechanisms of, requirements for, and efficacy with which TCRs with multiple types of xenoreactivity are 
tolerized. 
Identifying pig-reactive human TCRs 
Before the TCR Tg humanized mouse could be used to study mechanisms of human xenotolerance 
induction, we would need to first identify and characterize human pig-reactive TCRs.  At this time, 
although some characterization [314, 315] and clonal analysis [267] of human pig-reactive T cells has 
been performed, almost no human pig-reactive TCRs have been described.  We set out to isolate human 
pig-reactive T cell clones and clone out their TCRs.  We used classical approaches to identify putative 
human T cell clones that would be expected to be xenoreactive.  Using limiting dilution cloning, we will 
identify human xenoreactive T cell lines that are amenable to in vitro characterization.  Once these lines 





expression system, confirm the xenoreactivity of these cloned TCRs, and, eventually, incorporate them 
into TCR Tg humanized mouse experiments to better understand human xenotolerance induction.  
Preliminarily, we have identified the TCR from one putative swine-reactive CD4+ T cell clone, C05, and 
successfully cloned its TCR into a lentiviral expression system.  We have transduced the TCR 
successfully into an immortalized T cell line for more detailed in vitro characterization, and, if the TCR 
retains interesting xenoreactivity, we will be able to use this reagent to begin selection experiments in 






Figure 4 - 2: Human pig-reactive T cell clones were isolated by limiting dilution analysis. 
Human PBMCs were stimulated with irradiated swine PBMCs and cloned by limiting dilution.  Cells were plated 
at putative concentrations of 30, 3 and 0.3 cells per well.  After around 4 weeks of culture, wells were 
enumerated, and a. Poisson distribution was calculated to determine the likelihood that a given well in a dilution 
condition contained a clonal population.  b.-g. Multiple putative pig-reactive T cell clones were characterized by 
dye dilution MLR.  Solid histograms represent unstimulated clones; histogram outlines are proliferation dye 
analysis of replicates with the indicated stimulators.  Example clone analysis quantification is shown in b.  Clone 
dye dilution plots showing stimulator–CD3+ cells for clones c. CC_PL07_C02, d. CC_PL03_D11, e. 
DD_PL04_D02, and f. DD_PL02_F03 are shown, as well as dye dilution plots for g. CC_PL07_E04, an example 





Anti-pig T cell cloning 
Limiting dilution results 
Limiting dilution analysis was performed on human cells that had been stimulated against either SLA-
CC or SLA-DD swine PBMCs for two weeks.  Plates were seeded putatively containing 30, 3, and 0.3 
cells per well, then maintained in culture.  Wells containing growing clones were enumerated for all 
conditions.  Poisson distribution was calculated, comparing the number of wells seeded to the number of 
wells containing growing cells, to help assess the likelihood that a line growing in a given dilution 
condition is clonal.  This analysis, shown in Figure 4 - 2a, suggests that cells growing in wells in the 3 
cell and 0.3 cell per well conditions were likely clonal.  In total, 22 putative clones were identified from 
the SLA-CC stimulation and 16 putative clones were isolated from the SLA-DD stimulation.  Most 
identified clones were CD4+, with only one clone from the DD stimulation, PL02_F03, staining positive 
for CD8 (data not shown).  All clones have been cryopreserved for future use.   
A small number of clones from lines that had grown the most robustly and had the highest cell counts 
at takedown were thawed and characterized by dye dilution MLR.  Example characterization of 5 clones 
is shown in Figure 4 - 2b-g.  Of these clones, all but DD_PL02_F03 (Figure 4 - 2f) were CD4+.  Three 
clones, CC_PL03_D11, DD_PL04_D02 and the CD8+ DD_PL02_F03 clone each showed greater 
reactivity to swine PBMCs when autologous PBMCs were also present in the MLR and showed similar 
responses to SLA-CC and SLA-DD swine PBMCs (Figure 4 - 2d, e, f).  This may suggest that these T 
cell clones preferentially recognize swine antigen indirectly, presented by human APCs, and suggest that 
the clones may be responding to a swine antigen shared between pigs of the two different haplotypes.  
The results also could reflect that irradiated human PBMCs may provide growth factors or costimulation 
to aid in the xenogeneic response.  One clone, CC_PL07_C02, appears to preferentially respond to SLA-
CC swine PBMCs in the absence of human PBMCs, suggesting this T cell clone is directly reactive to 





To our surprise, we found that the majority of the clones characterized demonstrated both 
alloreactivity and xenoreactivity, with many showing a similar reactivity pattern to CC_PL07_E04 
(Figure 4 - 2g).  To ensure that this polyreactivity was not simply due to contamination by multiple T cell 
lines, we performed limiting dilution and single cell sorting of T cells from the CC_PL07_E04 line.  We 
performed MLR characterization on individual clones that grew from the CC_PL07_E04 subcloning, and 
indeed these lines retained the polyreactivity we had previously seen (data not shown).  For the time 
being, we have not further characterized or studied these polyreactive clones, but this result was 
unexpected.  While it may reflect a technical issue unique to this limiting dilution analysis, or a unique 
characteristic of the original human PBMC donor, it is also conceivable that some xenoreactive clones 
might also be alloreactive.  Repeating these studies using additional human PBMC donors to see if 
polyreactive clones are isolated from other humans and performing additional studies to further 
characterize the human xenoreactive TCR repertoire and how it compares to the alloreactive TCR 
repertoire may help clarify the nature of the human xenoreactive T cell response.   
For the time being, the four xenoreactive clones with minimal polyreactivity that we have identified 
each demonstrate interesting xenoreactive properties.  Importantly, our preliminary data suggests we have 
identified some directly and some indirectly xenoreactive clones.  Once the TCR sequences are identified 
and isolated from each of these T cell clones, they will represent useful and interesting reagents for 
understanding the human swine-reactive T cell response and the immunological basis for clinical 







Figure 4 - 3: Characterization of C05, a previously-isolated human pig-reactive T cell clone 
a. Flow staining shows that the C05 line is CD4+.  b. Dye dilution MLR analysis of C05’s reactivity, gated on 
stimulator– CD3+ cells.  Solid histograms represent unstimulated clones; histogram outlines are proliferation dye 
analysis of individual replicates under indicated stimulator conditions.   C05 proliferates only in the presence of a 
mixture of autologous human and SLA-CC swine PBMCs.  The ability of C05 to proliferate in the presence of 





C05: a TCR isolated from a pig-reactive T cell clone 
C05 T cell clone characterization 
C05 was a CD4+ T cell clone that had previously been generated by Dr. Chiara Borsotti, a 
postdoctoral fellow in the laboratory, using limiting dilution cloning.  C05 was identified based on its 
specific reactivity to swine SLA-CC in the presence of autologous human PBMCs.  To generate enough 
material for TCR identification, the C05 T cell line was expanded as described [263].  FCM staining and 
MLR characterization was performed to confirm that C05 retained its swine reactivity.  As expected, the 
C05 T cell line remained CD4+ (Figure 4 - 3a), and retained its ability to respond to SLA-CC swPBMCs 
in the presence of autologous human PBMCs (Figure 4 - 3b).  C05 did not show reactivity to SLA-DD 
swPBMCs.  Direct xenoreactivity was not assessed for this T cell clone. 
Identifying the TCR sequence of C05 
Using a nested PCR cloning approach previously described [264], we identified the TCRβ and TCRα 
sequences for the C05 TCR.  Sequence information for C05 is described in Table 3.   
Table 3: Sequence identification of the TCRα and TCRβ chains of the C05 putative pig-reactive human TCR 




CAGYGSSNTGKLIF J-Gene TRBJ1*01 J-Gene TRAJ37*02 
D-Gene TRBD2*01   
 
Cloning C05 TCR to lentivirus 
Having identified the C05 TCR sequence, we designed and ordered a synthetic lentiviral expression 
construct that would be compatible and easily cloned into the pHR lentiviral expression system used 
elsewhere in the described work.  The expression construct was designed as previously described, with 
the TCRα sequence followed by the TCRβ sequence, separated by a P2A sequence.  This construct was 
designed to facilitate cloning downstream of the EF1α promoter and upstream of the IRES sequence, 





The C05 expression sequence was obtained and successfully cloned into the pHR lentiviral expression 
system.  After confirming successful cloning, lentivirus was produced using this construct and JRT3-T3.5 
cells were transduced.  Staining for pan-TCRαβ and for the specific TCR Vβ of C05 have demonstrated 
that the C05 TCR can be expressed on the surface of T cells and confirms the identity of the C05 TCR 
(Figure 4 - 4a, b).   
Figure 4 - 4: The cloned C05 TCR lentiviral expression construct expresses appropriately in JRT3-T3.5 cells. 











Modification of TCR characterization approach to assess direct and indirect xenoreactivity  
Modification of the in vitro TCR characterization assay was needed to allow appropriate 
characterization of human xenoreactive TCRs.  Because human xenoreactivity may be either direct or 
indirect, the assay needed to be modified to allow detection of a human TCR-mediated response to both 
swine APCs directly and to swine antigens presented on human APCs.  Indeed, preliminary 
characterization of human T cell clones isolated by limiting dilution suggests that many of these clones 
may be indirectly reactive (Figure 4 - 2, 4 - 3).  As described in Chapter 2 and Chapter 3, we have used 
an in vitro assay to detect the response of immortalized T cells expressing a known human TCR to 
populations of APCs.  However, when irradiated stimulators from two different sources were mixed, for 
instance irradiated human and swine PBMCs, we found that we detected significant IL-2 secretion from 
the stimulators alone, leading to high background and difficulty characterizing the response of our Tg T 
cell line to these stimulators.  T cells in the irradiated stimulator population seem to be responsible for 
producing this IL-2, so we worked to eliminate T cells from our stimulator pools, using DCs pulsed with 
swine antigens instead.  We adapted an indirect assay previously developed by Dr. Heather Morris in our 
laboratory for incorporation into our IL-2 secretion assay.  The assay design is described in Figure 4 - 5a.  
We can use this indirect assay to detect human T cell responses to allogeneic and xenogeneic antigens 
loaded into CD209+ enriched autologous human DCs (Figure 4 - 5b-e).  Additionally, we validated that 
DCs could be successfully incorporated into the IL-2 secretion assay, demonstrating that CD209+ 
enriched HLA-A2+ human DCs can present MART1 peptide to MART1 TCR Tg Jurkat (Figure 4 - 5f).   
Figure 4 - 5: An in vitro assay for evaluating direct and indirect xenoreactivity of human TCRs 
a. Schematic of an in vitro assay to assess direct and indirect xenoreactivity of human TCRs.  TCR reactivity is 
measured by IL-2 production of TCR transduced JRT3-T3.5 cells, which do not otherwise express their own TCR.  
IL-2 production is assayed by measuring CTLL proliferation in response to cell supernatants by tritiated thymidine 
incorporation.  Direct xenoreactivity can be assayed by examining IL-2 production of transduced cells in response to 
irradiated human or swine PBMCs.  Because a mixture of irradiated human and swine PBMCs produces significant 
IL-2 backstimulation, IL-2-producing cells are removed from the stimulator pool by instead using CD209+ 
monocyte-derived human DCs that have been pulsed with swine apoptotic cells.  This approach allows us to detect 
an increased T cell response to human DCs loaded with c. allogeneic human or d. swine apoptotic cells compared to 
b. autologous DCs alone.  This result is quantified in e.  We have also confirmed that we can detect an IL-2 
production response from Tg JRT3-T3.5 cells to human DCs.  MART Tg JRT cells responded robustly to MART1 





We have designed and validated an in vitro assay system to allow characterization of human TCRs for 
direct and indirect xenoreactivity.  We have demonstrated that we can successfully load human DCs with 
allogeneic and xenogeneic antigens for presentation, and we have demonstrated that human DCs can 
present antigen to TCR Tg human JRT3-T3.5 cells and that we can detect this reactivity by measuring IL-
2 production by CTLL proliferation.  We will use this system to characterize the xenoreactivity of the 
C05 TCR.  Having now successfully generated C05 Tg JRT3-T3.5 cells (Figure 4 - 4), we hope to soon 





Validation of MHC class II blocking reagent to determine restriction 
For proper incorporation into TCR selection experiments, we will have to determine not just the 
xenoreactivity of novel human TCRs, but we will need to determine their HLA restriction to allow 
appropriate selection of human fetal tissues that will support positive selection of these TCRs.  Our 
Figure 4 - 6: Validation of anti-MHC class II blocking antibodies 
We have identified commercially-available αHLA-DQ and -DR (a., b,), and -DP (c., d.) antibodies and validated 





strategy to determine HLA restriction will begin by blocking specific MHC alleles to see which are 
needed for activation of a TCR of interest.  We have purchased commercially-available αHLA-DQ, 
αHLA-DR, and αHLA-DP reagents and have determined that these reagents can reduce CD4+ T cell 
proliferation in an allogeneic MLR reaction, as shown in Figure 4 - 6.  When preliminary characterization 
is complete to determine the xenoreactivity of the C05 TCR, these reagents will be available to help 
determine its restriction prior to initiation of in vivo selection experiments. 
Q > K mutant C05 
In the course of cloning and constructing 
the C05 TCR expression construct, we also 
generated a mutated C05 TCR sequence, 
where a glutamine at position 75, within 
Framework 3 in the TCRβ sequence, was 
replaced with a lysine.  This mutation 
prevents appropriate staining with an anti-
TRBV02 reagent.  However, the TCR 
construct appears to be able to assemble and 
be presented appropriately based on pan-TCRαβ staining of transduced JRT3-T3.5 cells, as shown in 
Figure 4 -7.  The reactivity of this TCR and indeed its ability to mediate TCR signaling has not been 
determined.  However, it is possible that this mutated C05 will represent a useful reagent, if only as a 
control TCR.  Further studies to determine its specificity, especially compared to that of the correct C05 
TCR sequence, may be of interest. 
Conclusions and future directions 
Using classical limiting dilution analysis, we have isolated several apparently-xenoreactive T cell 
clones.  Remarkably, many of the T cell clones isolated for their xenoreactivity were alloreactive as well, 
according to characterization by MLR.  We have not performed follow-up experiments to see if this 
Figure 4 -7: The Q > K mutant C05 
A mutated C05 TCR containing a Q > K substitution at 
position 75 within Framework 3 was generated during cloning 
of the C05 TCR.  This TCR appears to express normally by 
pan-TCRαβ staining on transduced JRT3-T3.5 cells (a.) but 





observation represents a generalizable phenomenon or was simply a unique feature of the human donor 
used for T cell cloning.  However, these preliminary findings support the idea that there may be 
significant overlap or commonalities between alloreactive and xenoreactive TCR repertoires that may 
warrant further investigation.   
We have also identified multiple xenoreactive T cell clones that do not show overt alloreactivity.  
Cells, genomic DNA, and RNA have been banked for these clones to allow identification of the sequence 
of their TCRs.  Additionally, we have been able to isolate and identify the TCR of one SLA-CC-reactive 
T cell clone, originally isolated in a different T cell cloning experiment.  This TCR has been cloned into 
the pHR lentiviral expression construct and has been shown to express appropriately in a transduced 
JRT3-T3.5 cells, an immortalized human T cell line that is TCRβnull.  When transduced with this TCR, the 
transduced T cell line can be stained for both pan-TCRαβ and for the expected TCR Vβ antibody.  Further 
characterization will be needed to verify that the TCR retains its xenoreactivity and to better determine 
whether the TCR recognizes pig antigens directly or indirectly, since the characterization performed on 
the original T cell clone did not distinguish between these kinds of reactivity. 
Fortunately, we have developed an in vitro system to allow characterization of directly and indirectly 
xenoreactive TCRs transduced into JRT3-T3.5 cells.  By assaying proliferation of CTLLs, an IL-2-
sensitive murine lymphoma cell line, we can measure IL-2 production by TCR-transduced cells in 
response to various stimuli.  We can use this assay to assess TCR-mediated T cell responses to human and 
swine irradiated PBMCs, and, ultimately, to human DCs loaded with antigens derived from apoptotic 
swine PBMCs.  Using this assay, we will be able to assess the xenoreactivity of the C05 TCR as well as 
any other TCRs that may be isolated from other putative xenoreactive T cell clones.   
Once the previously-identified TCR clone is fully characterized, it will be ready for use in TCR Tg 











CHAPTER 5: SELECTION OF AN AUTOREACTIVE TCR IN A 
HEALTHY, HLA-DQ8+ TCR TRANSGENIC FETAL MODEL 
 
Experimental design and data collection were performed by G. Nauman.  Analysis was performed in 
collaboration with R. Madley; Clone 5 humanized mouse model developed and optimized in collaboration 




Despite numerous immunological mechanisms in place to develop a human T cell repertoire that 
responds to foreign antigens but not to self, immunological self-tolerance sometimes fails.  This occurs 
for reasons that remain poorly understood, and these failures of immunological self-tolerance are difficult 
to predict or treat.  Diseases mediated by immune attack on self, or autoimmune diseases, present a major 
disease burden and many are increasing in incidence globally [316].  Many autoimmune diseases are 
associated with an emergence of self-reactive T cells [317-321].  Type 1 diabetes (T1D) is a T cell-
mediated autoimmune disease that impacts greater than 20 million people worldwide, with a particularly 
high incidence in children [41, 322].  In T1D, autoreactive T cells attack and kill pancreatic  cells, 
destroying the patient’s ability to produce insulin to appropriately regulate glucose metabolism.  This 
occurs despite mechanisms such as central tolerance, which takes place in the thymus to tolerize T cells 
expressing TCRs that might attack peripheral self-antigens [63, 82-85, 323-325].  However, autoreactive 
T cells are detected in mice with spontaneously-occurring autoimmune diabetes [32-34] and in patients 
with T1D [36-38], suggesting that at least sometimes these mechanisms of tolerance fail.  Better 
understanding how T cell self-tolerance is lost or broken will be critical for understanding and treating 
these patients, or for developing biomarkers to detect autoimmune diseases before extensive immune 
attack has occurred.   
Much of the previous work understanding the pathogenesis of T1D has been performed in the NOD 





including in the NOD mouse model, have not been well recapitulated in human studies.  Whether this is 
because of inherent differences in mouse and human immune cells or due to limitations of the NOD 
mouse to recapitulate all aspects of T1D pathogenesis in a diverse patient population remains to be seen.  
In any case, studies examining how T cell tolerance fails in humans with known genetic backgrounds, 
ideally in systems amenable to the genetic manipulation that facilitates detailed mechanistic studies, will 
be needed to improve our understanding of the origins of human T cell-mediated autoimmune diseases 
like T1D. 
Models such as the TCR Tg humanized mouse model could be used to address this gap, allowing 
observation of the immune development of transplanted human cells expressing autoreactive TCRs with 
known properties.  This model could allow us to study mechanisms of peripheral and central tolerance in 
human cells and assess how they fail in autoimmunity.  We have begun experiments using the TCR Tg 
humanized mouse model to study thymic selection of a diabetogenic TCR.  We have transplanted 
immunodeficient mice with human FLC CD34+ cells transduced with Clone 5, a known T1D-associated 
TCR [172, 237].  We co-transplanted these cells to immunodeficient NSG mice with fragments of human 
fetal thymus and performed preliminary studies to examine whether and how this known autoreactive 
TCR is selected and, potentially, tolerized, in human thymopoiesis. 
In thymopoiesis, developing thymocytes are selected based on the ability of their TCRs to weakly 
interact with self-peptide/MHC complexes.  However, because TCRs recognize foreign antigens in the 
context of self-MHC molecules, and because each MHC molecule can present a wide variety of antigens, 
some TCRs will also interact with self-antigens presented by MHC with too great an affinity for safety.  
In the thymus, TCRs with inappropriately high affinity for self-peptide/MHC complexes can be 
eliminated from the TCR repertoire by deletion [63, 64, 75-77].  In some cases, the cells expressing these 
self-reactive TCRs are not deleted, but instead are forced to express the FoxP3 transcription factor and 
become CD4+ Tregs, which dominantly suppress autoreactive responses in the periphery [78-81].  Cells 





than do cells that differentiate to conventional CD4+ T cells [78, 326].  However, more studies are needed 
to understand the factors that cause a specific autoreactive T cell to be either deleted or converted to the 
Treg fate in central tolerance, especially for human cells.   
Since mature T cells will eventually leave the thymus and migrate to peripheral tissues, they must also 
be tolerized to self-antigens specific to these tissues, including the pancreatic  cells.  Autoreactivity to 
antigens specifically produced and presented in the periphery, known as tissue-restricted antigens (TRAs) 
would be devastating.  Therefore, there are mechanisms in the thymus, as well as in the periphery as 
back-up, to ensure that the TCR in developing T cells is exposed to a broad pool of TRAs.  A specialized 
region in the thymus, the thymic medulla, contains a diverse array of APCs, including DCs, which 
tolerize developing thymocytes to hematopoietic and other TRAs, and B cells, which can also participate 
in tolerance induction [63, 327-329].  In addition, a population of thymic stromal cells, the mTECs, have 
a unique capacity to express TRAs.  mTECs use specialized transcription factors, including autoimmune 
regulator (AIRE), to stochastically activate transcription throughout the cell’s genome, ensuring that 
many genes normally restricted to limited peripheral tissues are presented to developing thymocytes [72].  
Insulin is a prototypical TRA that is mainly produced in a peripheral tissue, the islets of Langerhans in the 
pancreas, but is also found to be expressed in the thymus in an AIRE-dependent manner [330, 331].  Poor 
thymic expression of insulin is associated with T1D risk in mice [227] and humans [224, 332].  
Therefore, specialized cells in the thymus ensure that developing thymocytes are exposed to a wide 
variety of self-antigens, including insulin, during central tolerance.  Despite this, TCRs that react to 
TRAs, including insulin, are detected in the circulation both in mice and humans with T1D [234-237, 
333] and, frequently, in healthy individuals as well [231-233].  Better understanding how these cells 
escape tolerization in the thymus would improve our understanding of the etiology of T1D and may help 





Clone 5 is a diabetogenic TCR isolated from the blood of a T1D patient 
Clone 5 is well-characterized human HLA-DQ8-restricted TCR that was initially isolated from the 
peripheral blood of a patient with well-established T1D [36, 334].  HLA molecules including DQ8 have 
long been known to be a genetic risk factor associated with T1D [42, 43, 335].  Indeed, MHC haplotypes 
including HLA-DQ8 are by far the strongest risk variants associated with T1D in genome-wide 
association studies [36], and NOD mice, which spontaneously develop T1D, express a unique haplotype 
(I-Ag7) that is DQ8’s ortholog [336].  Therefore, assessing how an HLA-DQ8-restricted autoreactive TCR 
might be selected or tolerized might provide insight into how self-tolerance is lost in T1D.  Clone 5 
recognizes the insulin B:9-23 epitope.  Insulin is a key antigen in T1D and the B:9-23 peptide in 
particular has been shown to be a key epitope in the development of T1D in mouse models [31-35].  The 
murine and human insulin B:9-23 peptides have identical sequences, and human TCRs that react to it 
have been detected in the blood of many patients with T1D [36-39].  Finally, a recent study showed that T 
cells transduced with the Clone 5 TCR ex vivo can, in conjunction with streptozotocin treatment and 
immunization with the insulin B9:23 peptide, induce a T1D-like phenotype in a humanized mouse model 
[172], suggesting that human cells expressing this specific TCR can initiate pathogenic  cell attack. 
All these factors make Clone 5 an interesting candidate TCR for initial TCR Tg humanized mouse 
studies.  TCRs with properties like those of Clone 5 – DQ8-restriction and reactivity to insulin B:9-23 – 
are likely important in the pathogenesis of T1D.  Therefore, we have begun experiments using the TCR 
Tg humanized mouse model to compare selection and development of the Clone 5 TCR transduced in 
HLA-DQ8+ fetal liver CD34+ cells and selected in autologous HLA-DQ8+ fetal thymus grafts.  To assess 
deletion, we compared development of Clone 5-transduced cells in the DQ8+ fetal thymus to development 
of cells transduced with a TCRnull lentiviral construct encoding only an eGFP reporter, the GFP only 
virus.  Comparing development of Clone 5 and GFP only transduced cells in this system, we observed 
that GFP+ cells in Clone 5 animals but not GFP-only animals showed phenotypic characteristics 





transplanted with Clone 5 but not GFP-only transduced cells.  These data suggest that under normal 
circumstances, in the presence of the HLA-DQ8 restriction element, the Clone 5 diabetogenic TCR is 
deleted.  Additionally, these data have allowed us to identify characteristics of human TCR Tg cells 
undergoing deletion.  This preliminary work identifying a “deletion signature” will inform studies 
examining the tolerization of other autoimmune TCRs – as well as the xenogeneic TCRs identified in 







Figure 5 - 1: DQ8+ FLC CD34+ cells transduced with Clone 5 or GFP only virus repopulate transplanted mice.  
Representative transduction of HLA-DQ8+ FLCs transduced with a. Clone 5 or b. GFP only virus.  Peripheral blood 
reconstitution of mice transplanted with Clone 5 or GFP only virus, including c. proportions of huCD45+ cells (p < 
0.01), d. % GFP+ of huCD45+, e. proportions of human B cells; f. percent GFP+ of human B cells (p < 0.0001), g. 
proportions of human T cells (p < 0.05), h. proportion of human CD4+ T cells, i. percent GFP+ of CD4+ T cells, j. 
proportions of human CD8+ T cells, and k. percent GFP+ of CD8+ T cells.   Data are a compilation of n = 4 Clone 5 
and n = 3 GFP only mice transplanted with CD34+ and thymus tissue from a single HLA-DQ8+ fetal donor.  * = p < 







To assess how the diabetogenic Clone 5 TCR is selected on an HLA-DQ8+ genetic background in the 
absence of overt diabetic autoimmunity, we generated TCR Tg humanized mice using an autologous 
HLA-DQ8+ fetal thymus and liver tissue (Table 4).  Fetal liver CD34+ cells (FLCs) were transduced with 
lentivirus containing either the Clone 5 TCR transgene upstream of an eGFP reporter (Clone 5) or an 
eGFP reporter alone (GFP only), as described in Chapter 2.  As described, thymectomized NSG mice 
received full body X-ray TBI, followed by subrenal grafting of a human thymus fragment and intratibial 
co-transplantation of the lentivirally transduced human FLCs.  Small aliquots of transduced FLCs were 
cultured for 96 hours to allow transgene expression, then assessed by FCM for transduction efficiency.  
Representative transductions are shown for both Clone 5 (Figure 5 - 1a) and GFP only transduced FLCs 
(5 - 1b).  The kinetics of human peripheral chimerism in transplanted mice are depicted in Figure 5 - 1c-
k.  Only animals with robust thymopoiesis at takedown (> 2x106 cells per grafted thymus) were included 
in this analysis.  Overall, we observe that total human chimerism is similar between animals transplanted 
with GFP only compared to Clone 5 transduced cells (5 - 1c), although we observe a higher transduction 
efficiency and engraftment of GFP+ cells in mice transplanted with GFP only transduced cells (Figure 5 - 
1b, d, f, i, k).  We observe that the percentage of B cells that is GFP+ is consistently lower in Clone 5 
transduced compared to GFP only transduced cells (5 - 1e), which may be due to the reduced transduction 
efficiency seen with Clone 5 compared to GFP only virus.  While we do not observe differences in CD4 
or CD8 reconstitution between the two groups (5 - 1h, j), at 10-16 weeks post-transplant the percentage of 
CD4+ and CD8+ T cells that are GFP+ in mice receiving Clone 5 transduced cells appears to decrease (5 - 
1l, k).  This is not observed in mice transplanted with GFP only transduced cells (5 - 1l, k).  
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Phenotypic characteristics of transduced thymocytes suggests Clone 5 T cells are deleted 
intrathymically 
Using detailed FCM analysis of thymocytes of mice transplanted with Clone 5 compared to GFP only 
cells, we have identified multiple phenotypic markers which may correlate with deletion of the Clone 5 
TCR.  We used expression of GFP to identify Clone 5 Tg cells for this analysis, since it permits 
assessment of Clone 5 transduced cells prior to surface TCR expression.  Deletion of autoreactive 
thymocytes is rapid, and cells expressing Clone 5 TCR on their surface may disappear too rapidly to 
assess their phenotype.  
A previous report in a humanized mouse model found deletion of developing thymocytes was 
associated with PD1 upregulation [180].  Therefore, we assessed PD1 expression on early thymocytes, 
which we defined as CD4lo CD8lo.  PD1 expression appeared to increase on GFP+ cells compared to GFP- 
cells in mice receiving Clone 5 cells, while low expression of PD1 was seen on GFP+ and GFP- cells in 
mice receiving GFP only cells (Figure 5 - 2a-c).  
Additionally, we examined CD4 and CD8 double negative cells in the thymi of transplanted mice to 
assess the phenotype of the earliest thymocyte progenitors.  One of the earliest markers of commitment to 
T cell development in the thymus is CD1a [337-339].  When we assessed CD1a expression on GFP+ and 
GFP- cells in the thymi of transplanted mice, we observed an accumulation of CD1a+ cells among GFP+ 
cells in Clone 5-grafted animals (Figure 5 - 2d).  We did not see as much accumulation in other 
populations.  This may reflect deletion of Clone 5 transgenic thymocytes beyond the early CD1a+ double 
negative developmental stage; CD1a+ early thymocyte progenitors are enriched because more mature 











Finally, we observed differential CCR7 expression on GFP+ compared to GFP- cells in the thymi of 
mice receiving Clone 5 but not GFP only cells.  CCR7 is required for migration to the thymic medulla 
during thymocyte maturation [340, 341], and absence of CCR7+ cells has been associated with TCR 
deletion [69, 180].  We detect robust populations of CCR7+ cells among CD4SP thymocytes on GFP- 
thymocytes in mice receiving Clone 5 cells and on GFP+ and GFP- cells in mice receiving GFP only cells 
(Figure 5 - 3).  However, we do not see CCR7+ cells among GFP+ CD4SPs in mice receiving Clone 5 
cells (Figure 5 - 3a, c).  This suggests that the GFP+ CD4SP thymocytes we detect among GFP+ cells in 
mice receiving Clone 5 transduced cells are not able to reach maturation and migrate to the thymic 
medulla, or that these cells are undetectable shortly after migration to the medulla, likely because they are 
deleted. Taken together, these phenotypic data suggest that GFP+ cells in the thymi of mice receiving 
Clone 5 transduced cells undergo deletion in an HLA-DQ8+ thymus.  This suggests that Clone 5 is deleted 
Figure 5 - 2:  GFP+ cells in Clone 5 transplanted animals show phenotypic characteristics of deletion. 
Example staining of thymus grafts of mice transplanted with a. Clone 5 and b. GFP only transduced cells showing 
gating strategy and PD-1 expression on GFP- and GFP+ cells in the thymi of transplanted mice.  c. Quantification of 
PD-1 expression on CD4loCD8lo GFP+ or GFP- cells and d. quantification of CD1a expression on GFP+ and GFP- 
double negative thymocytes of mice transplanted with Clone 5 or GFP only transduced cells. 
Figure 5 - 3: GFP+ cells in Clone 5 transplanted animals do not upregulate CCR7.  Example staining of grafted 
thymi of mice transplanted with a. Clone 5 or b. GFP only transduced cells.  Cells are gated on GFP- or GFP+, then 
on CD4SP prior to analysis of CCR7 expression. c. Quantification of percent of CCR7+ CD4SP in GFP- or GFP+ 





under normal circumstances in an autologous human HLA-DQ8+ system.  They also begin to describe a 
phenotypic “signature” for cells undergoing deletion in the TCR transgenic humanized mouse system.  
Further replication studies and, eventually, single cell expression analysis will help confirm the 
phenotypic changes that we observe by FCM, and can help confirm that these phenotypes are truly 
associated with Clone 5+ cells undergoing deletion. 
Figure 5 - 4:  Reduced %GFP+ cells in peripheral T cells compared to B cells in Clone 5 but not GFP 
transduced mice.  Representative FCM analysis of splenocytes of mice transplanted with a. Clone 5 or b. 
GFP-only transduced HSCs.  c., d.  Percent GFP+ of B cells, CD4, and CD8 T cells in c. blood and d. spleen 
of mice transplanted with Clone 5 or GFP only transduced cells.  * = p < 0.05 by One-way ANOVA followed 





T cells but not B cells show reduced GFP expression in Clone 5 but not GFP only animals 
 At takedown, 14-16 weeks post-transplantation, we assessed the percentage of cells in peripheral 
populations that were GFP+.  As shown in Figure 5 - 4¸ we observed that the percentage of B cells that 
were GFP+ remained high in the blood (5 - 4c) and spleen (5 - 4d) of mice receiving Clone 5 transduced 
cells, but that the percentage of both CD4+ and CD8+ T cells that were GFP+ was significantly lower.  In 
mice receiving GFP only cells, GFP expression remained comparable in B, CD4+, and CD8+ T cells and 
no significant difference in the percentage of cells that were GFP+ was observed.   
Comparing repopulation of transgenic cells in periphery and thymus suggests Clone 5 T cells 
are deleted 
We next examined spleens of recipient mice for the proportion of GFP+ or GFP- cells that were 
transgenic.  Because Clone 5 recognizes an insulin peptide with an unusual presentation register on the 
DQ8 MHC molecule, no tetramer currently exists that detects Clone 5 TCR+ T cells specifically.  Instead, 
we stained for Clone 5’s TCR Vβ, the TCR Vβ11.  For peripheral analysis, we consider GFP+ Vβ11+ cells 
to be transgenic in mice receiving Clone 5 transduced cells.  Since we have enforced the co-expression of 
a Vβ11+ TCR with the GFP reporter, we would expect to see an overrepresentation of Vβ11+ CD4+ cells 
among GFP+ cells in mice receiving Clone 5 transduced cells.  Instead, when we quantified the 
percentage of transduced GFP+ versus untransduced GFP- cells that were Vβ11+ CD4+ in mice receiving 
Clone 5 and GFP only transduced cells was extremely similar (Figure 5 - 4a-c).  As previously 
mentioned, due to enforced expression of the Clone 5 TCR, Vβ11+ CD4+ cells would be expected to be 
enriched among GFP+ cells in mice receiving Clone 5 transduced cells.  However, the proportion of 
Vβ11+ CD4+ cells is similar among GFP+ and GFP- cells in animals receiving Clone 5 cells and is like 
what is observed among GFP+ cells in mice transplanted with GFP only transduced cells.  Staining for 
Vβ11 on cells transduced with GFP only virus reveals T cells that rearranged Vβ11 TCRs in ordinary 
V(D)J recombination, so the observation that Vβ11+ CD4+ cells are present with similar frequency among 





arrangement, not the increased expression that would be expected due to presence of the Clone 5 
transgene.  Experiments are planned to use repertoire analysis to verify that these cells and the GFP+ 
Vβ11- cells we observe in the spleens of grafted animals have indeed rearranged TCRs other than Clone 











We have generated a humanized mouse model that will be useful for studying how human autoreactive 
TCRs are selected and tolerized in a human thymus.  The preliminary data presented here suggest that we 
can use this model to detect deletion of Clone 5, a known diabetogenic TCR, on an autologous HLA-
DQ8+ background.  We observe phenotypic characteristics consistent with thymocytes undergoing 
deletion among GFP+ cells in Clone 5 transduced animals, but not among GFP+ cells in GFP only 
transduced animals or GFP- cells in either.  Additionally, the percent of cells that are GFP+ is reduced 
among both CD4+ and CD8+ T cells compared to B cells in the blood and spleen of Clone 5 transplanted 
mice but is similar in all populations in mice transplanted with cells transduced with GFP only virus.  
This suggests that relatively few transduced T cells complete thymopoiesis and migrate to the periphery 
in mice transplanted with Clone 5 transduced cells but not GFP only cells, possibly because those cells 
expressing Clone 5 are deleted.  This, to our knowledge, is the first evidence for negative selection of a 
human autoreactive TCR in the presence only of natural ligand.   
Additionally, we observe that relatively few GFP+ cells in the periphery of mice transplanted with 
Clone 5 cells express Vβ11+, the Clone 5 TCRβ chain.  Since we would expect Vβ11+ expression to be 
high in cells transgenic for the Clone 5 TCR, we interpret the poor reconstitution of Vβ11+ cells in the 
periphery of Clone 5 transduced animals as further evidence that this TCR is deleted in the described 
experiment.  Interestingly, we observe a population of GFP+ Vβ11- cells in in the periphery of mice 
transplanted with Clone 5 transduced cells and further work is needed to determine what these cells are.  
We hypothesize these cells have somehow rearranged endogenous TCRβs.  This is unexpected, because 
developing thymocytes expressing a rearranged TCR receive signals to prevent further rearrangement of 
the TCRβ locus [342, 343], in a process called allelic exclusion. It has been shown that signaling through 
Figure 5 - 5: Vβ11+CD4+ cells are present at similar frequencies among GFP+ and GFP- splenocytes in mice 
transplanted with Clone 5 or GFP only transduced cells, despite transduction with a Vβ11+ TCR in Clone 5 
mice.  Representative staining of splenocytes of mice transplanted with a. Clone 5 or b. GFP only transduced 





TCR transgenes, including lentivirally transduced ones like the ones used in this study [177], mediate 
allelic exclusion.1  Thus, allelic exclusion would be expected to prevent rearrangement of the endogenous 
TCRβ locus in cells transduced with the Clone 5 TCR.  Despite this, we observe a robust proportion of 
GFP+ Vβ11- cells, suggesting that either rearrangement of the endogenous receptor has occurred, or that 
transduced cells were somehow able to silence or eliminate the Clone 5 TCR transgene but not the eGFP 
reporter.  In either case, this result may reflect efficient Clone 5 deletion in this model.  While transgene 
silencing or endogenous TCR rearrangement would be expected to be unusual events that would occur 
rarely, and in relatively few thymocytes, if thymocytes expressing Clone 5 are deleted efficiently, these 
rare thymocytes might be expected to preferentially survive thymopoiesis and thus be enriched in the 
periphery.  Sequencing studies will be necessary to confirm if the GFP+ Vβ11- cells we detect are indeed 
Clone 5 transduced cells that have rearranged endogenous TCRs.  Single cell analysis may be needed to 
determine whether individual GFP+ Vβ11- cells contain both the Clone 5 TCR transgene and 
endogenously rearranged TCR β chains. 
Future studies will also need to determine whether conversion of Clone 5 TCR+ thymocytes to the 
Treg fate can be detected in this experimental system.  We were not previously able to assess the 
development of Clone 5 TCR+ Tregs due to difficulties detecting co-expression of GFP and FoxP3, but 
optimization of staining protocols should permit this in the future.  Additionally, studies combining single 
cell expression and repertoire analysis of thymocytes and splenocytes of mice transplanted with Clone 5 
transduced cells could help better define the molecular signatures associated with TCR deletion and 
definitively distinguish between TCR deletion and failure of positive selection.  Finally, to determine if 
efficient tolerization of autoreactive TCRs is a generalizable phenomenon, we have cloned two additional 
autoreactive TCRs into our lentiviral expression system for future selection experiments.   
 
1 Allelic exclusion does not completely prevent genomic rearrangement of the TCRα locus, so rearrangement and 
expression of alternate TCRα chains is observed relatively frequently in studies of both normal and transgenic TCRs 





So far, apparent deletion of the Clone 5 TCR has been detected in animals transplanted with 
transduced HLA-DQ8+ FLCs and a DQ8+ thymus.  This is the first example we are aware of showing 
negative selection of a known autoreactive human TCR under normal conditions in a human thymus.  
This occurs even though Clone 5’s restriction element, HLA-DQ8, is a major risk factor for the 
development of T1D [42, 43, 335].  This suggests that the presence of high-risk restricting MHC alone is 
not sufficient to prevent tolerization of autoreactive TCRs and suggests that other factors must be 
involved to allow this TCR, at least, to escape mechanisms of normal thymic central tolerance.  
Additionally, the insulin B9:23 epitope binds weakly to the HLA-DQ8 molecule and in an unusual 
conformation [333], which might prevent efficient B9:23 presentation in the thymus.  However, we 
observe deletion of Clone 5, suggesting that TCRs that recognize the B9:23 peptide can be tolerized under 
normal circumstances.  The fact that Clone 5 and other HLA-DQ8-restricted, B9:23-reactive TCRs are 
observed in T1D patients suggests then that additional genetic or environmental factors must intervene to 
disrupt tolerization of these autoreactive TCRs in patients who develop autoimmunity. 
Indeed, numerous non-HLA genetic factors have been identified that contribute to T1D risk, many of 
which may reduce the efficiency of central tolerance induction [28, 40].  The Clone 5 TCR Tg model, 
where a known diabetogenic TCR is deleted, could be used to assess how these variants contribute to 
failed tolerization of Clone 5.  We initially intend to address this by introducing the Clone 5 transgene 
into our patient-derived Personalized Immune mouse model.  In this model, immunodeficient mice are co-
transplanted with CD34+ cells obtained from healthy controls or patients with T1D and a fragment of 
partially HLA-matched human fetal thymus [9].  We observe that mice repopulated with T1D compared 
healthy control immune systems display immunological differences, likely due to underlying differences 
between diabetogenic and non-autoimmune immune systems [9, 10].  By introducing the Clone 5 TCR 
transgene to healthy control or T1D patient cells to compare Clone 5 tolerization in both types of immune 
systems, we may be able to identify the immunological differences that lead to impaired central tolerance, 
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Interactions with antigen-presenting cells in the periphery Peripheral reconstitution  
Interactions APCs are critical for maintaining normal peripheral human T cell function.  Therefore, 
any model to study physiologically-relevant human T cell development and function must have robust 
human peripheral APC reconstitution.  Unfortunately, human APC engraftment and maintenance is 
thought to be suboptimal in humanized mice transplanted with CD34+ cells from human fetal liver cells 
(FLCs).  Decades of effort have gone into engineering animal strains to better support human myeloid 
engraftment and B cell development [14, 108, 112, 344, 345].   
We have developed a humanized mouse model that permits transplanting immunodeficient mice with 
CD34+ cells from adult bone marrow cells (aBM), which allows us to generate humanized mice from 
patient bone marrow samples, reconstituting the patient’s immune system in an experimentally tractable 
mouse model [9, 10].  Generating humanized mice from patient bone marrow, along with a partially 
HLA-matched, thymocyte-depleted human fetal thymus graft, provides a novel opportunity to understand 
the pathophysiology of diseases that do not present in fetal development.  Comparing humanized mice 
transplanted with aBM from patients with T1D to those generated with aBM from partially HLA-matched 
healthy individuals has allowed us to elucidate immunological differences between healthy and patient-
derived human immune systems, including increased B cell production and changes in T cell homeostasis 
[9, 10].  However, we observe that humanized mice transplanted with aBM have reduced human 





FLC-derived mice, mice generated using aBM cells show reduced maintenance of human B cell and 
monocyte chimerism at late time points (14-18 weeks) post-transplant, while human T cell populations 
persist. 
We aimed to better understand our observation that APC populations are reduced in humanized mice 
transplanted with aBM compared to FLC CD34+ cells.  We performed a detailed characterization of 
human myeloid APC populations in mice transplanted with FLCs compared to aBM.  We hypothesized 
that the reduced human APC reconstitution observed in the peripheral blood of humanized mice would be 
recapitulated in tissues, including the spleen and bone marrow, and that it might extend to DC populations 
as well as monocytes and B cells.  Therefore, we compared reconstitution of human B cells; monocytes; 
CD11c+ cDCs, including CD141+ and CD1c+ cDC subsets; and plasmacytoid DCs, or pDCs, in the 
spleens and bone marrow of mice transplanted with FLC or aBM CD34+ cells.  We also compared 
engraftment and maintenance of human hematopoietic and APC progenitors to better understand how the 
differences we observed in human APC chimerism might be produced and maintained.  Here we show 
that human HSCs are reduced in both input CD34+ cells and transplanted mice generated using aBM 
CD34+ cells compared to FLC CD34+ isolates and mice.  Because circulating monocytes, DCs, and 
immature and naïve B cells are continually renewed from bone marrow progenitors while T cells are 
relatively long-lived [146, 346], reduced human APC maintenance could result from a reduced HSC pool 
in the bone marrow of aBM compared to FLC transplanted mice.  If so, improving aBM HSC 
maintenance, perhaps by using more optimal host animals, providing improved cross-reactive cytokine 
and stromal support, and transplanting aBM CD34+ cells directly into the mouse bone marrow niche, 














Human antigen-presenting cell populations are poorly maintained in the blood of aBM 
compared to FLC-transplanted humanized mice  
We compared immune reconstitution in humanized mice made by co-transplanting human fetal 
thymus to NSG mice and either FLC or aBM CD34+ cells intravenously (see Figure 6 - 1a).  Humanized 
mice made with aBM consistently showed reduced human chimerism among PBMCs compared to those 
receiving FLCs.  This difference was observed in six independent experiments, with data from one 
representative experiment shown (Figure 6 - 1b-e).  While human CD45+ chimerism, calculated as the 
percentage of human CD45+ cells among total mouse and human CD45+ cells, was significantly reduced 
in mice transplanted with aBM compared to FLCs (Figure 6 - 1b), it generally rose to about 20% of total 
PBMCs by 6-10 weeks post-transplant and remained steady through the time-points measured.  From 6-
10 weeks post-transplant onward, FLC-derived cohorts show higher levels of human immune 
reconstitution overall compared to aBM-derived animals.  Proportion of B cells, T cells and monocytes 
were determined. As previously reported, B cells were reduced in aBM compared to FLC-transplanted 
mice (Figure 6 - 1c, [10]), and human chimerism was reduced in all populations in mice receiving aBM 
compared to those receiving FLCs (Figure 6 - 1c-e).  Notably, mice receiving aBM showed poor 
maintenance of monocytes and B cells at late time points (Figure 6 - 1c, e), with a dramatic decline 
beginning 12-16 weeks post-transplant in aBM-transplanted animals.  By contrast, monocytes and B cells 
Figure 6 - 1: Reduced human chimerism and maintenance of B cells and monocytes in humanized mice 
transplanted with adult bone marrow compared to fetal liver CD34+. 
a. Schematic of experimental system. Peripheral blood chimerism of mice transplanted with aBM (open triangles) 
compared to FLC (black squares) CD34+ cells. b. Human CD45+ cells, p < 0.0001; c. human B cells, p < 0.0001; d. 
human T cells, p < 0.0001; and e. human monocytes, p < 0.0001 as a percentage of peripheral blood mononuclear 
cells.  Mean + SEM is shown.  **** = p < 0.0001, ** = p < 0.01, * = p <0.05.  Chimerism analysis was performed 
using two-way ANOVA followed by Sidak’s multiple comparisons test.  Proportions of CD3+, CD19+ and CD14+ 
cells among human CD45+ cells in f. spleen and g. bone marrow at takedown, 22 weeks post-transplantation. *** = 
p < 0.001, ** = p < 0.01, * = p < 0.05 by unpaired student t-test with Welch’s correction. n = 5 age-matched NSG 
female mice per group, irradiated with 1.5 Gy TBI and transplanted with 1x105 fetal or adult CD34+ cells I.V., each 





remained stable among PBMCs in mice transplanted with FLCs until at least 18-20 weeks post-transplant 
(Figure 6 - 1c, e).  While human T cell chimerism was lower in aBM compared to FLC-transplanted 
animals (6 - 1d), human T cell populations were stable at week 12-20 post-transplantation and did not 
show the decline observed among B cells and monocytes.  At takedown, 22 weeks post-transplant, T cells 
made up a larger proportion of human CD45+ cells and B cells and monocytes were reduced in the spleen 
(6 - 1f) and bone marrow (6 - 1g) of aBM compared to FLC recipients.  We examined proportions of 
human CD45+ cells and B cells among total splenocytes (mouse + human CD45+ cells; indicated as SPCs; 
Figure 6 - 2a) and bone marrow cells (BMCs; Figure 6 - 2e) as well as absolute numbers (Figure 6 - 2c, 
g), and found they were reduced in aBM compared to FLC transplanted mice.  The reduced B cell 
proportions did not merely reflect reduced total human chimerism, since T cell proportions among 
splenocytes and bone marrow cells were similar between mice transplanted with aBM or FLCs (Figure 6 
- 2b, f).  Total numbers of T cells and CD4+ T cells were lower in the spleens of aBM compared to FLC-
transplanted mice (Figure 6 - 2d) but were not significantly different in the bone marrow of aBM and 
FLC-transplanted mice (Figure 6 - 2h).  In sum, while total human, B cell, and monocyte chimerism is 
reduced 22 weeks post-transplant, T cell engraftment is reasonably comparable between aBM and FLC-
transplanted mice.  These data suggest that mice transplanted with aBM show reduced maintenance of 
peripheral APCs, but relatively comparable maintenance of T cells at late time points post-transplant 







Figure 6 - 2: Takedown proportions and cell counts in mice transplanted with FLC vs. aBM CD34+ cells.   
a., b., e., f. Proportions and c., d., g., h. absolute numbers of human cell populations among total CD45+ (mouse + 
human) cells in the (a.-d.) spleens and (e.-h.) bone marrow of mice transplanted with FLC or aBM CD34+ cells. n = 
5 age-matched NSG female mice per group, irradiated with 1.5 Gy TBI and transplanted with 1x105 fetal or adult 
CD34+ cells i.v., each from a single donor. Mean + SEM is shown. **** = p < 0.0001, ** = p < 0.01, * = p < 0.05 






Figure 6 - 3: Gating strategy for spleen and bone marrow APC analysis.   
Example gating of bone marrow of humanized mice transplanted with a. FLC or b. aBM-derived CD34+ cells to 





Altered human antigen-presenting cell reconstitution 
We analyzed additional APC populations in aBM compared to FLC-transplanted mice 22 weeks post-
transplant (Figures 6 - 3, 6 - 4).  APC populations were gated as shown (Figure 6 - 3a, b).  Ter119-
muCD45- huCD45+ HLA-DR+ gated cells were analyzed for monocytes (CD14+), plasmacytoid dendritic 
cells (pDCs, CD14- CD1c- CD123+) and CD11c+ conventional dendritic cells (cDCs, CD14- CD11c+).  We 
first examined APC proportions within the transplanted human immune system, as a percentage of 
huCD45+ cells.  To our surprise, while B cells were reduced among human cells in animals transplanted 
with aBM compared to FLCs (Figure 6 - 4f, g), we found that some APC populations were present at 
Figure 6 - 4: Analysis of human antigen- presenting cells (APCs) confirms a reduction in APC populations in 
aBM compared to FLC mice.   
huCD45+HLA-DR+ cells were analyzed for monocytes (CD14+), pDCs (CD14- CD123+), CD11c+ DCs (CD14-
CD11c+), and CD141+ DCs (CD14- CD11c+ CD141+), and CD1c+ DCs (CD14- CD11c+ CD1c+) in humanized mice 
transplanted with aBM compared to FLC CD34+ cells.  Proportions of monocytes, pDCs, and CD11c+ DCs (a., c.) 
and CD141+ and CD1c+ DCs (b., d.) among huCD45+ cells in the spleen (a., b.) and bone marrow (c., d.). 
Proportions (e.-h.) and total number (i.-l.) of monocytes, pDCs, and CD11c+ DCs (e., g., i., k.) and CD141+ and 
CD1c+ DCs (f., h., j., l.) among total splenocytes cells in the spleen (e., f., i., j.) and bone marrow (g., c., k., l.) of 
transplanted mice.  Age-matched female NSG animals were transplanted with 1x105 fetal or adult CD34+ cells and 
analyzed 22 weeks post transplantation.  Mean + SEM is shown.  **** = p < 0.001, *** = p < 0.005, ** = p < 0.01, 





similar proportions or were enriched in aBM compared to FLC transplanted animals (Figure 6 - 4a-d).  
CD11c+ cDCs and CD141+ cDCs were enriched among human cells in the bone marrow of aBM 
compared to FLC transplanted animals (6 - 4c, d), while splenic monocyte and CD11c+ and CD1c+ cDC 
proportions were similar between FLC and aBM-transplanted animals (Figure 6 - 4a, b). Only pDCs 
were reduced among human cells in the spleen and bone marrow of aBM-transplanted animals compared 
to FLC transplanted animals (Figure 6 - 4b, c).  We next calculated APC proportions among total 
(murine + human) CD45+ cells in the spleen (SPCs, Figure 6 - 4e, f) and bone marrow (BMCs, Figure 6 
- 4g, h) and determined their absolute numbers (Figure 6 - 4i-l) in aBM and FLC-transplanted mice.  By 
these metrics, we found that APC populations were globally reduced in aBM recipients.  Thus, while 
some APC populations were relatively well-represented among human cells in the transplanted immune 
system, human APCs were overall less abundant in aBM compared to FLC transplanted mice.  Our 
observation that CD11c+ and CD141+ DC cell populations are better represented among human cells in 
aBM compared to FLC-transplanted mice suggests that transplanted aBM cells have variable capacity to 
maintain different types of APCs.   
Progenitor reconstitution in aBM versus FLC recipients  
Since APC populations develop from hematopoietic progenitors, we compared engraftment of human 
hematopoietic progenitor populations in the bone marrow of aBM and FLC-transplanted mice by FCM, as 
described in Figure 6 - 5.  We assessed proportions and numbers of total CD34+ cells in the bone marrow 
of aBM or FLC-transplanted mice at 22 weeks post-transplantation.  We observed that the percentage 
Figure 6 - 5: Progenitor analysis in the bone marrow of humanized mice. 
Gating strategy used to analyze APC progenitor populations in the bone marrow of transplanted mice in Figure 6 - 





(Figure 6 - 6a) of CD34+ cells among huCD45+ cells was reduced in the bone marrow of aBM compared 
to FLC recipient mice.  This reduction was also reflected in the percentage of total CD45+ cells (Figure 6 
- 6b) and absolute number (Figure 6 - 6c) of human CD34+ cells in the bone marrow of aBM compared 
to FLC recipients.   
CD34 is expressed by a variety of hematopoietic progenitor cells at various stages of differentiation 
and lineage commitment [150].  To determine if poor maintenance of APCs in aBM mice is because aBM 
cells are less able to differentiate to myeloid lineages in mouse bone marrow, we used multiparameter 
FCM to define the progenitor cells at sequential differentiation stages of myelopoiesis among CD34-
expressing progenitors in the bone marrow of aBM and FLC transplanted mice.  We examined the 
following populations: hematopoietic stem cells/multipotent progenitors (HSC/MPPs), multipotent 
lymphoid progenitors (MLPs); B/NK progenitors (B/NKs); megakaryocyte-erythrocyte progenitors 
(MEPS); common myeloid progenitors (CMPs); granulocyte, monocyte, and DC progenitors (GMDPs); 
monocyte DC progenitors (MDPs) and common DC progenitors (CDPs), as previously described [150, 
151, 347] and as diagrammed in Figure 6 - 5a.  The proportions of each cell type among CD34+ 
progenitors in the bone marrow of aBM and FLC transplanted humanized mice are presented in Figure 6 
- 6d.  In general, most progenitor populations made up a similar fraction of CD34+ cells in the bone 
marrow of aBM or FLC-transplanted animals, suggesting that the differential APC maintenance is not due 
to skewing of progenitor populations away from myeloid lineages.  However, HSC/MPPs and MEPs were 





We next quantified engraftment of progenitor populations.  We examined the proportion of human 
CD45+ cells and absolute number of cells per leg that made up each progenitor lineage (Figure 6 - 6d-m).  
HSC/MPPs were reduced among human cells in the bone marrow of aBM compared to FLC mice 
(Figure 6 - 6e), as were B/NK progenitors (Figure 6 - 6h) and CDPs (Figure 6 - 6i).  Other APC 
progenitor populations were present at comparable proportions among huCD45+ cells.  When we 
calculated the abundance of APC progenitor populations in the bone marrow of transplanted mice as a 
percentage of total CD45+ BMCs (murine + human, Figure 6 - 6f, j, k), we found that nearly all 
progenitor populations were present at lower frequencies in the bone marrow of aBM compared to FLC 
recipients.  However, absolute numbers of APC progenitor populations were low in the bone marrow of 
aBM compared to FLC-transplanted mice, most were not significantly reduced (Figure 6 - 6g, l, m).  
Only B/NK progenitors were significantly reduced in absolute numbers (Figure 6 - 6l) in the bone 
marrow of aBM compared to FLC transplanted mice.   Overall, these data suggest that APC progenitors 
are globally reduced in the bone marrow of aBM compared to FLC transplanted mice.  Poor APC 
maintenance in aBM mice compared to FLC mice does not seem to be associated with a bias away from 
specific APC lineages in aBM mice, but instead seems to correlate with reduced proportions of 
HSCs/MPPs among CD34+ progenitors and reduced hematopoietic progenitors in the bone marrow of 










 Adult human HSCs persist in the bone marrow of transplanted mice 
Previous reports have shown that HSCs are rare and have reduced repopulation potential in aBM 
compared to FLCs [156].  We hypothesized that the reduction in aBM HSC/MPPs was due to a lower 
number of HSCs in the source material, resulting in lower pluripotent HSC engraftment, leading to 
globally reduced hematopoiesis in aBM compared to FLC mice that is most apparent among APC 
populations due to their more rapid turnover [141-147, 348].  When we analyzed HSCs in aBM and FLC 
mononuclear cells and in the bone marrow of aBM mice, we confirmed that CD34+ CD38lo CD45RA- 
CD90+ phenotypic HSCs, which include very early human hematopoietic progenitors [349], are rare in 
aBM cells compared to FLCs (Figure 6 - 7a). However, CD45RA- CD90+ cells represented an increased 
Figure 6 - 6: APC progenitors are reduced in the bone marrow of mice transplanted with aBM compared to 
FLC CD34+ cells.   
Proportions within a. huCD45+ and b. total CD45+ cells, and c. total numbers of CD34+ cells in the bone marrow of 
transplanted mice.  Data are from a representative experiment using one aBM and one FLC donor.  d. Proportions of 
APC progenitors among CD34+ cells in the bone marrow of aBM or FLC transplanted mice.  e., h., i. Percent among 
human CD45+ cells and f., j., k. percent and g., l., m. absolute numbers of APC progenitors among total bone 
marrow cells, including e., f., g. early hematopoietic stem cells and multipotent progenitors (HSCs/MPPs), h., j., l.  
erythroid (megakaryocyte-erythrocyte progenitors, MEPs) and lymphoid-biased progenitors (multipotent lymphoid 
progenitors or MLPs, and B/NK progenitors), and k., l., o. monocyte, granulocyte and dendritic cell-biased 
progenitors (common myeloid progenitors, CMPs; granulocyte, monocyte, and DC progenitors, GMDPs; common 
dendritic cell progenitors, CDP; and monocyte/dendritic cell progenitors, MDP).  Data are a compilation of three 
mice per group transplanted with cells derived from two aBM and one FLC donor.  Mean + SEM is shown.  **** = 
p < 0.001, ** = p < 0.01, * = p < 0.05 by student t-test. 
Figure 6 - 7: Phenotypic HSCs expand in the bone marrow of aBM-transplanted mice. 
a. Phenotypic analysis of aBM and FLC mononuclear cells prior to transplantation and bone marrow cells from b. 
aBM transplanted mice gated on huCD45+Lin-CD34+CD38- cells.  c. Quantification of human CD90+ 
CD45RA- phenotypic HSCs as a percent of huCD45+Lin-CD34+CD38- cells in aBM mononuclear cells and in bone 
marrow of aBM transplanted from nine aBM donors, and nine aBM-transplanted mice transplanted with cells from 





proportion among huCD45+ Lin- CD34+ CD38lo cells in the bone marrow of aBM transplanted mice 
compared to the adult bone marrow mononuclear cells (Figure 6 - 7a-c), consistent with similar 
observations made in a previous paper [156].  We performed secondary transplants to assess the 
repopulation capacity of engrafted human bone marrow of aBM recipient mice.  2.1x107 human T-
depleted bone marrow cells from aBM transplanted mice 29 weeks post-transplantation were injected 
intravenously to 1.5Gy irradiated aged-matched female NSG recipients.  Two of eleven secondary 
recipient mice showed low but extant chimerism up to 17 weeks post-transplantation (Figure 6 - 8).  
Example staining from an untransplanted (Figure 6 - 8a) mouse and a secondary recipient of aBM from a 
PI mouse (Figure 6 - 8b) are shown.  Repopulation beyond 16 weeks post-transplant requires 
transplantation of functional HSCs [350].  Monocytes and B cells, especially the immature and naïve B 
cells most commonly observed in humanized mice [10], are short-lived cells and would likely not be 
maintained in transplanted mice at such extended time post-transplant [141, 142, 146, 147].  Thus, these 
data indicate that functional HSCs were present, if rare, in the bone marrow of aBM transplanted mice.  
Recipient mice with detectable human chimerism also showed human B cells and monocytes at 17 weeks 
post-transplant (Figure 6 - 8b), indicating that aBM HSCs are capable of supporting multilineage APC 
development in a secondary host.  These data suggest that, despite nearly undetectable levels of CD45RA- 
CD90+ HSCs in the human aBM, a small number of HSCs engraft in primary aBM recipients and 
CD45RA- CD90+ cells may expand.  At takedown, roughly 22 weeks post-secondary transplant, human 
chimerism was detected in the blood, spleen, and bone marrow of the two reconstituted mice (Figure 6 - 
9).  Although myelopoiesis may decrease in the weeks following engraftment, aBM HSCs remain 









Table 5: Tabular summary of secondary transplant experiments, showing primary human reconstitution 
prior to takedown and secondary reconstitution.  In Experiment 1, eleven secondary recipient mice received 
2.1x107 T-cell depleted bone marrow cells from eleven primary recipients transplanted with cells from a single 
aBM donor.  In some cases, aBM CD34+ cells had been incubated for two hours with DMSO or PGE2 prior to 
primary injection; in other cases primary recipient animals were NSG-PCT, and some animals received CD34+ 
cells intratibially while others received it intravenously.  In Experiment 2, primary recipients were NSG female 
mice that were transplanted intravenously with cells from one FLC donor or one aBM donor.  Secondary recipient 





To our knowledge, this is the first report that aBM can repopulate secondary recipients after 
transplantation in primary immunodeficient mice.  This is likely because previous studies examining the 
repopulation capacity of aBM CD34+ transplanted fewer T-depleted bone marrow cells to secondary 
recipients [156].  Indeed, when we performed a replication study, we transplanted secondary recipients 
with only 1.2 x 107 T-cell depleted bone marrow cells from aBM transplanted mice due to limitations in 
cell numbers and did not observe secondary reconstitution, so it seems likely that the high cell dosage is 
needed to see secondary repopulation.  It is also possible that the secondary reconstitution observed was 
due to a unique property of the original aBM CD34+ donor.  Replication studies are needed to confirm 
these observations.  It must also be noted that the aBM primary recipient animals used in this experiment 
originated from an experiment comparing approaches to improve aBM engraftment, so input animals 
represent a variety of animal strains and routes of CD34+ transplantation.  Additionally, in some cases 
CD34+ cells were treated with PGE2 or DMSO prior to transplantation.  Animal conditions are described 
in Table 5.  We only observed 
secondary reconstitution in two of 
the eleven transplanted animals, 
one of which (Figure 6 - 8b) 
received T-depleted bone marrow 
from an NSG mouse who had 
received untreated aBM cells 
intravenously.  Thus, we cannot 
conclude whether any of the 
treatments implemented improved 
repopulation of secondary 
recipients.  In all, though, we 
observe that phenotypic HSCs 
Figure 6 - 8: T-depleted bone marrow from aBM-transplanted mice 
repopulates secondary recipient mice. T-cell depleted bone marrow from 
aBM-transplanted humanized mice was transplanted to irradiated NSG 
secondary recipient mice. Phenotypic analysis of peripheral blood of an a. 
untransplanted and a b. aBM secondary recipient mouse 17 weeks post-
transplant. Two of eleven mice that received secondary transplant showed 





persist in the bone marrow of mice transplanted with aBM CD34+ cells that these cells can repopulate 






Figure 6 - 9: Low levels of human chimerism are detected in the periphery of two of 11 mice after transplant with T-depleted bone marrow from 
mice transplanted with aBM CD34+ cells. 
Peripheral chimerism analysis at takedown of two animals with detectable human chimerism 22 weeks after secondary transplant with bone marrow from 










Bone marrow from FLC-transplanted mice robustly reconstitutes secondary recipients 
We compared repopulation of T-cell depleted bone marrow from recipients of aBM or FLC CD34+ 
cells in secondary recipients.  1.2x107 T cell-depleted bone marrow cells were harvested from primary 
recipients 20 weeks post-transplant, then transplanted intravenously to irradiated age-matched, female 
NSGs (See Table 5, Experiment 2).  Human peripheral blood chimerism kinetics of aBM and FLC 
primary and secondary recipients are shown in Figure 6 - 10a-d.  T cell-depleted bone marrow from FLC 
primary recipients robustly reconstituted human CD45+ cells (Figure 6 - 10a), B cells (Figure 6 - 10b), 
and human monocytes (Figure 6 - 10d) in secondary recipients.  Human T cells also expanded in 
secondary recipients (Figure 6 - 10c), although the animals did not receive human thymus grafts.  Two-
way ANOVA analysis showed no significant difference in the chimerism kinetics of primary versus 
Figure 6 - 10:  Human FLC CD34+ cells repopulate secondary recipients more efficiently than aBM CD34+ 
cells. a.-d. Peripheral blood chimerism kinetics of primary and secondary recipient mice receiving either aBM or 
FLC CD34+ cells or T cell-depleted bone marrow from mice 20 weeks post primary transplantation with 1.2x107 
aBM or FLC CD34+ cells.  Reconstitution of a. human CD45+ cells, b. B cells, c. T cells, d. and monocytes.  In all 
cases, bone marrow from one primary recipient was transplanted to one secondary recipient intravenously.  
Chimerism kinetics are shown for individual mice; n = 5 each primary and secondary aBM recipients; n = 4 each 
primary and secondary FLC recipients.  Kinetics of primary recipient mice are also shown in Figure 1.  Secondary 
recipients were all NSG female mice that received 1.5 Gy TBI prior to transplantation and did not receive a human 
thymus graft. 





secondary reconstitution from FLC CD34+ cells in human, B cell, monocyte, or T cell lineages.  By 
contrast, human cell repopulation was difficult to detect above background in secondary recipients of 
aBM in this experiment, perhaps because fewer cells were used for secondary transplantation than in the 
first experiment.  Human chimerism was significantly reduced in the spleen (Figure 6 - 11a) and bone 
marrow (6 – 11b) of secondary compared to primary aBM recipients.   
huCD45+ repopulation was sufficiently robust in FLC secondary recipients to permit comparison of 
repopulation of mature, APC, and progenitor human populations in the spleen and bone marrow of 
transplanted mice.  B cells were reduced, and T cells were increased in the spleens of secondary 
compared to primary recipient mice as a percentage of huCD45+ in the spleens (Figure 6 - 11c) of 
secondary recipients, although this trend was not observed in absolute numbers of splenocytes in 
secondary recipient animals (Figure 6 - 11f).  Absolute numbers of human populations tended to be lower 
in the spleens and were significantly decreased in the spleens and bone marrow of secondary recipient 
animals (Figure 6e - h).  APC populations, including monocytes, pDCs, and CD11c+ cDCs were present 
in similar proportions among huCD45+ cells (6 - 11e) in the spleens of secondary versus primary recipient 
mice.  In contrast, CD11c+ cDCs were increased as a proportion of huCD45+ cells (6 - 11f) in the bone 
marrow of secondary compared to primary FLC recipients.  We assessed progenitor reconstitution in 
secondary recipients of FLC CD34+ cells.  While the total percent of CD34+ cells and early progenitor 
populations (CD34+ CD38lo cells) were not significantly reduced among huCD45+ cells (Figure 6 - 11g, 
h), CD34+ CD38+ late progenitors, which include B/NK, CMP, MEP, CDP, MDP and GMDPs, were 
significantly reduced in secondary compared to primary recipients (6 - 11i).  Finally, we examined the 
proportion of hematopoietic progenitors among CD34+ cells in the bone marrow of primary and 
secondary FLC recipients (6 - 11j).  We found that erythroid and granulocyte progenitors, MEPs and 
GMDPs, were enriched in secondary FLC recipients compared to primary recipients, while common 





Figure 6 - 11: Reconstitution of human populations in primary and secondary FLC recipients.  a., b. Human 
CD45+ chimerism in primary and secondary recipients of aBM and FLC CD34+ cells from Experiment 2.  c., d. 
Primary and secondary reconstitution of human B and T cell populations as a percent of huCD45+ cells in primary 
and secondary FLC recipients in Experiment 2.  e. Total number of splenocytes and of f. huCD45+, B and T cells in 
primary and secondary FLC recipients.  g., h. Total number of cells per leg and of g. huCD45+, B and T cells in 
primary and secondary FLC recipients.  i.-m. Primary and secondary reconstitution of antigen presenting cell and 
progenitor populations as a percentage of huCD45+ cells in primary and secondary recipients of FLC CD34+ cells in 
Experiment 2.  j. Hematopoietic progenitor proportions as a percent of CD34+ cells in primary and secondary FLC 





Providing a more supportive HSC niche and transplanting aBM intrabone improves aBM 
APC reconstitution 
Our data suggested that poor maintenance of APCs by aBM transplanted mice is more likely due to 
reduced HSC and progenitor dosage and engraftment than to a reduced ability of aBM HSCs to produce 
APCs.  Thus, we explored strategies to try to improve APC reconstitution in aBM transplanted mice 
(Figure 6).  We used female recipient mice, which we have found have improved B cell engraftment [10].  
Additionally, a recent study demonstrated that direct injection of human HSCs into the bone increased 
human reconstitution compared to intravenous injection [351].  Other studies suggested that mesenchymal 
stem cell (MSC) coinjection enhanced human stem cell engraftment in clinical bone marrow 
transplantation [352, 353].  Additionally, in humanized mice reconstituted with fetal liver or cord blood-
derived HSCs, using human cytokine knock-in mice as hosts [14, 108, 112] or dosing transplanted mice 
with human cytokines [354] increased human APCs.  We observed that using mice transgenic for three 
porcine cytokines, IL-3, GM-CSF, and SCF (data not shown) and that using female recipients [10] 
improved APC reconstitution by aBM.  Based on these findings, we modified our standard aBM model, 
diagrammed in Figure 6-12a, by combining the described treatments to produce an optimized aBM 
model, as shown in Figure 6 - 12b.  Compared to historical personalized immune mouse data the 
combined measures led to enhanced reconstitution of human CD45+ cells (6 - 12c), B cells (6 - 12d), and 
monocytes (6 - 12f), without changing human T cell reconstitution (6 - 12e). These results suggest that 
procedures to increase local HSC dose and provide a more optimal environment for human hematopoietic 











Studies using immunodeficient mice transplanted with aBM-derived CD34+ cells (as used in 
“personalized immune” mice) have provided insight into human immune biology and autoimmune 
pathogenesis [9, 10].  However, human monocytes, B cells, and DC populations are poorly maintained in 
mice with human immune systems generated with aBM compared to those generated with the more 
widely-used FLC CD34+ cells.  T cells rely on signals from APCs for peripheral homeostasis [103] and to 
mount immune responses, so maintaining these cell types is critical for reconstructing a fully-functional 
human immune system in aBM-transplanted mice over long-term experiments.  Our progenitor 
population analysis suggested that reduced APC maintenance in aBM-transplanted animals is likely due 
to a global reduction in progenitor populations in the bone marrow of aBM compared to FLC and in the 
mice receiving them, including a reduction in the proportion of the most primitive CD34+ hematopoietic 
progenitors, the HSCs and multipotent progenitors (HSCs/MPPs).  APC populations are shorter-lived 
than naïve T cells and turnover more rapidly [141, 142, 146, 147], and thus may be more reliant on 
continual repopulation from bone marrow HSC/MPP populations.   
Analysis of FLC and aBM cells confirmed that phenotypic HSCs were rarer among aBM than FLC 
populations, such that humanized mice generated using aBM cells receive quantitatively fewer HSCs 
compared to those transplanted with FLCs.  Increasing the local dose of HSCs by transplanting aBM 
CD34+ cells directly into the mouse bone marrow niche, in conjunction with providing a more supportive 
bone marrow niche via MSC injection and using female recipient mice, which better engraft human B 
cells [10], and which expressed transgenic cytokines, improved human APC reconstitution.  Simply 
Figure 6 - 12: Optimization of the aBM humanized mouse model prolongs APC development. 
Schematic of a. the standard aBM transplantation model and b. the aBM transplantation model with optimization 
strategies.  b. Human CD45+ cells, p = 0.0075; c. human B cells p < 0.0001; d. human T cells; and e. human 
monocytes, p < 0.0001 from historical aBM data compared to optimized aBM mice, where aBM is transplanted 
intrabone in female porcine cytokine transgenic mice which are coinjected with mesenchymal stem cells. Data is a 
compilation of 25 aBM transplanted mice derived from five adult CD34+ donors compared to 9 optimized aBM 
transplanted mice derived from two adult donors.  Mean + SEM is shown.  **** = p < 0.001, *** = p < 0.005, ** = 





increasing the number of aBM CD34+ cells injected compared to FLC cells might also improve APC 
reconstitution, but typically numbers of aBM cells obtained from patient bone marrow aspirates are 
limiting.  Approaches to increase or expand HSCs from adult bone marrow could further improve human 
APC reconstitution in humanized immune mice generated using aBM CD34+ cells.   
Robust human repopulation was seen in secondary recipients of FLC CD34+ cells.  Secondary 
reconstitution by T cell-depleted bone marrow from humanized mice was almost indistinguishable from 
primary FLC CD34+ reconstitution in most populations examined.  By contrast, repopulation of 
secondary aBM recipients was much less robust, as previously reported [156].  This is evident despite the 
persistence of phenotypic HSCs (CD34+ CD38lo CD90+ CD45RA- cells) in the bone marrow of aBM 
transplanted mice, indicating that enrichment of phenotypic HSCs does not necessarily reflect expansion 
of functional HSCs.  We observed that most non-B cell APC populations reconstituted similarly in 
primary and secondary FLC recipients, suggesting that human FLC CD34+ cells generally retain their 
ability to support human APC populations in a murine environment.  However, CD11c+ cDCs were 
enriched and monocytes reduced in the bone marrow of secondary FLC recipients, echoing our 
observation that CD11c+ cDCs were enriched and monocytes reduced among human cells in primary 
recipients of aBM compared FLCs.  It will be important to discern whether this reflects the ability of the 
murine environment to better support some human cell populations than others or changes in the ability of 
human HSCs to produce and support specific cell types over time. 
Our comparison of APC maintenance in aBM compared to FLC mice led to efforts to optimize APC 
maintenance in aBM mice.  Poor human myeloid and B cell maintenance is a longstanding concern in 
humanized mouse research, including in fetal tissue-derived models [14, 108, 140, 344], and more 
research will be needed to fully optimize human APC development regardless of the CD34+ cell source.  
We and others [140] have observed that even in FLC humanized mice, human monocyte proportions in 





humans CD1c+ DCs are typically present at higher frequencies in most tissues compared to CD141+ cDCs 
[120, 131], but we observed similarly-sized populations of CD1c+ cDCs and CD141+ cDCs in FLC 
animals and quite small populations of CD1c+ cDCs in aBM-transplanted humanized mice.  Thoroughly 
comparing human APCs and hematopoietic progenitors in aBM and FLC mice has revealed biological 
differences in progenitor reconstitution.  Better understanding the biology and requirements of human 
stem cell engraftment and APC production potential from different source CD34+ cells could better 
inform additional efforts to improve the personalized immune and other humanized mouse models.  
Ideally, these improvements will allow this valuable patient-derived humanized mouse model to more 
fully recapitulate all aspects of central and peripheral T cell development and to improve our 








CHAPTER 7:  CONCLUSIONS AND FUTURE DIRECTIONS 
 
Developing therapeutic approaches for transplantation tolerance induction and better understanding 
the pathogenesis of autoimmune diseases will require experimental systems that allow detailed, 
physiological studies of human thymopoiesis, central tolerance, and T cell function.  In the studies 
described, we demonstrated that by using lentivirus to transduce human fetal CD34+ cells, we can 
generate something resembling a human TCR Tg model in an immunodeficient mouse.  This system can 
be used to answer questions about human T cell development and selection that were previously not 
amenable to experimentation.  Much of what we know about mouse TCR selection was determined using 
TCR Tg mouse models, mice genetically modified to encode a single pre-arranged TCR with known 
characteristics.  Previous studies of human T cell selection were limited to in vitro culture experiments 
[355-357] or repertoire analyses [173].  These are valuable experimental systems and provide important 
insights.  However, in vitro culture systems are artificial and may introduce artifacts, and repertoire 
analysis usually only supports descriptive studies.  A human TCR Tg system like the ones used here 
could provide useful, fully in vivo experimental systems to further validate and expand on previous 
findings.   
Additionally, because T cells rely on interactions with APCs for peripheral homeostasis, function, and 
tolerance maintenance, reduced human APC engraftment in humanized mouse models is a barrier to 
recapitulating physiological human T cell behavior in a mouse.  We have observed that human APC 
maintenance is suboptimal in mice transplanted with CD34+ cells from bone marrow of adult humans.  
Transplanting mice with cells from adult patients provides a unique opportunity to recapitulate the 
immune system of individuals with known health histories and diverse genetic backgrounds and to model 
human T cell development in those contexts.  Suboptimal APC maintenance limits the potential 





mice transplanted with either adult bone marrow or fetal liver derived CD34+ cells.  We found that 
reduced APC populations correlated with lower HSC reconstitution in aBM transplanted mice.  
Fortunately, we also found that approaches to dose aBM CD34+ cells directly into the murine bone 
marrow niche while providing appropriate cytokine and stromal support improved APC maintenance in 
humanized mice transplanted with aBM CD34+ cells.  Patient-derived humanized mouse models with 
superior APC maintenance will likely better recapitulate physiological human T cell function, including 
more consistent vaccination responses [108].  This will facilitate improved human T cell studies to better 
understand both basic human immunology and the pathophysiology of autoimmunity. 
In vivo experimental systems to study human TCR selection and human peripheral T cell homeostasis 
and function, like the ones described here, will be essential for better understanding human T cell 
development.  These experiments demonstrate and improve upon the utility of these systems to address 
pressing questions for human xenotolerance induction and autoimmunity; questions that become more 
urgent as clinical xenotransplantation becomes a reality and as the burden of autoimmune disease 
continues to increase. 
TCR transgenic mouse models to study xenotolerance induction and 
autoimmunity 
 In the work described here, we used TCR Tg humanized mice to address previously unanswerable 
questions about the ability of a transplanted pig thymus to support the positive selection of human-
restricted TCRs.  For a transplanted pig thymus to provide a future patient with a functional human 
immune system, it will likely have to support the selection and maturation of human TCRs that can 
respond to antigens presented by human APCs.  Our previous studies suggest that in xenogeneic thymic 
transplantation, T cells are selected based on their ability to interact with swine pMHC complexes 
exclusively [285].  Previous data using conventional humanized mouse models transplanted with 





models) had shown that a diverse repertoire of human TCRs is selected in a swine thymus, but did not 
provide information about the restriction or reactivity of those TCRs [210].  Experiments in the same 
model demonstrated that human cells selected in a pig thymus could mount human-restricted immune 
responses, but, while these experiments did not directly compare the strength of the human-restricted 
immune response in T cells selected in a pig or human thymus, the human-restricted tetanus vaccination 
response of human T cells selected in a pig thymus appeared to be less robust than that of T cells selected 
in a human thymus [7].  Additionally, there is evidence in the pig-to-mouse thymus transplantation model 
that T cells selected on thymic MHC that differ from those in the periphery have poor peripheral 
homeostasis, which may contribute to autoimmunity [212-214].  This would be an unacceptable risk for 
future patients.  Therefore, it was very important to be able to better address the ability of a transplanted 
pig thymus to support the selection of TCRs that were known a priori to be human-restricted.   
We were able to use the TCR Tg humanized mouse model to do this, introducing a well-characterized 
human-restricted TCR into fetal human CD34+ cells to see if it could be positively selected in a pig 
thymus graft.  Using this model, we demonstrated that the HLA-A2-restricted MART1 TCR is not 
positively selected in a pig thymus, as GFP+ MART1 TCR+ cells were present at reduced proportions in 
pig thymus grafts compared to HLA-A2+ thymus grafts.  We also showed that MART1 TCRbright T cells 
were only detected in the spleens of mice transplanted with HLA-A2+ thymus grafts and not swine 
thymus grafts.   
This result contrasts with previous studies in the pig-to-mouse model, where a mouse-restricted TCR 
was shown to be positively selected within a pig thymus [223].  This occurred even when the mouse did 
not express mouse MHC that could positively select the TCR; in this case, the TCR was not positively 
selected in a native mouse thymus but could be positively selected in a grafted pig thymus, indicating that 
porcine MHC alone was sufficient and solely responsible for positive selection of this mouse TCR [223].  





possible that this result reflects a difference in human and mouse immune biology.  It is also possible that 
different results were observed because the TCR used in mouse studies was class II MHC-restricted rather 
than class I MHC-restricted.   
CD8+ T cells, which are restricted to class I MHCs, have been shown to be exquisitely host-restricted 
in murine bone marrow chimera experiments [358-360].  Indeed, a typical class I MHC-restricted human 
TCR has higher affinity for its specific pMHC combination than does a class II MHC-restricted TCR 
[56].  Thus, weakly cross-reactive TCR/pMHC interactions that may allow swine MHC to support 
positive selection of a xenogeneic class II MHC-restricted TCR may not be enough for a class I MHC-
restricted TCR.  Given that class I MHC-restricted CD8+ T cells are cytotoxic and can cause extensive 
damage when activated inappropriately, it would make sense for the requirements for CD8+ T cell thymic 
selection to be more stringent, to keep these potentially destructive T cells on a shorter proverbial leash.  
This, combined with the studies described here, would suggest a xenogeneic thymus may be less likely to 
support positive selection of human class I MHC-restricted TCRs in general.  If the reduced selection of 
MART1 TCR is a generalizable phenomenon, a future swine thymus-transplanted patient might be more 
vulnerable to viral infections and tumorigenesis.  More studies will be needed to assess selection of 
additional class I MHC-restricted human TCRs and compare it to that of human class II MHC-restricted 
TCRs in a pig thymus.  In the meantime, this result lends additional urgency to efforts in the lab to 
develop a hybrid organ system to improve positive selection of human-restricted TCRs in a swine thymus 
[361].  The MART1 TCR Tg model will be an ideal in vivo experimental system to assess whether these 
approaches improve positive selection of human-restricted TCRs. 
It is important to understand whether a transplanted pig thymus can support positive selection of 
human-restricted TCRs, but it will also be useful to understand how and how efficiently a pig thymus can 
tolerize human pig-reactive TCRs, and, especially, to ensure we understand in advance which cell types 





and splenic T cells in the pig-to-humanized mouse models suggest that human T cells are tolerized to 
swine antigen through a mixture of deletional and regulatory tolerance [7], but did not elucidate which 
types of TCRs are deleted or converted to Treg, or what is required to mediate this tolerance.  
Incorporating pig-reactive TCRs into future studies using TCR Tg models will be helpful for 
understanding mechanisms of T cell xenotolerance induction, as well as what is required to achieve and 
maintain them.  For instance, in a model of xenogeneic mixed chimerism, we found that continued 
deletion of mouse thymocytes required persistence of donor MHC class II positive APCs in the recipient 
thymus [202], which were likely DCs of hematopoietic origin.  Using the TCR Tg humanized mouse 
model, we may find that porcine hematopoietic APCs also contribute to tolerizing human pig-reactive 
TCRs in a transplanted pig thymus.  However, APCs like DCs are relatively short-lived and require 
continued repopulation from the hematopoietic compartment [142].  Maintaining these cells in the thymus 
might require inducting stable pig-human mixed chimerism, which so far has been difficult to achieve.  
Using the TCR Tg humanized mouse model, we could assess whether tolerization of xenoreactive TCRs 
continues after porcine hematopoietic APCs are no longer detected in the transplanted thymus. 
Additionally, we would need to assess that biological processes are in place to efficiently tolerize all 
types of xenoreactive TCRs.  For instance, either swine TECs or hematopoietic DCs or both may be able 
to efficiently tolerize directly pig-reactive human TCRs, which react to swine MHC/peptide complexes.  
However, indirectly pig-reactive human TCRs, which respond to swine antigen presented on human 
MHC, are likely to be a major concern in xenotransplantation [310, 311] and would likely require 
presentation of pig antigen on human hematopoietic DCs for tolerization.  This requires human DCs that 
seed a transplanted pig thymus to pick up and present porcine antigen efficiently.  This will require 
efficient transfer of antigens between porcine and human APCs in the transplanted thymus, across a 
species barrier.  Maintaining human tolerance of the transplanted organ would likely require transfer of 
porcine tissue-restricted as well as ubiquitous antigens to human APCs for antigen presentation.  





thymus in the TCR Tg model would help us assess whether interactions between human and swine APCs 
adequately support presentation of swine antigen on human MHC for tolerization in the transplanted 
thymus.   
These important questions were not addressable without a TCR Tg system using well-characterized 
pig-reactive TCRs with both direct and indirect xenoreactivity.  Now, five potentially interesting human 
pig-reactive T cell lines have been successfully identified.  One was cloned into a TCR lentivirus and 
appears to express appropriately on the surface of transduced JRT3-T3.5 cells, an immortalized TCRnull 
human T cell line.  Strategies to characterize this and other TCRs in vitro to better understand their 
xenoreactivity have been optimized as well.  This represents a useful toolkit for future xenotolerance 
induction studies. 
We have also performed preliminary work assessing the thymic selection of Clone 5, a known 
autoreactive TCR in an autologous HLA-DQ8+ fetal system, studying the selection and tolerization of this 
known diabetogenic TCR in the presence of an HLA molecule associated with increased T1D risk.  
Preliminary data in this system suggest the Clone 5 TCR is deleted under these conditions.  This suggests 
that HLA-DQ8 does not inherently support the selection of or fail to tolerize some autoreactive TCRs like 
the Clone 5 TCR, despite its association with T1D risk.  The observed deletion of Clone 5 is also 
interesting, since the insulin epitope it recognizes, B9:23, is known to bind weakly to HLA-DQ8, and is 
thought to be presented in an atypical conformation within the HLA-DQ8 binding cleft [333].  It was 
thought that these unusual properties might prevent appropriate presentation of insulin B9:23 in the 
thymus, allowing Clone 5 cells to escape deletion.  However, we observe that Clone 5 is in fact deleted in 
the thymus, which suggests that TCRs can be tolerized to insulin B9:23, despite its unusual properties.  It 
is possible that Clone 5 recognizes insulin B9:23 in a register that is more conducive to appropriate 





observation.  Future studies examining the selection of additional autoreactive TCRs could help determine 
whether this observed robust deletion of an autoreactive TCR is a generalizable phenomenon.   
In the meantime, this study represents the first observation of a human autoreactive TCR being 
negatively selected under relatively natural conditions in a human thymus and opens the door for future 
studies examining the development of human autoimmunity.  While HLA-DQ8 confers increased risk for 
T1D development, at least 60 non-HLA loci also increase T1D risk [42, 362, 363], including mutations to 
the insulin gene itself or that affect intrathymic insulin expression [224, 332], and many of these 
mutations may contribute to inefficient tolerization of autoreactive TCRs.  Using the Clone 5 TCR Tg 
humanized mouse model, we could assess the combined effects of these other risk loci to determine if 
these additional mutations lead to inefficient tolerization of the Clone 5 TCR.  We will begin doing this 
by introducing the Clone 5 TCR transgene to CD34+ cells obtained from healthy adults or patients with 
T1D, to determine if tolerization of Clone 5 is less robust in an immune system generated with CD34+ 
cells from a patient with T1D. 
We hope to use this model to better understand the biology of negative selection of human TRA-
reactive T cells.  In central tolerance a mixture of thymic stromal cells and APCs of hematopoietic origin 
present self-antigen to developing thymocytes.  The thymic stromal cells in the medulla have a 
specialized ability to produce TRAs, which are antigens normally produced in peripheral tissues.  
However, studies in mice have shown that hematopoietic APCs in the thymus can pick up and present 
these TRAs and play an important role in tolerizing thymocytes to them [364-366].  We could use the 
TCR Tg system to assess how different human APC populations contribute to tolerizing the Clone 5 TCR 
to insulin, a prototypical TRA.  Preliminary experiments in our lab are exploring whether expression of 
HLA-DQ8 on hematopoietic APCs is required for Clone 5 deletion.  This can be done simply by 
transducing HLA-DQ8+ or HLA-DQ8- FLC CD34+ cells with the Clone 5 transgene and co-transplanting 





deleted in the absence of DQ8+ hematopoietic APCs, histological studies in this model could assess if 
DQ8- hematopoietic APCs acquire HLA-DQ8 molecules from human thymic stroma, or if HLA-DQ8 on 
the thymic stroma alone can mediate deletion.  Development of Clone 5 Tg cells in an HLA-DQ8- thymus 
could also be assessed, although the Clone 5 TCR is not expected to be positively selected in the absence 
of its restriction element. 
The Clone 5 TCR Tg humanized mouse model is also likely to be important for future studies of 
xenogeneic tolerance induction.  We can use this model to assess whether human autoreactive TCRs are 
appropriately tolerized in a transplanted swine thymus.  TRA presentation depends on stochastic 
expression of genes in the genome of thymic epithelial cells, so a transplanted swine thymus which 
contains only swine thymic epithelial cells will only be able to express swine TRAs.  This may mean that 
some human autoreactive TCRs may escape deletion in a swine thymus if there is poor homology 
between the antigens.  Even if there is high sequence homology between antigens, as in the case of 
insulin, the swine mTECs will only present insulin peptides on swine MHC molecules to developing 
thymocytes for tolerization.  Thus, thymocytes that might react unduly to human MHC/insulin peptide 
complexes may not be tolerized adequately.  We will have to assess the likelihood that swine thymus 
transplantation will leave future patients vulnerable to autoimmunity, so experiments examining whether 
Clone 5 and other autoreactive TCRs can be tolerized in a pig thymus – likely performed using the TCR 
Tg humanized mouse model – will be necessary.   
The studies described demonstrate the utility of the TCR Tg humanized mouse model to continue 
answering longstanding questions in xenotolerance induction and autoimmunity.  Future experiments, 
including further exploring positive selection of human-restricted TCRs in a pig thymus, studying 
mechanisms of xenotolerance induction using well-characterized pig-reactive human TCRs, and assessing 
tolerization of autoreactive human TCRs in a transplanted pig thymus will help assess and predict 





human TCRs have been characterized in patients with T-cell mediated autoimmunity, and the TCR Tg 
humanized mouse model could be used to assess whether these autoreactive TCRs are typically tolerized 
in normal thymic development.  In short, the studies described here are, hopefully, only the initial studies 
utilizing the TCR Tg humanized mouse model to study important, therapeutically-relevant questions 
about human T cell immunology.   
Hopefully, future experiments will be able to expand on the studies described here.  Staining 
optimization that is now complete should allow us to assess the selection and development of Tregs in the 
TCR Tg humanized mouse model, adding a dimension to our selection analysis that we had not 
previously included.  Implementing modern single-cell analytic technologies in the context of these 
models may allow us to associate molecular signals with the phenomena we observe, allowing us to 
identify the molecular signature for human thymocytes actively undergoing deletion, positive selection or 
Treg conversion.  Because these models allow us to examine human cells with known manipulations 
undergoing normal immunological processes, they present a novel opportunity to characterize those 
processes in detail. 
Ultimately, the TCR Tg humanized mouse model could also be used to address questions related to 
human peripheral T cell function.  While the experiments described so far have used the TCR transgenic 
humanized mouse model to study thymocyte development, much of what is known about peripheral T cell 
function in mice was also elucidated using murine TCR Tg models, such as the ovalbumin-reactive OT-I 
and OT-II mouse lines.  These lines have often been used as sources of defined populations of T cells for 
adoptive transfer experiments.  They make it possible to track antigen-specific T cells through 
homeostasis, vaccination responses, and memory formation.  There is no reason to imagine that TCR Tg 
humanized mouse models could not be used in a similar manner.  TCR Tg human cells could conceivably 
be harvested from transplanted animals for experiments studying human peripheral responses in 





reconstituted with human APC populations determined that different T cell subsets required different 
APCs to expand and convert from the naïve to the memory phenotype [103].  Similar experiments might 
be facilitated by having the transplanted cells express a single TCR with known properties.  An analogous 
experiment, using T cells harvested from a humanized mouse and lentivirally-transduced with a TCR, has 
been used to model insulitis induction [172], and may pave the way for additional uses of this model. 
Future experiments will need to address some seemingly artifactual observations described in these 
studies.  As discussed in Chapter 3, we observe bimodal staining with MART1 tetramer on peripheral T 
cells in the MART1 TCR Tg humanized mouse model.  Based on previous data in murine and humanized 
mouse Tg models, we interpreted MART1 TCRbright cells as true MART1 Tg cells and hypothesized that 
MART1 TCRdim cells had rearranged an endogenous TCRα chain, thus co-expressing multiple TCR 
specificities to facilitate positive selection in non-selecting thymocytes.  This hypothesis was supported 
by our observation that MART1 TCRbright and MART1 TCRdim cells showed similar surface expression of 
CD3.  CD3 expression correlates with TCR expression with a known stoichiometry [289, 290], so this 
supports the notion that MART1 TCRdim cells express multiple TCRs.  If needed, single cell repertoire 
analysis could confirm that MART1 TCRdim cells do indeed express multiple TCRα chains.  While 
repertoire analysis shows that a high percent of normal human T cells – between 10-30% – rearrange and 
express multiple TCRα chains [173, 292], a much higher proportion of GFP+ MART1 TCR+ falls into this 
TCRdim population, at least in some mice.  This occurred regardless of the selecting thymus and in both 
CD4+ and CD8+ T cells.  It will be interesting to observe in future experiments if similar proportions of 
TCRdim cells emerge in other TCR Tg humanized mouse models.  It is possible that the low expression of 
the HLA-A2-restricted MART1 TCR gives TCRdim cells an advantage in the periphery of mice 
transplanted with human HLA-A2+ CD34+ cells.  We have observed that CD8+ T cells in humanized mice 
have reduced ability to persist in the periphery [7], and having enforced expression of a human-restricted 





A potentially artifactual population was also observed in the preliminary Clone 5 selection studies.  A 
substantial GFP+ Vβ11- population is observed among T cells in the Clone 5 model.  Since these cells are 
identified by TCR Vβ staining, this population cannot be explained by rearrangement of endogenous 
TCRα chains and must reflect a more complex process.  Perhaps endogenous TCRβ chains have 
rearranged in these cells.  This would seem to be unlikely, since expression of a pre-arranged TCR should 
cause allelic exclusion and prevent rearrangement of the endogenous TCRβ [177].  However, if Clone 5 
TCR+ cells are deleted efficiently in this experimental system, perhaps only the T cells that can overcome 
allelic exclusion on rearranged endogenous TCRβ can survive thymopoiesis and escape to the periphery.  
This might lead to an enrichment of this otherwise unexpected cell population.  More experiments are 
needed to better understand the significance of the TCRdim or GFP+ Vβ11- populations in these models, to 
understand if they represent physiologically important immune processes or artifacts of the TCR 
transgenic system.  If they are indeed artifactual, we will have to take them into account in interpreting 
our results, as described in previous chapters.  TCR Tg systems are somewhat artificial, including in the 
regular TCR Tg mouse models, and sometimes unusual, non-physiological phenomena do occur.  
However, these models are still extremely useful for working out mechanisms of T cell selection and 
tolerance. 
Finally, in future experiments we hope to incorporate in vivo and ex vivo culture approaches to further 
validate the observations we make in vivo using the TCR Tg humanized mouse.  Experiments in the 
laboratory are ongoing to optimize human fetal thymic organ cultures to incorporate human TCR Tg 
thymocytes into in vitro selection studies.  Observing the same patterns of thymocyte selection and 
tolerization in an in vitro system and in transplanted mice will increase our confidence in the data 
obtained thus far. 
In sum, the experiments described here lay the groundwork for future work using this in vivo 





reactivity.  This system could be used to answer many longstanding and clinically relevant questions in 
human immunology, particularly for transplantation tolerance and autoimmunity.  
Improving human peripheral APC compartments for autoimmunity 
While experimental systems to study thymic selection of T cells provide interesting and valuable 
insights, understanding thymic selection is largely important because of what happens in the periphery of 
humans and animals after thymic selection is complete – whether the T cells that emerge from thymic 
development express TCRs that can mediate normal immune function without causing autoimmunity.  
Emerging thymocytes and mature T cells must receive signals from peripheral APCs to mature correctly 
and to maintain peripheral homeostasis [89, 91, 92, 367].  Because of this, it is critical that humanized 
mouse models appropriately reconstitute and maintain physiological levels of human APCs, including 
monocytes and DCs.  Human APC reconstitution is largely considered suboptimal in humanized mouse 
models and decades of work have gone into improving it [14, 108, 112, 344, 345].  Even so, 
immunodeficient mouse strains that can both support optimal human myeloid engraftment and long-term 
studies of a developing human T cell responses have not yet been developed.   
We have found that human APC maintenance is further suboptimal in our PI mouse model, which uses 
stem cells from patients, usually adults or adolescents, to reconstitute an individual’s immune system in 
transplanted mice.  We observe this especially at later times post-transplant.  This is likely due to 
ontogenetic differences between adult bone marrow and fetal liver CD34+ cells, but it could limit the 
utility of the PI mouse model.   If APCs are not maintained long-term in these models, they will not be 
present to mediate physiological interactions with T cells over long-term experiments, preventing the PI 
model from appropriately recapitulating normal human immune cell functions.   
To better understand the biology underlying this reduced APC maintenance, we directly compared 
human APC and hematopoietic progenitor reconstitution in humanized mice transplanted with either adult 





peripheral blood of aBM compared to FLC transplanted mice.  We also saw that APC populations were 
globally reduced in aBM compared to FLC mice, while T cell populations were less affected.  This 
seemed to correlate with a reduction in early progenitor populations in the bone marrow of mice 
transplanted with aBM compared to FLC cells.  Interestingly, when we examined the proportions of 
APCs within human CD45+ cells, we found that some populations were maintained at a similar or even 
increased percentages in aBM compared to FLC-transplanted mice.  We examined the proportions of 
progenitors within CD34+ cells to see if aBM hematopoietic progenitors were somehow skewed away 
from APC lineages.  Our observations did not support this, and instead indicated that the main differences 
in the bone marrow of aBM compared to FLC mice is a reduced percentage of the earliest progenitors, 
coupled with a global reduction in progenitor populations.  Analyzing freshly-isolated aBM and FLC 
mononuclear cells showed that early hematopoietic progenitor populations were present at a reduced 
frequency in aBM compared to FLC.  This suggests that aBM mice may simply receive fewer HSCs than 
FLC mice in transplantation.  Because APC populations tend to be short-lived compared to T cells [141-
147], they are likely more reliant on continual renewal from hematopoietic stem and progenitor cells, so 
reduced hematopoiesis due to a smaller pool of stem cells transplanted in aBM mice would likely be first 
detected as a reduction in APC population maintenance. 
Notably, while early progenitors were reduced in the bone marrow of aBM compared to FLC mice, 
they persisted, and, while much less robust than FLCs, were able to repopulate secondary recipients with 
APC populations in some instances.  Based on our characterizations we hypothesized that steps to 
enhance local progenitor dose to the bone marrow and provide a more supportive progenitor niche could 
help improve APC maintenance in aBM mice.  A combination of approaches to do just this effectively 





Future directions  
In these experiments we explored a possible explanation for why APC maintenance is different in 
patient-derived PI humanized mice compared to mice made with fetal liver CD34+ cells and drew on that 
insight to inform strategies to improve APC maintenance in the PI model.  Hopefully these modifications 
will allow us to use the PI mouse model to more completely model autoimmune pathogenesis in models 
representing individual patients.  Previous studies in the PI mouse model have shown that immune 
systems generated using CD34+ cells from healthy donors or patients with T1D reconstituted their APC 
populations differently, with an increased B cell reconstitution in mice that received CD34+ cells from 
T1D individuals [10].  If differences in APC reconstitution distinguish between healthy and 
autoimmunity-prone immune systems, it is even more critical that humanized mouse models using 
patient-derived immune systems recapitulate APC engraftment and reconstitution from the human host.  
Therefore, future studies using the PI mouse model will adopt the optimization strategies explored here. 
Efforts to improve APC maintenance in humanized mouse models, including the FLC model and our 
PI model, will continue in the lab.  The APC characterization described here suggests that, even in the 
FLC model, peripheral repopulation of monocytes and DCs differs from what has been reported in 
humans [131].  Future characterization studies examining human APC repopulation should include 
comparisons to human donor controls to see if these differences are real.  Major differences seem to be a 
reduced frequency of CD1c+ cDCs in humanized mice compared to what has been reported in humans 
[131], and lower overall APC populations in the spleen compared to bone marrow of aBM mice.  CD1c+ 
DCs traffic between peripheral tissues and lymphoid tissues, which are known to be poorly developed in 
most humanized mice [368], and previous reports have suggested that human APCs do not receive signals 
needed to promote their optimal egress from the mouse bone marrow [369]. Further studies would be 
needed to compare APCs in humanized mice and in healthy human immune systems to confirm these 





APC maintenance in humanized mouse models, including providing more supportive niches for human 
secondary lymphoid structures for CD1c+ DC maturation and better understanding of limitations on 
human APC development in the murine bone marrow and peripheral environments. 
In the meantime, studies following up on the differences in APC population reconstitution that were 
observed are warranted.  While APCs were globally reduced in aBM compared to FLC mice, when we 
examined the proportions of APC populations among the human immune cells, we observed that some 
populations were maintained quite well as a percentage of huCD45+ cells in aBM mice compared to FLC 
mice.  CD11c+ DCs were enriched among huCD45+ cells in aBM compared to FLC mice, although their 
absolute numbers were lower.  However, other APC populations, like pDCs, were reduced among 
huCD45+ cells in aBM compared to FLC mice.  It would be interesting to understand the biology 
underlying this observation.  Additional studies could help elucidate whether these differences have to do 
with what the different types of CD34+ cells give rise to at different stages of ontogeny, or if they reflect 
an ability of some cell populations rather than others to more readily survive and proliferate in a murine 
environment. 
The studies described raise questions about the biology of human APC development and maintenance 
in a transplanted mouse that would be worth exploring.  However, by improving APC maintenance in 
aBM-derived mouse models, they have also helped us reproduce a more physiologically normal 
peripheral human immune system in an experimentally tractable patient-derived mouse model.  Such 
models will be useful for studying peripheral homeostasis and function of human T cells, allowing us to 
answer questions about human T cell immunology that were previously difficult to answer, and hopefully 
allowing us to explore the development of autoimmune disorders in patients.  In the future, mice with 
fully-optimized patient-derived immune systems, with physiological human APC compartments, could 
conceivably be combined with the TCR Tg humanized mouse system to study mechanisms of selection 





the humanized mouse models described here hopefully represent useful tools for exploring human 
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APPENDIX: A NOVEL IMMUNODEFICIENT MOUSE STRAIN FOR 
HUMAN STEM CELL TRANPLANTATION 
 
Mouse husbandry and analysis performed in collaboration with Éstefania Chavez, Andrea Vecchione.  
NOD-SCID IL15Rα-/- mice were generated at The Jackson Laboratory in collaboration with Racheal 
Wallace, Dr. Michael Wiles, and Dr. David Serreze. gRNA design was done in collaboration with Dr. Lei 
Ding. 
 
Immunodeficient mouse strains for transplantation of human cells 
Rationale for developing the NOD-SCID IL15Rα-/- mouse 
As described in Chapter 6, human immune cell engraftment, especially of human APCs, is thought to 
be suboptimal in immunodeficient mice transplanted with human CD34+ cells [14, 110, 112].  Perhaps 
because of this, interactions between T cells and peripheral APCs, especially B cells, are thought to be 
suboptimal in current mouse models with human immune systems.  Poor interactions between human B 
and T cells in transplanted immunodeficient mice are thought to explain the observation that mice 
transplanted with human CD34+ cells do not mount consistent vaccination responses with class-switched 
antibodies [108].  These B-T interactions may not occur in transplanted mice in part because secondary 
lymphoid structures develop poorly in commonly-used immunodeficient mouse strains, particularly the 
current gold standard NOD-SCID γcnull (NSG) mouse [368, 370].  NSG mice have been adopted as 
popular hosts for human cell transplantation because they have been shown to support increased human 
peripheral blood chimerism compared to NOD-SCID mice, which have an intact γc chain [371].  This is 
thought to be because NOD-SCID mice, unlike NSG mice, produce NK cells, which can attack human 
cells.  However, NOD-SCID mice but not NSG mice have been shown to develop more robust peripheral 
lymphoid structures [368] which may support improved B-T interactions and thus more robust function of 





Peripheral lymphoid structures develop in NOD-SCID but not NSG mice because NOD-SCID mice 
retain γc receptor signaling.  Numerous cytokines signal in part through receptors containing γc, including 
IL-4 [372], IL-7 [373], IL-9, and IL-21 [374], in addition to IL-2 and IL-15 [375].  Some of these 
cytokines are thought to contribute to secondary lymphoid development, especially by supporting the 
development of lymphoid tissue inducer cells [376], which is prevented from happening in NSG mice due 
to the loss of γc receptor signaling.  Indeed, work in other labs has shown that overexpressing TSLP to 
activate lymphoid tissue inducer cells in the absence of IL-7 signaling improved both secondary lymphoid 
structures and vaccination response on a Balb/c Rag2-/-IL2rg-/- SirpaNOD background [377], suggesting that 
reintroducing at least one γc cytokine signaling pathway can improve the secondary lymphoid structure 
and thus function of engrafted human immune cells.  We therefore hypothesized that an optimal 
immunodeficient mouse for human cell transplantation would be able to mediate most γc cytokine 
Figure A - 1 Schematic and PCR confirmation of generated IL15Rα KO alleles. 
a., c., e. Diagrams of the IL15Rα locus showing the seven exons that make up the gene, with targeted sites indicated.  






signaling without producing murine NK cells.  IL15Rα deletion has been shown to prevent murine NK 
cell development and function [378, 379].  Therefore, we hypothesized that a NOD-SCID IL15Rα-/- 
mouse would represent an immunodeficient strain that could support optimal secondary lymphoid 
development but would retain the increased human cell engraftment seen in immunodeficient mice that do 
not make NK cells.  
Use of CRISPR to generate a variety of IL15Rα knockout alleles on a NOD-SCID 
background 
We used CRISPR/Cas9 technology to rapidly target the IL15RA locus.  Previous IL15Rα deletion 
strategies using traditional methods have targeted exons 2 and 3 of the IL15RA locus to generate IL15Rα 
KO mice.  We targeted two sites in the vicinity of the IL15Rα start codon (ATG), hypothesizing that 
targeting the start codon would prevent expression of IL15Rα.  We cloned gRNAs into the pX335 vector, 
which encodes for a modified Cas9 enzyme that generates nicks, rather than double strand breaks, at the 
site of gRNA targeting.  This approach helps to decrease off-target effects of CRISPR/Cas9, which are 
often a major concern [380, 381].  Additionally, our collaborators at The Jackson Laboratory (Bar Harbor, 
ME) generated gRNAs targeting Exon 6 of the IL15Rα, since this region of the gene had the primary 
sequence characteristics of a transmembrane domain and thus might be required for cell surface 
expression and signaling.  We also used both sets of gRNAs to generate animals where almost all the 
IL15Rα locus had been deleted, from the start codon to exon 6.  Schematics of the IL15Rα knockout 
alleles, as well as example gel electrophoresis confirming generation of said alleles, is shown in Figure A 
- 1. 
Appendix: Supplemental Methods 
CRISPR 
We generated guide RNAs targeting the start codon of the IL15RA locus (IL15Rα ATG) using the 





available at https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design-help.  We confirmed 
that the recommended gRNA sequences were appropriate by comparing to the NOD/ShiLtJ reference 
sequence available on the Wellcome Sanger (Hinxton, UK) website, 
https://www.sanger.ac.uk/science/data/mouse-genomes-project.   
gRNA sequences are shown in Table 6.  The gRNAs were purchased (Integrated DNA Technologies, 
Coralville, IA) and cloned into the pX335 plasmid, which was provided to us as a gift from Dr. Lei Ding.  
The pX335 plasmid was selected because it encodes a genetically modified Cas9 endonuclease which 
generates nicks, rather than double-strand breaks, in targeted DNA [382].  Using a nickase combined with 
multiple targeting gRNAs may help reduce off-target effects, a major concern with standard CRISPR 
approaches.   
gRNAs were validated in EL4, a murine cell line [383] that expresses IL15Rα.  EL4 cells were 
propagated in CML medium, as described in Chapter 2.  gRNA_pX335 plasmids were transduced into the 
EL4 line by nucleofection using an Amaxa nucleofector and the Cell Line Nucleofector Kit L (Lonza, 
Basel, Switzerland) according to manufacturer’s instructions.  Appropriate targeting of the IL15Rα was 
confirmed using the IDT Surveyor Mutation Detection Kit (Integrated DNA Technologies, Coralville, 
IA) per manufacturer’s instructions.  We confirmed that gRNA targeting led to a reduction in surface 
IL15Rα expression by antibody staining 120hrs after transfection, using an anti-IL15Rα antibody (APC-
labeled DNT15Ra, eBiosciences, San Diego, CA). 
Table 6: gRNA sequences for targeting the IL15Rα ATG 
gRNA Sequence 
gA 5’- CAC CGT CCC CAG CAG TGA CCC AAC - 3' 
gB1 5’- CAC CGT CGC CGC AGC TCC GGG GCT A - 3' 






NOD-SCID IL15Rα knockout mice were generated by our collaborators at The Jackson Laboratory.  
Animals were made by injecting gRNAs into NOD-SCID embryos.  IL15Rα E6-/- animals were generated 
using NOD-SCID Emv30null embryos.  Progeny were screened by The Jackson Laboratory to detect 
knockout animals.  Once knockout animals were generated, animals were sent to us and further 
propagated in-house in our HPPF animal facility.  In some cases, The Jackson Laboratory provided us 
with heterozygous knockout animals, which we crossed in-house to generate NOD-SCID animals for 
controls.  NSG animals were also obtained from The Jackson Laboratory and propagated in-house. 
All animal procedures were approved by the Institutional Animal Care and Use Committees of the 
Columbia University Irving Medical Center and The Jackson Laboratory. 
Liver cell processing 
Single cell suspensions of mouse livers were generated by mechanical dissociation and filtered 
through a 100μm cell strainer (BD Falcon, Franklin Lakes, NJ).  Dead cells and other debris were 
removed by Percoll separation using 37.5% isotonic Percoll (Fisher Scientific, Waltham, MA).  
Erythrocytes were subjected to lysis buffer treatment and remaining cells passed through a 40μm filter 
prior to FCM analysis. 
NK cell functional assays 
For interferon gamma (IFNγ) secretion assays, bulk splenocytes were depleted of erythrocytes by hypo 
osmotic lysis, then incubated for 4 hours at 37ºC with 5% CO2 in RPMI 1640 (Thermo Fisher Scientific, 
Waltham, MA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gemini BioProducts, 
West Sacramento, CA) in the presence of phorbol 12-myristate 13-acetate (PMA) and Ionomycin (Sigma 
Aldrich, St. Louis, MO).  Brefeldin A (eBiosciences) was added after 1.5 hours. Intracellular staining for 
IFNγ was performed using a FoxP3/Transcription Factor Staining Buffer Set Kit (eBiosciences) per 





Yac-1 and RL♂1 murine target cell lines were cultured in RPMI 1640 and 10% FBS.  Erythrocyte-
depleted splenocytes from NSG mice were used as control non-target cells.  Control and target cell 
populations were labeled with fluorescent amine binding dyes (CFSE, Molecular Probes, Eugene, OR; 
and e450, eBioscience, respectively) and combined. Bulk splenocytes from age and sex-matched NOD-
SCID and IL15RαE6-/- were harvested and mixed with the Target/Control mixture at the indicated ratios. 
Bulk splenocytes were used, since NK cells are the only cytotoxic populations present in either mouse 
strain. Cells were incubated together for 4 hours at 37ºC with 5% CO2, stained for viability with DAPI 
(4',6-Diamidino-2-Phenylindole, Dilactate, Sigma Aldrich) and analyzed by multicolor FCM. 
Target/Control ratio was calculated as: 
% 𝐷𝐴𝑃𝐼− 𝑇𝑎𝑟𝑔𝑒𝑡 𝑐𝑒𝑙𝑙𝑠
% 𝐷𝐴𝑃𝐼− 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠
 
Statistical analysis 





NK cells are present and functional in NOD-SCID IL15Rα E6-/- mice 
We detected similar proportions and numbers of NK cells in the spleens of IL15Rα E6-/- compared to 
NOD-SCID mice (Figure A - 2).  Similar results were observed in the peripheral blood, bone marrow, 
and liver (not shown).  Given the unexpected observation that E6-/- animals still had NK cells, we wanted 
to see if the loss of exon 6 had affected their function.  We did not detect significant differences in splenic 
NK cell IFNγ secretion of NOD-SCID and IL15Rα E6-/- splenic NK cells in response to PMA/ionomycin 
stimulation (Figure A-3a, b).  Additionally, we measured NK cell functionality using a dye-based killing 
assay to detect killing of murine target cell lines (Figure A-3c-e).  No differences in NK killing activity 
were detected between splenic NK cells from NOD-SCID compared to IL15Rα E6-/- mice.  In all, we 
could not detect any difference in NK cell proportions, number, or function in IL15Rα E6-/- animals 
compared to those with wildtype IL15Rα. 
Figure A - 2: No reduction of NK cell proportion and number in IL15Rα E6-/- compared to NOD-SCID mice. 
Example flow analysis of splenocytes from a. NOD-SCID or b. IL15RαE6-/- animals. Splenocytes are gated on 
CD45+ CD3- and NK cells are defined as CD45+ CD3- DX5+ NKp46+. c. Quantification of NK cells as a proportion 







Figure A - 3: NK cells from IL15RαE6-/- mice do not show reduced function. 
a., b. NK cells from E6-/- mice have the same levels of IFNγ secretion as WT mice; a. example staining and b. 
quantification of IFNγ secretion of NK cells in splenocytes of WT or E6-/- mice. c. NK cytotoxicity was assessed 
using an FCM-based assay. Control cells (NSG splenocytes) and indicated target cells were labeled with amine-
binding dyes and mixed. Splenocytes from age and sex-matched NOD-SCID and IL15RαE6-/- mice were harvested 
and added with the control/target mixture at the indicated ratios. Splenocytes were incubated together for 4 hours at 
37ºC with 5% CO2, then stained with DAPI and analyzed by FCM. c. Example FCM analysis. Target/Control ratio 
was calculated as the % DAPI negative Target Cells divided by the % DAPI negative Control cells. Killing 
efficiency was analyzed by Two-Way ANOVA and showed no significant difference in killing efficiency of either 





In all, our data suggest that the Exon 6 putative transmembrane domain of IL15Rα is not necessary for 
murine NK cell development or function, at least on the NOD-SCID background.  This finding is not 
completely unexpected, given that it has long been known that cytoplasmic signaling does not play a 
major role in IL15Rα’s function [384], although it has a role in maintaining appropriate IL15/IL15Rα 
endosomal recycling [385].  Indeed, previous deletion efforts had mostly targeted the Exon 2/Exon 3 
domains of the IL15Rα, which encode the sushi domain that interacts with IL15 [219, 378].  Many studies 
have suggested that much of the signaling mediated by IL15/IL15Rα occurs in trans, meaning that the 
complex of IL15/IL15Rα present either on another cell [385] or in secretion [386, 387] can interact with 
IL2Rβ and γc to induce signaling.  While we have not confirmed that the E6-/- deletion leads to reduced 
cell surface expression of IL15Rα, and while further experiments would be needed to better understand 
the biology at work here, on the whole, these data lend further credence to the idea that IL15Rα does not 
require cell surface binding or cytoplasmic signaling to support normal NK cell development or function.  
Previous experiments in other models had suggested this was the case, but because IL15/ IL15Rα 
signaling also plays a key role in T cell homeostasis [388, 389], generating this knockout on a T cell-null 
NOD-SCID mouse background makes it easier to isolate the effects of IL15Rα E6 deletion on NK cells.  
Additionally, while these IL15Rα knockout animals have functional NK cells and are thus unlikely to be 
better host animals than NOD-SCID mice for human transplantation, IL15Rα is known to be pleiotropic, 
with documented functions in the brain [314, 390] and muscle [305, 391].  While the exon 6 putative 
transmembrane domain appears dispensable for murine NK development and function, further research 





Additional NOD-SCID IL15Rα-/- alleles 
Validating ATG gRNAs 
We next generated IL15Rα knockout mice by using gRNAs to target the start codon of the IL15Rα 
locus (ATG).  Prior to performing embryo injections, we validated the efficacy of these gRNAs in-house, 
both verifying that the gRNAs effectively targeted the IL15Rα locus by performing Surveyor nuclease 
Figure A - 4: Validation of IL15Rα ATG-targeting gRNAs. 
Appropriate targeting of the IL15Rα start codon by in-house designed gRNAs.  gRNAs described in Table 6 were 
cloned into the pX335 CRISPR/Cas9 vector.  Pairs of gRNA-containing plasmids were transfected into EL4, an 
IL15Rα+ murine cell line, using nucleofection.  gRNAs 1 consisted of gA + gB1 while gRNAs2 consisted of gA + 
gB2, as described in Table 6.  a., b. Targeting of the IL15Rα start codon was confirmed by Surveyor nuclease 
analysis.  gDNA was extracted from transfected EL4 cells and the IL15Rα start codon was amplified by PCR using 
high-fidelity DNA polymerase.  The Surveyor endonuclease assay was then performed according to manufacturer’s 
instructions.  a. Gel electrophoresis of IL15Rα amplicon from gRNA of transfected EL4  cells after Surveyor 
endonuclease treatment.  b. Quantification of results of the Surveyor assay.  c., d. At 120hrs post transfection, EL4 
cells transfected with the gRNAs 1 pair showed reduced surface expression of IL15Rα compared to cells transfected 





analysis on a PCR amplified region of targeted gRNA from murine EL4 cells transfected with plasmids 
containing gRNAs (Figure A - 4a, b).  Surveyor analysis demonstrated that gRNAs could effectively 
target the IL15Rα locus.  Additionally, we verified that transduced EL4 cells showed a reduction in 
IL15Rα surface staining 120hrs post transfection with gRNAs (Figure A - 4c, d).  We found the gRNAs 
1 combination (gA and gB1) seemed to be most effective in reducing IL15Rα surface expression.  These 
gRNAs were used by our collaborators at The Jackson Laboratory to generate IL15Rα ATG-/- mice, as 
shown in Figure A - 1c and d, as well as in combination with the gRNAs used to target Exon 6 to 






Preliminary line characterization 
We have generated and propagated NOD-SCID IL15Rα ATG-/- and IL15Rα Full-/- mice.  Preliminary 
characterization of IL15Rα ATG-/- mice has shown that NK cells are reduced in the blood and spleen of 
these mice compared to NOD-SCID mice (Figure A - 5).  Peripheral blood analysis of IL15Rα Full-/- 
animals also showed a reduction in peripheral blood NK cells, although replication studies are needed to 
confirm this observation.  NK cells were still detectable in the liver of IL15Rα ATG-/- mice (Figure A - 
5).  NK cell development occurs in the liver, so it is possible that these NK cells are at an intermediate 
Figure A - 5: NK cells are reduced in blood and spleen, but not liver of IL15Rα ATG-/- mice. 
FCM staining of PBMCs, splenocytes, and liver cells, gated on CD45+ CD3- cells showing proportions of NK 





differentiation stage that may not significantly limit human cell engraftment.  Functional assays will be 
needed to determine if these hepatic NK cells are functional and might limit engraftment of transplanted 
human cells.   
Thymic lymphoma in NOD-SCID IL15Rα-/- mice 
In addition to the presence of murine NK cells, a barrier to using NOD-SCID mice for human cell 
transplantation has been the fact that these animals have a high incidence of thymic lymphoma, a tumor 
that develops naturally in the thymus at a relatively young age, becoming evident typically around 20 
weeks of age [306, 392].  This limits the potential duration of humanized mouse experiments, a major 
concern for studying immunological phenomena that may take extended time to develop.  Additionally, 
Figure A - 6: Reduced survival of IL15Rα KO animals that lack NK cells compared to IL15Rα KO 
heterozygous or WT mice, likely due to increased incidence of thymic lymphoma. 
a., b. Kaplan-Meier survival curves of comparing survival of untransplanted NOD-SCID IL15Rα WT and 
heterozygous animals compared to a. NOD-SCID IL15Rα ATG-/- and b. NOD-SCID IL15Rα Full-/- animals.  Poor 
survival of ATG-/- and Full-/- animals may be due to thymic lymphoma; c. IL15Rα KO animals are sometimes 
observed to have enlarged thymic tumors.  d. CD4 and CD8 staining of ungated cells.  Mouse thymic lymphoma 
was detectable by FCM analysis of in the mouse native thymus and peripheral tissues of a NOD-SCID IL15Rα Full-/- 
animal.  This suggests that we will be able to detect the development and metastasis of mouse thymic lymphoma in 
the peripheral blood of transplanted animals.   





unpublished observations made by Dr. Markus Hölzl in our laboratory suggest that thymic lymphoma 
cells metastasize at late time points post-transplant, and these metastasizing cells can infiltrate secondary 
lymphoid structures, disrupting any improved lymphoid structure that may be present in humanized 
NOD-SCID animals.  Since IL15Rα ATG-/- and IL15Rα Full-/- animals have reduced NK cells, and NK 
cells are known to play an important role in anti-tumor immunity [307, 393, 394], it seemed possible that 
thymic lymphoma would develop more rapidly and metastasize more aggressively in these animals.  
Indeed, we have observed that IL15Rαko animals that largely lack peripheral NK cells have significantly 
shorter lifespans even compared to animals on the NOD-SCID background that retain spleen and blood 
NK cells (Figure A - 6a, b).  In at least some cases, we can confirm that this reduced lifespan correlates 
with the presence of fulminant thymic lymphoma that is apparent as an extremely enlarged murine 
thymus in some animals upon necropsy (Figure A - 6c).  We additionally were able to use FCM to detect 
populations in the periphery of some NK null mice that we believe to be murine thymic lymphoma cells 
(Figure A - 6d).   
The thymic lymphoma we observe in the IL15Rα ATG-/- and Full-/- animals presents a major obstacle 
to using these animals for transplantation of human cells.  It shortens the useable lifespan of IL15Rα–
deficient transplantable animals, and, because of its ability to metastasize and infiltrate peripheral tissues, 
will make it very difficult to accurately assess human cell engraftment.  Therefore, we are pursuing 
multiple strategies to reduce the incidence of thymic lymphoma in transplanted mice.  First, since we have 
developed laboratory expertise in surgically excising the mouse native thymus, we are pursuing whether 
thymectomy of NOD-SCID IL15Rα-/- mice, especially at very early ages (4-10 weeks) can protect against 
thymic lymphoma.  Additionally, it has previously been shown that Emv30, a murine endogenous 
retrovirus, is encoded in the NOD mouse genome.  Previous studies have suggested that deleting Emv30 
from NOD-SCID mice prevents the development of metastatic thymic lymphoma [306].  We are 





determine whether removing the endogenous retrovirus can help prevent the early development of 
metastatic thymic lymphoma in NOD-SCID animals that lack NK cells. 
Conclusions and future directions 
The experiments described here are preliminary data, but they represent the successful generation of 
three lines of NOD-SCID IL15Rα-/- mice.  Two of the mouse lines, the IL15Rα ATG-/- and Full-/- mice, do 
not appear to have NK cells in the blood or spleen.  We do observe NK cells in the liver of ATG-/- mice.  
We have not yet confirmed the presence of NK cells in the liver of Full-/- mice.  However, these 
observations are based on analysis of relatively small numbers of mice and need to be repeated.  
Additionally, functional assays will need to be performed to determine whether the NK cells detected in 
ATG-/- mouse livers retain their ability to attack human cells and limit human engraftment.  However, our 
initial characterization suggests that we have successfully generated a NOD-SCID mouse line that lacks 
most peripheral NK cell populations while still retaining a wildtype γc receptor and thus, presumably, 
retaining γc signaling and the consequent improved secondary lymphoid tissue development.  Further 
studies will be needed to assess whether this animal strain can support improved human peripheral 
lymphoid reconstitution, human B-T interaction, and ultimately human vaccination responses in animals 
transplanted with human CD34+ cells. 
Our observation that NOD-SCID mice that largely lack NK cells are more vulnerable to thymic 
lymphoma may present a major obstacle to using this mouse strain for human transplantation.  We will 
continue monitoring survival and health of these strains, both as is and as we explore thymectomy and 
backcrossing to the Emv30null strain to see if these approaches confer protection, extending the life of the 
animals and preventing peripheral infiltration by thymic lymphoma cells.  
In the meantime, preliminary human transplantation experiments are in progress to assess whether 





improved secondary lymphoid structures that better support human adaptive immune cell maturation and 
function in these animals. 
 
